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Prematurity
Neonates with a gestational age <37 weeks are called preterm. This thesis, however, 
presents studies in very preterm infants (gestational age <28 weeks), some being even 
extremely preterm (gestational age <26 weeks). Apart from gestational age, preterm 
neonates can be classified according to birth weight: low birth weight infants, weighing 
<2500 gram; very low birth weight infants, weighing <1500 gram; and extremely low 
birth weight infants, weighing <1000 gram. The cause of prematurity is multifactorial. 
Maternal factors (preeclampsia, life style, age, infection), pregnancy factors (placenta 
previa, premature rupture of membranes, polyhydramnion) , as well as fetal factors 
(multiple gestation, congenital anomalies) play a role (1).
Our ability to treat increasingly preterm infants has improved significantly, as reflected 
by the substantial increase in survival over the years. In two cohorts of VLBW infants 
born in 1989 and 1994, it was reported that mortality decreased nearly 50% for VLBW 
infants in 5 years (2). One third of this decline was attributed to improved condition on 
admission, reflecting improved obstetric and delivery room care. The other two thirds of 
the decline in mortality was attributed to intensive care treatment, including improved 
respiratory and cardiovascular support, such as surfactant use, application of antenatal 
steroids and availability of ultrasound techniques.
Increased survival, on the other hand, poses new challenges to neonatal care. As 
more preterm infants survive the direct neonatal period, prematurity related morbid-
ity increases (3). Figure 1 shows incidence of a number of major prematurity related 
diseases in our neonatal intensive care unit. Apart from a certain maladjustment to neo-
natal life arising from immature organ systems, the etiology of many of these diseases, 
such as bronchopulmonary dysplasia, periventricular leukomalacia, and retinopathy of 
prematurity is largely unknown.
Compared to other innovations in neonatology, such as artificial ventilation, progress 
in the field of nutrition has been lagging behind, probably since malnutrition or even 
complete absence of nutrients has no short-term life threatening consequences. The 
priority for adequate nutrition as soon as possible after birth, in particular for protein 
accretion, is increasingly being recognized. However, this is complicated by the relative 
intolerance preterm infants exhibit to enteral nutrition. For this reason, they are primar-
ily dependent on parenteral nutrition in the immediate postnatal phase.
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Parenteral amino acid solutions for the preterm 
infant
From past to present
Parenteral nutrition became available for routine use in the neonatal intensive care units 
(NICUs) in the early 1970s, and development is still continuing. The first amino acid 
(AA) solutions were found to cause metabolic disturbances in newborn infants (4). Stud-
ies reporting these adverse effects had and still have a profound effect on nutritional 
policies. Though it was recognized that withholding proteins resulted in a catabolic 
state, AAs were being withheld assuming that the preterm infant was ’intolerant’ to AA 
solutions. We have now come to realize that both manufacturing mode and composition 
of the AA solution are likely to have caused complications such as hyperammonemia 
and metabolic acidosis, rather than the AAs per se. In fact, after the umbilical cord is 
cut following preterm birth, the concentrations of essential AAs start to fall rapidly. 
Nowadays, we know this can trigger a response referred to as ‘metabolic shock’, a 
starvation response of the body which is accompanied by irrepressible endogenous 
glucose production, which causes glucose intolerance and further consumption of AAs 
Figure 1. Incidence of bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) and 
necrotizing enterocolitis (NEC) divided by birth weight in a cohort of 670 infants, born in the Sophia 
Children’s Hospital between 2002 and 2006.
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1for gluconeogenic substrates. Indeed, the need for AAs may never be more urgent that 
directly following birth.
Nevertheless, fear of metabolic derangements is still firmly rooted in clinical prac-
tice.
Guidelines, such as presented by the Committee on Nutrition of the American Academy 
of Pediatrics, have stressed the importance of AA administration to preterm neonates 
already since the 1970s (5). The goal stated at that time remains valid today: a postna-
tal growth rate that duplicates fetal growth rate. An additional present aim is mimicking 
body composition of the age-matched fetus. However, the exact timing of initiation of 
AA supplementation was not addressed until recently. Recent guidelines state that even 
one day of starvation can be detrimental to the preterm infant (6).
Intrauterine nutrition
Through the umbilical cord, the fetus receives a continuous supply of AAs. While pre-
term birth causes this supply to cease abruptly, in the age-matched fetus the ongoing 
delivery of AAs is vital for growth and neurodevelopment. Yet, preterm infants often 
do not receive sufficient amounts of AAs, or even do not receive them at all during the 
first postnatal days. Clinical issues such as patent ductus arteriosus and respiratory 
distress with a subsequent strict fluid management might complicate adequate nutrient 
provision.
Nutritional uptake in utero is large, not only for accretion of new tissue and a high 
oxidation rate, but also for replacement of body water with protein and fat. Water 
content of fetal tissue will drop from 89% at 24 wks to 74% at 40 wks gestation. This 
drop is counterbalanced by a rise in lipid content from 0 to 11 % in the last trimester, 
and a rise in protein content from 8.8% to 12% (7).
AA contribution to human fetal oxidation is largely unknown and the few available 
data are contradictory. Obligatory nitrogen excretion in fasting premature neonates 
is approximately 0.6 - 1.0 g/(kg·d) (8, 9). Animal fetal research in physiological con-
ditions indeed demonstrates that intrauterine AA oxidation is much higher and that 
uptake is far beyond AA requirements for body accretion (10, 11). The human fetus also 
showed considerable intrauterine urea production (12). Total AA uptake is 3.5 to 4.0 
g AA/(kg·d). Protein requirements at two months of age after term birth only slightly 
decrease to approximately 2.5 to 3.0 g/(kg·d) as tissue protein content does not further 
increase.
It must be noted that these values are derived from tissue composition of deceased 
fetuses or newborns whose growth might also have been affected; thus these figures 
might be underestimations. Nevertheless, we may still assume that the fetus receives a 
diet rich in protein and poor in fat. Yet, present postnatal nutritional strategies dictate 
12
the preterm infant be given a high fat, high carbohydrate, and moderately high protein 
diet. While a high caloric diet indeed stimulates a preterm infant’s growth, mass accre-
tion would have been different in composition had the infant still been in utero. Indeed, 
preterm infants were found to gain larger than desirable fat deposition after birth (13, 
14).
Achieving a body composition closer resembling fetal body composition, usually im-
plies a larger AA intake. This should be accomplished as soon as possible after birth. 
Note, however, that growth failure is not the same as weight loss. The initial weight 
loss in the first postnatal days represents rearrangements of body fluids necessary for 
adapting to extrauterine life, rather than catabolism.
Early amino acid administration
In early studies AAs were initiated not until after one week in the smallest infants 
(15) or after 3 days in 1700 g-infants (16), leaving infants dependent on exogenous 
glucose only for their metabolism during the bridging period. With the introduction of 
solutions specifically designed for neonates (17), researchers started to study effects 
of shortening time span of withholding AAs (8, 18-21). In two separate studies, Van 
Goudoever et al. and Murdock et al. were the first to administer AAs immediately after 
birth, though using only 1.15 and 1.35 g/(kg·d) in infants weighing a mean 1400 g and 
1500 g, respectively (9, 22). Neither of these or the other studies reported metabolic 
acidosis, hyperaminoacidemia, or, when measured, hyperammonemia. Beneficial ef-
fects – improvements in nitrogen balance, stable isotope balance, or plasma AA profile 
– were observed in all studies.
NICUs now usually start AA infusion in premature infants between 0 and 36 hours after 
birth. However, amounts at which AA administration are initiated may vary considerably 
and not seldom are started at only 0.5 or 1.0 g/(kg·d) increasing step wisely up to 3.0 
g/(k·d) over several days. The motivation for the stepwise increase of AA intake is not 
empirically based, but rather dictated by fluid limitations, concerns of intolerance, and 
fear of hyperglycemia in case of mixed glucose/AA solutions.
However, over the years quality of intravenous AA solutions has improved, and so has 
the general condition of the preterm infant before and immediately after delivery. Yet 
there is a need for more research on nutrition in the immediate postnatal phase. In-
deed, the sudden change from a usually well-fed intrauterine state to the extrauterine 
environment, makes the sick premature most vulnerable and, therefore, in urgent need 
of balanced nutrition.
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Conditionally essential amino acid requirements in neonates
AAs can be categorized into essential, non-essential and conditionally essential AAs.
An important factor in premature infant feeding is the biochemical immaturity. Sev-
eral metabolic processes are not fully developed in utero and are activated after birth. 
The following AAs are therefore considered to be conditionally essential in preterm 
infants: arginine, cysteine, glutamine, glycine, proline, taurine and tyrosine. In this 
thesis, cysteine, glycine and taurine are of particular interest, since cysteine and glycine 
are substrates for glutathione synthesis, which will be discussed later, and taurine is a 
product of cysteine catabolism. These AAs will be shortly discussed below.
Cysteine
Cysteine is synthesized de novo from the essential AA methionine by the transsulfura-
tion pathway. Cysteine is a sulfur-containing AA and has several metabolic functions: it 
is a precursor for taurine and, more importantly, for glutathione. Cysteine synthesis is 
assumed to be impaired in preterm infants due to low or absent activity of the enzyme 
cystathionase (23, 24). However, cystathionase is rapidly activated in the first month 
after birth (24, 25). Viña et al. reported that plasma cysteine levels were significantly 
lower in preterm infants receiving a cysteine-free PN solution intravenously compared 
to term infants (26). Stegink and Den Besten suggested that the gastro-intestinal tis-
sues are an important site for cysteine synthesis (27). They showed that plasma cystine 
concentration dropped significantly in human adults fed a cystine-free diet intravenously 
and increased rapidly to almost normal during intragastric infusion. Cysteine require-
ment might be even higher in preterm neonates fed PN than term babies during the first 
days of life due to these two factors. Nevertheless, recent studies have shown that the 
transsulfuration pathway in VLBW neonates is active 48 hours after birth, whereas the 
capacity was directly related to neonatal maturity (28, 29). These studies suggest that 
cysteine is not a conditionally essential AA, but can be synthesized de novo by preterm 
infants. However, these results have to be confirmed in larger studies.
Cysteine is not stable in solution and oxidizes easily to cystine, which is insoluble, and 
most standard parenteral solutions therefore contain little cysteine or are cysteine-free, 
which puts parenterally fed infants at risk for cysteine deficiency.
To compensate for these low cysteine concentrations, parenteral solutions contain 
relatively high levels of methionine. Neonates receiving a high dose of methionine show 
high plasma methionine and low plasma cysteine concentrations. This implies that ex-
cess of methionine is not used for cysteine synthesis. Moreover, high methionine levels 
in rats induce functional and structural hepatic injury and could be an important factor 
in the pathogenesis in TPN-associated cholestasis (30).
14
N-acetyl-L-cysteine (NAC) is stable in solution but when it was supplemented to par-
enteral solutions, high concentrations of NAC were detected in the urine, confirming its 
low bioavailability (31). So, supplementation of NAC does not seem to be an adequate 
approach to increase the bioavailability of cysteine.
Glycine
Glycine is formed by reversible conversion from serine, which is synthesized de novo. It 
is extensively metabolized in the liver where it serves as an ammonia donor. It functions 
as an inhibitory neurotransmitter in the central nervous system and is also, like cysteine, 
a precursor for glutathione synthesis. The demand for glycine in preterm infants might 
be increased during critical illness or during oxidative stress. Glycine requirement then 
may be temporarily higher in these infants and might need to be supplemented in PN 
solution. Another indication for additional glycine supplementation is derived from [15N]
glycine studies in which, particularly in SGA infants, hardly any added supplemented 
tracer could be found in urinary urea (8, 32).
Taurine
Taurine is a small β-AA and is endogenously formed from cysteine. It is important for 
fetal neurological development but is not produced by the fetus. Taurine is not used 
for protein synthesis, but remains free in the intracellular water. Plasma values drop in 
infants receiving a taurine free PN solution. Taurine has several important functions and 
deficiency results in impaired fat absorption, bile acid secretion, retinal function, and 
hepatic function, all of which can be reversed by taurine supplementation (33). Cysteine 
sulfinic acid decarboxylase is the rate-limiting enzyme for taurine synthesis and its 
activity might be lower in preterm infants compared to adults. Also, as PN contains 
no or little cysteine, exogenous cysteine supplementation is not optimal for taurine 
production and, therefore, it is indeed conditionally essential.
Oxidative stress, antioxidants and related 
morbidity
Oxidants & Antioxidants – general aspects
The intrauterine environment is hypoxic relative to the extrauterine environment. More 
specific, the uterus has a low oxygen tension (pO2 = 20-25 mm Hg) as compared to 
room air (pO2 = 150-160 mm Hg) (34). Fetal and adult gene expression is different, 
enabling the fetus to thrive in this hypoxic intrauterine environment, while it is capable 
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1to anticipate to the relative hyperoxia following term birth. The latter primarily involves 
protection which is required against an increased load of oxidants evolving as by-prod-
ucts of oxidative metabolism, i.e. the reduction of O2 to H2O which takes place during 
the process of energy generation. These oxidants are referred to as reactive oxygen 
species (ROS), and include free radicals, such as superoxide (O2
-·) and the extremely 
reactive hydroxyl radical (OH·) as well as non-radical substances, such as hydrogen 
peroxide (H2O2). These ROS can extract electrons from other molecules rendering them 
either irreversibly damaged or new radicals which may continue the cascade. From this 
it can be concluded that oxygen, although required to sustain life, has toxic properties. 
Hence the phrase oxygen paradox.
It is important to note that, in the physiological state, ROS are present and maintained 
at low concentrations at which they are of benefit in regulating gene expression and 
several types of cellular signaling (35). In vitro, H2O2 and O2
-· in extremely low concen-
trations stimulate growth of various cell types (36, 37). During fetal life, they lead to the 
digit individualization in developing limbs by means of carefully programmed apoptosis 
(38). In addition, neutrophils and macrophages contain high concentrations of free 
radicals which are released during inflammation in order to eliminate pathogens.
At higher concentrations, ROS inflict damage to cellular constituents, ultimately result-
ing in apoptosis (Figure 2). This damage can be quantified by measuring concentrations 
of specific markers, which in the healthy state are either absent or present in minimal 
amounts. These markers can reflect protein oxidation (e.g. advanced oxidized protein 
products, dityrosine), lipid peroxidation (e.g. malondialdehyde, isoprostanes), and DNA 
damage (e.g. 8-hydroxy-2’-deoxyguanosine).
Tissue damage evoked by ROS can be prevented by reducing agents or antioxidants. 
An antioxidant, by definition, can be “any substance that delays, prevents or removes 
oxidative damage to a target molecule” (39). Antioxidants can be classified according 
to many criteria: some can be synthesized in vivo whereas others should be consumed 
Figure 2. ROS mediated cellular damage.
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within the diet; they can act primarily in the intracellular or in the extracellular environ-
ment; they can be enzymatic or non-enzymatic.
Imbalance between oxidants and antioxidants in favor of the former is referred to 
as oxidative stress. In other words, oxidative stress is a physiological stress on the 
body that is caused by the cumulative damage done by ROS inadequately neutralized 
by antioxidants, which can either result from increased oxidant production, inadequate 
antioxidant production, or a combination of both.
A number of important antioxidants will be briefly discussed below:
Glutathione
Glutathione (GSH) is a tripeptide composed of glutamate, cysteine, and glycine, by the 
consecutive action of the enzymes glutamate cysteine ligase (GCL) (EC 6.3.2.2) and 
glutathione synthase (EC 6.3.2.3). It is primarily an intracellular antioxidant, synthesized 
by virtually all mammalian cells. Cellular concentrations are extremely high, typically 
in the millimolar range. Its half life ranges from minutes to several days and is tissue 
specific (40-43). It increases during pathologic conditions such as oxidative stress. GSH 
can function as an antioxidant independently, by means of the cysteine moiety, which 
has a reducing sulfhydryl group. It scavenges ROS and can be considered as first line 
defense (44). In addition, GSH is a cofactor for numerous antioxidant enzymes, such 
as GSH-peroxidases (EC 1.11.1.9) and GSH-S-transferases (EC 2.5.1.18) which col-
lectively form a second line defense system eliminating noxious byproducts of ROS. The 
monomeric form is the reduced, or active form of GSH. While reducing harmful ROS, 
GSH itself is oxidized to form the dimeric form, typically abbreviated as GSSG since the 
two GSH monomers are coupled by a disulfide bond. Intracellular GSSG concentrations 
are extremely low and the GSH/GSSH equilibrium is tightly controlled as it regulates a 
number of metabolic processes, such as enzyme activity and gene expression (45).
To maintain the reduced intracellular environment, GSSG will be either exported ex-
tracellularly, or recycled to GSH by GSH reductase (EC 1.8.1.7). This reaction requires 
NADPH as a co-factor, which is yielded from the pentose phosphate pathway. This whole 
process of reduction and oxidation is called the GSH redox cycle (Figure 3).
Although all cells synthesize GSH, the liver is the main producer and exporter, its 
export accounting for over 90% of total GSH turnover (46). GSH cannot be transported 
as a tripeptide across cellular membranes. For this reason, it seems of little benefit 
to supply GSH as part of parenteral nutrition to increase intracellular GSH concentra-
tions. On the other hand, indirect transport and subsequent intracellular resynthesis is 
facilitated by the γ-glutamyl cycle in a few organs such as the kidney and intestine. The 
organs possess γ-glutamyl transpeptidase, an outer surface enzyme which splits GSH 
into cysteinylglycine and a γ-glutamyl moiety, which is transferred to an amino acid 
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acceptor, which most often is cystine. The cysteinylglycine and γ-glutamyl cystine are 
subsequently transported intracellularly. Cysteinylglycine are then split into cysteine and 
glycine and γ-glutamyl cystine is split into γ-glutamylcysteine and cysteine. Altogether, 
these metabolites can be used to resynthesize GSH. If another amino acid acceptor 
than cystine is used, the γ-glutamyl amino acid is converted into 5-oxoproline and the 
corresponding amino acid. 5-oxoprolinase subsequently rediscovers glutamate.
Whereas we will focus on GSH as an antioxidant in this thesis, it is important to 
realize that it has a number of other metabolic functions. It is conjugated to drugs to 
make them more water soluble; it is involved in AA transport across cell membranes 
(the γ-glutamyl cycle) (47); it regulates redox-sensitive signal transduction and gene 
expression (48) and is involved in the rearrangement of protein disulfide bonds.
Cysteine is generally considered the rate limiting substrate for GSH synthesis. The 
apparent Km values of GCL for glutamate and cysteine are 1.8 and 0.1 – 0.3 mM, 
respectively (49). Since the intracellular glutamate concentration is several folds higher 
than the Km value of GCL for glutamate, but the intracellular cysteine concentration 
approximates the Km value of GCL for cysteine, availability of cysteine most significantly 
influences the rate of GSH synthesis.
Vitamin C (ascorbic acid)
As opposed to most mammalian species, vitamin C cannot be synthesized by humans 
and should, therefore, be supplemented in the diet (50). To date, there is no universal 
agreement on the recommended intake. According to the Dutch Health Council, the 
daily requirement for ‘a healthy person’ is 70 mg/day. Alike GSH, vitamin C is a very 
potent electron donor. In addition, it reduces antioxidants such as GSH and vitamin E 
Figure 3. Glutathione redox cycle. GSH can reduce ROS independently or, such as in the case of H2O2, 
by means of GSH peroxidase (GPx). GSH reductase (GR) subsequently reconverts GSSG to GSH at the 
cost of NADPH which is yielded from the pentose phosphate pathway which uses glucose-6-phosphate 
dehydrogenase (G6PD) to regain NADPH. 
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from their oxidized states (51). While donating electrons, vitamin C itself is oxidized, 
rendering the relatively stable and ureactive ascorbyl radical and subsequently de-
hydroascorbic acid. Part of the dehydroascorbic acid will be recycled into vitamin C, 
whereas the majority will be hydrolyzed. Though vitamin C is a powerful antioxidant, 
it may paradoxically exhibit pro-oxidant features when administered at (extremely) 
high doses. This is mediated by stimulation of Fenton chemistry (52), which involves 
the transition metal catalyzed reduction of H2O2 to generate the extremely reactive and 
harmful OH· radical.
Vitamin E (α-tocopherol)
In contrast with GSH and vitamin C, which are water-soluble antioxidants, vitamin E 
is a fat-soluble component. It acts as a preventing, chain-breaking antioxidant that 
scavenges lipid peroxyl radicals, thereby blocking the propagation of lipid peroxidation, 
while maintaining the integrity of cell membranes. During this process, vitamin E is 
oxidized to a tocopheroxyl radical. At this stage, it requires other antioxidants such as 
vitamin C to be reduced again, otherwise it will propagate the oxidative chain reaction 
itself. Interaction of vitamin C with the tocopheroxyl radical to regenerate vitamin E 
thus moves radicals from the lipid phase into the aqueous phase and thereby preventing 
tocopherol-mediated peroxidation (53).
Albumin
Albumin is a protein (66 kD) comprising over half of the total plasma protein pool. It 
has great storage capacity for both GSH and its constituent cysteine. Albumin acts 
as an extracellular antioxidant via its sulfhydryl groups. In addition, its heme-binding 
properties prevent transition metals such as iron and copper from generating the ex-
tremely reactive OH· radicals during Fenton reactions (54, 55). Also, its presence in high 
quantities enables it to intercept a substantial part of the oxidant burden, providing it 
with passive antioxidant power.
Bilirubin
Unconjugated (indirect) bilirubin is an intracellular antioxidant that acts by binding to 
membranes to protect them from peroxidation. Since unconjugated bilirubin can diffuse 
into any cell, mild hyperbilirubinemia after birth may protect the infant during the tran-
sition from the low-oxygen intrauterine environment to the oxygen-rich extrauterine 
environment (56, 57).
19
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1Vitamin A, thioredoxins, enzymes such as superoxide dismutase or catalase, and 
trace elements such as selenium all have important antioxidant properties, which will, 
however, not be discussed in this thesis.
Oxidative Stress In Preterm Infants
Transition from the fetal to the neonatal state requires a large number of highly complex 
adaptations. These include expansion of the lungs with subsequently the initiation of 
breathing, establishment of adult type circulation, thermoregulation, and numerous 
metabolic adaptations. Consequently, birth may be considered physiologically the most 
dramatic event in life.
Due to immaturity, adequate anticipation to extrauterine life is complicated in pre-
term birth. In term infants, antioxidant defenses are present at birth to counteract 
this hyperoxic challenge, since the antioxidant enzymes mature during late gestation 
(58). Several weeks prior to birth, parallel with the rapid rise in lung surfactant, there 
is a 150-200% increase in superoxide dismutase and glutathione peroxidise as well as 
upregulation of other antioxidant enzymes (59-61). Also, there is an increased transfer 
of several antioxidants across the placenta during the last days of pregnancy, as to 
prepare the unborn child for the relative hyperoxia imposed by extrauterine life (58). 
Preterm birth, however, lacks this preparation (62, 63). In addition, due to surfactant 
deficiency and respiratory distress, preterm infants often require ventilatory support 
with supplemental oxygen, which further adds to the oxidant load. These infants are 
prone to develop oxidative stress.
Apart from hyperoxia, oxidative stress in preterm infants is also mediated by a number 
of other events. One of them is sepsis: during infection, cytokines are expressed which 
induce neutrophil activation followed by formation and release of ROS (64). Another, 
seemingly paradoxical contributor to oxidative stress is hypoxia followed by reperfusion. 
Hypoxia and anaerobic metabolism results in the accumulation of purine metabolites 
(hypoxanthine and xanthine) and accumulation of xanthine oxidase, which breaks down 
hypoxanthines. Activity of xanthine oxidase is limited during hypoxia since oxygen is 
needed to activate this enzyme. With reperfusion, oxygen availability increases rapidly, 
xanthine oxidase is activated, and the breakdown of accumulated hypoxanthine coin-
cides with a burst of ROS.
In 1989, Ola Saugstad proposed the term oxygen radical disease in neonatology 
(ORDN) to describe a series of major diseases, which primarily affect the preterm 
newborn and were believed to share an oxidative stress mediated pathophysiology 
(65). This ORDN included bronchopulmonary dysplasia, retinopathy of prematurity, 
necrotizing enterocolitis, periventricular leukomalacia, patent ductus arteriosus, and 
possibly other diseases. A link has also been described between perinatal exposure to 
20
100% oxygen and childhood cancer (66, 67). Direct evidence of an association between 
these diseases and oxidative stress is still lacking. Whether oxidative stress would have 
a causative role or is merely a direct consequence of these diseases is also unclear. A 
short outline of these diseases is presented below.
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease of prematurity, 
is defined as the need for supplemental oxygen at 36 weeks’ postmenstrual age. Histo-
logical findings include endothelial and epithelial cell damage, bronchial smooth muscle 
hypertrophy, interstitial fibrosis, and simplification of the acinar structure with reduction 
in total number and surface area of alveoli (68).
It affects approximately 10% of VLBW infants and 40% of ELBW infants who survive to 
discharge (69). Although the etiology is known to be multifactorial, predisposing factors 
including high positive airway pressures, inflammation, pneumonia, genetic susceptibil-
ity and meconium aspiration (70), histological findings in experimental pulmonary O2 
toxicity are similar to those seen in BPD (71, 72). Indeed, ROS have been implicated in 
the pathogenesis of BPD (73). In addition, markers of oxidative stress are increased in 
infants who develop BPD (74). A number of antioxidants have been used in trials aimed 
at preventing BPD. Although vitamin A slightly decreased the risk of developing BPD in 
ELBW infants (75), vitamin E, superoxide dismutase, or N-acetylcysteine (a precursor 
of cysteine), did not (76-78).
Periventricular leukomalacia
Periventricular leukomalacia (PVL) results from degeneration of white matter adjacent 
to the cerebral ventricles following cerebral hypoxia or brain ischemia in neonates. PVL 
is the principal neurologic problem affecting children born extremely premature and 
the major pathological finding underlying cerebral palsy (79). Approximately 25% of 
VLBW infants who survive to discharge exhibit moderate to severe permanent motor 
deficits, such as spastic diplegia. The diagnosis is made by neuroimaging examinations 
(cerebral ultrasound and/or magnetic resonance imaging). Although its pathogenesis is 
multifactorial, a maturational dependent susceptibility of developing oligodendrocytes 
to oxidant stress seems to play an important role. Evidence was obtained using im-
munocytochemical markers in autopsy brain tissue of human preterm infants (80). The 
authors report protein nitration and lipid peroxidation in immature oligodendrocytes 
which was not found in control tissue. Recently, Gerstner et al. found that formation 
of ROS following hyperoxia triggers apoptosis in immature oligodendrocytes in the 
neonatal rat brain, and leads to white matter injury (81). GSH depletion aggravated 
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1injury to immature oligodendrocytes, whereas providing substrates for GSH synthesis 
ameliorated oligodendrocyte injury in the developing brain (82, 83).
Retinopathy of prematurity
Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the immature retina 
primarily affecting preterm infants. Hyperoxia and the resulting high oxygen satura-
tion produces vasoconstriction and impairs vascularization, which leads to ischemia 
in certain parts of the retina, followed by vasoproliferation. During the last years, the 
role of VEGF, or vascular endothelial growth factor, has become apparent as a crucial 
factor in the pathogenesis of ROP. VEGF is inhibited by hyperoxia, which in turn leads to 
delayed blood vessel growth of the retina. The resulting hypoxia upregulates VEGF with 
uncontrolled neovascularization as a result. However, there is evidence of ROS playing 
part in the pathogenesis of ROP as well. In two studies, increased concentrations of 
hypoxanthine were found in the eyes of infants suffering from ROP (84, 85). In addition, 
the immature retina is deficient in most antioxidants. Papp et al. found lower plasma 
concentrations of GSH and selenium in infants who developed ROP as compared to 
control infants (86).
Necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is a serious disease affecting predominantly preterm 
infants. Alike the other diseases presented above, which have a higher incidence, its 
pathogenesis is multifactorial, involving pathogenic bacterial colonization, hypoxia, and 
either withholding or providing too much enteral feedings in the early neonatal phase. 
ROS evolve following hypoxia and reperfusion as discussed earlier. Gut epithelial cells 
are particularly rich in xanthine oxidase, which is activated during hypoxia and reacts 
with oxygen during reperfusion, producing a burst of ROS. A number of animal studies 
have shown beneficial effects of administration of antioxidants, such as superoxide 
dismutase and vitamin E, in preventing intestinal damage in experimental models of 
NEC (87-90).
Hypotheses & outline of the thesis
This thesis describes a number of studies on early nutritional interventions in (preterm) 
infants and their impact on neonatal wellbeing, as reflected by protein metabolism and 
antioxidant defense. Note: “early nutrition” is used throughout to designate any nutri-
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tional strategy that involves introduction of amino acid administration in a substantial 
amount (> 2 g/(kg·d)) shortly after birth (within hours).
The main hypotheses that will be tested are:
•	 AA administration is safe and results in anabolism, accomplished by increased pro-
tein synthesis.
•	 Energy for protein synthesis is derived from increased glucose oxidation.
•	 GSH consumption is increased in preterm infants and AA administration increases 
GSH synthesis rates and decreases oxidative stress.
•	 Cysteine availabilityadditional cysteine supplementation above a standard dosage 
will further increase GSH synthesis.
•	 Infants on ECMO and infants suffering from perinatal asphyxia experience increased 
oxidative stress as compared to healthy preterm infants.
Chapter 1 gives an overview of the subject of this thesis and describes current knowl-
edge and research questions.
Part I – Amino acid administration and protein metabolism
Chapter 2 presents the results of a randomized clinical trial determining general 
aspects of safety and efficacy of early amino acid administration in promoting anabolism 
in a large group of preterm infants. In chapter 3, a stable isotope study, investigating 
the effects of early amino acid administration in preterm infants on protein synthesis, 
protein breakdown and glucose oxidation, is described. Whereas this chapter presents 
results on whole body protein kinetics, Chapter 4 describes a study carried out to 
specifically investigate synthesis rates of albumin, which is the main plasma protein 
and an important extracellular antioxidant. Chapter 5 presents a short report on the 
neurodevelopmental outcome in infants described in chapter 2 at two years of age.
Part II – Amino acid administration and antioxidant defense
Chapter 6 describes a novel method using stable isotope techniques for studying 
glutathione metabolism in extremely small sample volumes, such as is required for 
measurements in preterm infants. In Chapter 7, we present an observational longi-
tudinal study in preterm infants in which we measured synthesis rates of glutathione 
and protein oxidation markers during the first week of life. Chapter 8 describes a 
randomized clinical trial determining stimulatory effects of early amino acid administra-
tion on glutathione synthesis rates and its potential to lower oxidative stress in preterm 
infants. In Chapter 9, we describe a study investigating glutathione synthesis rates 
and protein damage in the immediate postnatal phase. This study was carried out to 
investigate whether glutathione synthesis is already stimulated within a few hours after 
birth. Chapter 10 describes a randomized clinical trial which addresses the hypothesis 
that a high dose cysteine stimulates glutathione synthesis as compared to a lower dose 
in preterm infants considering cysteine is an essential amino acid in very preterm in-
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1fants. In Chapter 11, two observational studies are described on glutathione synthesis 
and protein damage in term infants suffering from perinatal asphyxia and term infants 
requiring extracorporeal membrane oxygenation (ECMO). In Chapter 12, the general 
discussion, the results of this thesis are discussed, and compared with data obtained by 
others. In addition, suggestions for future research are being made. Lastly, Chapter 13 
provides an overall summary.
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Abstract
The objective of this study was to test the hypothesis that the administration of 2.4 g 
amino acids (AAs)/(kg·d) to very low birth weight infants is safe and results in a positive 
nitrogen balance.
We conducted a randomized, clinical trial. Preterm infants with birth weights <1500 
g received either glucose and 2.4 g AAs/(kg·d) from birth onward (n = 66) or solely 
glucose during the first day with a stepwise increase in AA intake to 2.4 g AAs/(kg·d) 
on day 3 (n = 69). Blood gas analysis was performed daily during the first 6 postnatal 
days; blood urea nitrogen levels were determined on days 2, 4, and 6; AA plasma 
concentrations and nitrogen balances were determined on days 2 and 4. Student t tests, 
Mann-Whitney tests, and χ2 tests were performed to compare groups.
Infants supplemented with AAs had no major adverse side effects. Their blood urea 
nitrogen levels were higher, nitrogen balance turned positive upon AA administration, 
and more AA concentrations were within reference ranges.
In conclusion, high-dose AA administration to very low birth weight infants can be 
introduced safely from birth onward and results in an anabolic state.
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Introduction
After birth, very low birth weight (VLBW) infants are dependent on externally admin-
istered nutrients, as hardly any stored energy is at their disposal (1). Both fat tissue 
and glycogen levels are limited, especially in small for gestational age (SGA) VLBW 
infants. Consequently, without adequate exogenous nutrient supply, protein breakdown 
will increase in these infants, resulting in a catabolic state.
Despite a growing body of literature regarding the safety and efficacy of early amino 
acid (AA) administration, there is still wide variability in practice. Often, carbohydrates 
are still the only exogenous nutrients administered in the immediate postnatal period. 
In the past, AAs were often withheld since formerly used AA mixtures were found to 
result in metabolic acidosis and hyperammonemia (2, 3). In utero, fetuses are supplied 
with large amounts of AAs, which not only are used for protein synthesis but also 
serve as an important fuel source (4-7). It seems logical, therefore, to supply newborn 
infants with adequate amounts of both energy and growth substrates to meet energy 
requirements and to promote protein accretion for ongoing growth. Indeed, several 
studies indicate that the currently used crystalline solutions seem well suited for the 
preterm infant, who may benefit from the anabolic effects (8-14). However, in most of 
these studies, either low amounts of AAs were administered, administration started only 
after the first day of life, infants with higher birth weights were studied, or the number 
of infants studied was small.
Hypothesizing that premature infants may benefit from the anabolic effects of AAs 
without metabolic derangement, we investigated the safety and efficacy of relatively 
large amounts of AAs supplied postnatally to a large group of VLBW infants.
Methods
A randomized, blinded trial was performed in the neonatal intensive care unit (NICU) 
of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands. For logistic 
reasons, it was not possible to perform the study using a double-blinded fashion. The 
trial was investigator-initiated, with no funding from the pharmaceutical industry. The 
study protocol was approved by the Erasmus MC Medical Ethical Committee, and pa-
rental consent was obtained before random assignment and subsequent enrollment in 
the study.
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Study Design
Prematurely born infants with birth weights equal or less than 1500 g born between 
March 2003 and September 2004 in the hospital and admitted to the NICU were ran-
domly assigned to receive one of two parenteral nutritional schemes, as indicated in 
Table I. The amount of 2.4 g AAs/(kg·d) was chosen because that was the amount that 
resulted in a positive nitrogen balance in an earlier study (14).
After the third day of life, all nutrient intakes, including enteral feedings, were the 
decision of the attending neonatologist. Minimal enteral nutrition (6 to 12 feedings of 
1.0 mL) was whenever possible started on postnatal day 2 to day 3 and advanced to 
full enteral nutrition in the subsequent days if tolerated. We recorded birth weight, ges-
tational age, percentage of SGA infants (<−2 SD) (15), sex ratio, number of prenatal 
corticosteroid doses (0, 1, or 2), and severity of illness at entry to the study with Apgar 
and CRIB scores (16). Exclusion criteria were known congenital abnormalities, chromo-
some defects, metabolic diseases, and endocrine, renal, or hepatic disorders.
Analysis
Safety
We analyzed blood gas and glucose concentrations 12 hours after delivery, followed 
by daily measurements at 8 am until day 6. Blood urea nitrogen (BUN) concentrations 
were monitored on days 2, 4, and 6 (Roche Hitachi 912, Roche Diagnostics, Basel, 
Switzerland). On days 2 and 4, we determined plasma AA concentrations (Biochrom 20, 
Table I: Targeted intravenous macronutrient intake in mg/(kg·min) (glucose) or g/(kg·d) (AAs and 
lipids).
Day
1 2 3 4
Glucose 5.5 5.6 5.7 7.1
Intervention AAs * 2.4 2.4 2.4 2.4
Lipids † 0 1.4 2.8 2.8
Glucose 5.5 5.6 5.7 7.1
Control AAs * 0 1.2 2.4 2.4
Lipids † 0 1.4 2.8 2.8
If enteral feedings were tolerated, parenteral glucose intake was decreased.
* Primene 10%, Baxter, Clintec Benelux NV, Brussels, Belgium. 
† Intralipid 20%, Fresenius Kabi BV, ‘s Hertogenbosch, the Netherlands.
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Biochrom Ltd, Cambridge, England) in a subset of patients (intervention group n = 17, 
control group n = 14) to identify possible hyperaminoacidemia (ie, above reference 
ranges, as defined in Reference 22). We also recorded fluid intakes and medications.
Efficacy
Efficacy of early AA administration was studied by quantifying the nitrogen balance in 
both groups on postnatal days 2 and 4. Because most nitrogen leaves the body in urine, 
we collected urine during a 12-hour period on both study days. Urinary nitrogen content 
was measured with a CHN elemental analyzer (ANA 1500; Carlo Erba Strumentazione, 
Milan, Italy). By subtracting the calculated nitrogen excretion rates from the precisely 
recorded nutritional intakes, nitrogen balances could be defined under the assumption 
that 1 g of nutritional AAs equals 160 mg of nitrogen. Although 24-hour collections 
of urine are preferable, 12-hour or even 6-hour collections can be used to establish 
reasonable estimates of nitrogen excretion (17). Many investigators used 12-hour urine 
collections accordingly (8, 11, 12, 18). Finally, to express efficacy in terms of a measur-
able clinical variable, we recorded on which postnatal day infants regained their birth 
weight.
Statistics
Differences between groups were tested by Student t tests, Mann-Whitney tests, and χ2 
tests, using SPSS version 11.0 (SPSS Inc, Chicago, IL). Depending on distribution and 
type of test, values are expressed as mean ± SD, as median (min-max), or as percent-
age, respectively. Significance level was set at P < .05. However, because of multiple 
variables assessed on single samples, differences in AA concentrations were considered 
to be statistically significant at P < .01. From previous findings, we calculated that with a 
power of 0.80, group size needed to be at least 26 to detect a difference in the nitrogen 
balance of 150 mg N/(kg·d), with a standard deviation of 120 mg N/(kg·d). However, 
as we intended to study safety aspects as well, we continued to include patients for the 
full 18 months.
Results
We included 66 infants in the intervention group and 69 in the control group; all infants 
were included on the basis of intention to treat (Table II). Despite random assignment, 
infants in the intervention group were more frequently exposed to prenatal corticos-
teroids (P = .017). According to study design, the infants in the intervention group 
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received AA within 2 hours after birth (median, 1 hour, 33 minutes). Nonprotein energy 
intakes did not differ between groups, except on day 5 (68 ± 14 [intervention] vs 63 ± 
14 [control] kcal/[kg·d]; P = .033) (Figure 1).
Table II: Clinical characteristics of the infants in the intervention and control group.
Intervention Control
N (male/female) 66 (34/32) 69 (31/38)
Birth weight (g) * 1039 ± 235 989 ± 252
Gestational age (wk) * 28.4 ± 2.0 28.4 ± 1.9
SGA infants (<−2 SD) 20% 29%
CRIB score † 3 (0–13) 4 (0–14)
Apgar (5′) score † 9 (1–10) 8 (2–10)
Prenatal corticosteroids (% 0/1/2 doses) 18/18/64 39/19/42
* Values are expressed as mean ± SD.
† Values are expressed as median (min-max).
Figure 1. Total nonprotein energy intakes (parenteral and enteral) during the first postnatal week. * 
Statistically significant; P < 0.05 (Student t test).
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Safety
Results of blood gas analysis and whole blood glucose levels 12 hours after birth and 
on the second day are shown in Table III. Between postnatal days 3 and 6, there were 
no differences. BUN levels are shown in Table IV.
Table V shows individual plasma AA concentrations on the second day of life. No 
statistical differences between the two groups were found on the fourth postnatal day.
Medications, including sodium bicarbonate for metabolic acidosis, were not different 
between groups.
Efficacy
As follows from study design, nitrogen intake on the second day was higher in the 
intervention group (Figure 2). On the fourth day, intakes were similar between groups. 
Nitrogen excretion rates in the intervention group exceeded excretion rates in the 
control group on both day 2 and day 4. Furthermore, within the intervention as well 
as within the control group, rates of excretion did not change between days 2 and 
4. Consequently, nitrogen balance was higher in the intervention group on day 2 as 
compared with the control group, which had a negative nitrogen balance. On the fourth 
Table III: Blood gas analysis and whole blood glucose concentrations in the intervention and control 
groups 12 hours postnatally and on postnatal day 2.
12 h Day 2
Intervention Control Intervention Control
pH 7.33 ± 0.08 7.34 ± 0.08 7.31 ± 0.06 7.32 ± 0.07
BE (mmol/L) −4.8 ± 3.1 −3.7 ± 3.3 −5.7 ± 2.4 * −4.4 ± 2.4
Bicarbonate (mmol/L) 20.5 ± 2.6 * 21.5 ± 2.6 20.3 ± 2.5 * 21.4 ± 2.2
Glucose (mmol/L) 5.7 ± 3.2 6.1 ± 2.4 4.4 ± 1.9 * 5.3 ± 2.1
Values represented as mean ± SD and tested with Student t test.
* Statistically significant; P < 0.05.
Table IV: BUN levels in mmol/L and (mg/dL), respectively on postnatal days 2, 4, and 6.
Intervention Control
day 2 9.6 ± 2.8 (27.0 ± 7.8) * 6.0 ± 1.8 (16.7 ± 5.2)
day 4 9.4 ± 3.5 (26.4 ± 9.8) * 6.0 ± 3.3 (16.8 ± 9.2)
day 6 8.4 ± 3.8 (23.6 ± 10.7) * 6.7 ± 3.1 (18.7 ± 8.7)
Values represented as mean ± SD.
* Statistically significant; P < 0.05.
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day, nitrogen balances in both groups were positive. However, in the control group, 
the balance was more positive than in the intervention group. There was no correla-
tion between antenatal steroid administration and nitrogen excretion or balance. Fluid 
intakes were higher in the intervention group on both postnatal day 1 and day 2 due to 
the administration of AA. On all other days, fluid intakes were similar. Fluid balances, 
determined on postnatal days 2 and 4, did not differ between groups. Age to regain 
Table V: Plasma AA concentrations in the intervention and control groups on postnatal day 2 (mean 
± SD) and reference values from healthy term breast-fed infants on postnatal day 11 (reference 22). 
Values are expressed as µmol/L.
Intervention Control Reference range
Leucine ** 148 ± 43 47 ± 13 86 – 171
Isoleucine ** 88 ± 33 18 ± 8 31 – 124
Valine ** 281 ± 90 88 ± 23 56 – 154
Threonine 125 ± 48 123 ± 63 67 – 143
Lysine ** 345 ± 144 98 ± 34 65 – 282
Histidine ** 103 ± 53 52 ± 19 25 – 126
Methionine * 42 ± 22 22 ± 9 21 – 55
Phenylalanine ** 92 ± 31 58 ± 10 35 – 112
Cystine 31 ± 79 22 ± 12 33 – 55
Tyrosine 83 ± 43 122 ± 57 48 – 122
Alanine ** 265 ± 139 124 ± 67 137 – 362
Proline * 175 ± 89 102 ± 56
Serine * 186 ± 89 116 ± 49 79 – 227
Glycine 282 ± 161 205 ± 70 66 – 432
Arginine ** 70 ± 19 29 ± 12 11 – 88
Glutamine 507 ± 296 313 ± 153 147 – 623
Glutamate ** 64 ± 34 22 ± 9 76 – 551
Asparagine 39 ± 23 49 ± 24 16 – 21
Aspartate * 35 ± 16 18 ± 14 5 – 46
Taurine 150 ± 87 106 ± 112
Citrulline 54 ± 67 31 ± 44 20 – 84
Ornithine ** 180 ± 87 40 ± 13 39 – 386
OH-Proline 47 ± 26 46 ± 28
* Statistically significant; P < 0.01.
** Statistically significant; P < 0.001.
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birth weight was not statistically different; newborn infants in the intervention group 
regained their birth weight at day 8 (2-25) (median and [min-max]), those in the 
control group at day 10 (2-26) (P = 0.286).
Discussion
The currently available AA solutions are safe and can be administered to premature 
infants during the first few days of life (8-14). We performed the largest study to date 
confirming the safety and anabolic effects of early AA administration beginning within 
2 hours after birth. Unlike most other reports, we did find modestly altered blood gas 
values and increased BUN levels with early AA administration. This could be due to the 
inclusion of fewer infants in other studies, with subsequently the possibility of reduced 
statistical power. Another explanation could be the early start of AA administration in 
our study, which was within 2 hours instead of 24 hours after birth (10, 12) or even 
later (14). In addition, others used a smaller amount of AAs (≤1.5 g/[kg·d]) (8, 13) or 
included infants with higher birth weights (13, 14).
We found that early AA administration normalized the plasma concentrations of most 
AAs and that nitrogen balance was positive on day 2 of life, despite a relatively low 
energy intake (<40 kcal/[kg·d]). BUN levels were higher in the intervention group, 
which theoretically could have increased urine production but in fact did not (data not 
shown). Besides, fluid balance is usually tightly controlled in NICUs. To our knowledge, 
no other potential side effects of increased BUN levels have been reported. The higher 
BUN levels are a reflection of a higher AA oxidation rate. This resembles the intrauterine 
situation in which AA seem to be a key nutrient for energy generation (5, 7) and where 
Figure 2. Nitrogen balances on postnatal days 2 and 4. * Statistically significant; P < 0.05 (Student t 
test). Hatched bars represent the intervention group; open bars the control group.
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BUN reference values for human umbilical cord blood are 7.5 to 14.3 mmol/L (21.0 to 
40.1 mg/dL) (19).
In conjunction with the higher BUN levels, the higher amounts of excreted nitrogen in 
the intervention group also indicate a higher oxidation rate. Higher BUN levels should, 
therefore, not be interpreted as a sign of AA intolerance but rather as a reflection of 
AA oxidation, just like in utero, where the AAs are partly oxidized and partly used for 
protein synthesis.
Many of the infants in the intervention group had on average less hyperglycemia than 
did the control group, which might be explained by higher insulin concentrations trig-
gered by relatively higher plasma arginine and leucine concentrations (12, 20, 21). In 
addition to these two AAs, all essential AA levels, except for threonine and most of the 
nonessential AA concentrations, were higher and were within the reference range in the 
intervention group on the second day of life (22). Although the plasma concentrations 
of valine, lysine, and asparagine exceeded the reference values measured postnatally 
in term breast-fed infants, the former two AA concentrations fit within intrauterine 
reference ranges (23).
The nitrogen balance was calculated by subtracting nitrogen excretion from nitrogen 
intake. However, nitrogen excretion is often modestly underestimated, because of in-
complete urine collections and stool, breath, and skin losses, which are not accounted 
for (24). Furthermore, although nitrogen balance measurements demonstrate net loss 
or accretion of protein, they do not reveal the mechanisms underlying these conditions. 
Previously performed studies using stable isotope techniques showed that premature 
infants supplied with AAs have an improved balance, which is due to increased protein 
synthesis, while proteolysis is not suppressed (8, 12, 14, 25).
Inasmuch as premature infants cannot survive without growth, we conclude that the 
administration of AAs soon after birth with the aim of promoting anabolism is safe and 
effective.
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Abstract
We previously showed that, in prematurely born infants, an anabolic state without 
metabolic acidosis can be achieved upon intravenous amino acid (AA) administration 
in the immediate postnatal phase, despite a low energy intake. We hypothesized that 
the anabolic state resulted from an increased protein synthesis and not a decreased 
proteolysis. Furthermore, we hypothesized that the energy needed for the higher pro-
tein synthesis rate would be derived from an increased glucose oxidation. To test our 
hypotheses, 32 ventilated premature infants (<1500 g) received intravenously either 
solely glucose or glucose and 2.4 g AAs/(kg·d) immediately postnatally. On postna-
tal day 2, each group received primed continuous infusions of either [1-13C]leucine 
or [U-13C6]glucose. 
13CO2 enrichments in expiratory air and plasma [1-
13C]α-KICA (as 
an intracellular leucine precursor) and [U-13C6]glucose enrichments were measured by 
mass spectrometry techniques. The AA administration resulted in an increased incorpo-
ration of leucine into body protein and a higher leucine oxidation rate, whereas leucine 
release from proteolysis was not affected. Glucose oxidation rate did not increase upon 
AA administration. In conclusion, the anabolic state resulting from AA administration 
in the immediate postnatal period resulted from increased protein synthesis and not 
decreased proteolysis. The energy needed for the additional protein synthesis was not 
derived from an increased glucose oxidation.
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Introduction
A series of studies on AA administration in premature infants within the first few post-
natal days show a positive effect on nitrogen retention or plasma AA concentrations 
starting immediately after birth (1, 2), within or at 24 h postnatally (3-5), or later (6). 
In our latest study regarding early AA administration, we administered 2.4 g AAs/(kg·d) 
to one half of 136 VLBW infants within 2 h postnatally (1). This resulted in a positive 
nitrogen balance and converted plasma AA concentrations to levels fitting reference 
ranges. Furthermore, there were no major metabolic disturbances in comparison with 
the group receiving solely glucose.
However, nitrogen balance calculations provide no information on how a particular 
nutritional status was reached. An anabolic state can arise from increased protein syn-
thesis, decreased protein breakdown, or a combination of both. To clarify the mechanism 
by which an anabolic state is reached in VLBW infants, we conducted in a first trial a 
stable isotope study using L-[1-13C]leucine. We speculated that the anabolic state would 
have been induced by an increased protein synthesis, a phenomenon also observed in 
other studies, none of which, however, started AA supplementation immediately after 
birth (3, 5, 6). Furthermore, by collecting 13CO2 we were able to quantify leucine oxida-
tion rates.
We hypothesized that the extra energy required for protein synthesis would be de-
rived from additional glucose oxidation. Therefore, we studied glucose metabolism in 
a second trial in which infants also received either solely glucose or glucose and AAs, 
using D-[U-13C6]glucose as a tracer.
Methods
The included infants were a subset of the patients included earlier by Te Braake et al. 
(1) in a study determining safety and efficacy of high-dose early AA administration. 
The present study was designed as a randomized open trial and was performed in the 
neonatal intensive care unit of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, 
the Netherlands. The study was investigator initiated with no funding from industry. 
The protocol was approved by the Erasmus MC Medical Ethical Committee and parental 
consent was obtained before the study.
Patients
Thirty-two prematurely born infants with a birth weight <1500 g, who were born in the 
Erasmus MC – Sophia Children’s Hospital, were mechanically ventilated, had an arterial 
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catheter, and were expected to be completely dependent on parenteral nutrition for 
the first 2 d of life, were directly after birth randomly assigned to receive either i) only 
glucose during the first 2 d (control group, n = 16) or ii) glucose and 2.4 g of protein/
(kg·d) as AAs (Primene 10%, Baxter, Clintec Benelux N.V., Brussels, Belgium) within 2 
h postnatally (intervention group, n = 16).
AA and/or glucose solutions were constantly infused without interruptions during the 
study. Lipids and/or (minimal) enteral feedings were not administered until after the 
study period. Exclusion criteria were known congenital abnormalities, chromosome de-
fects, and metabolic, endocrine, renal, or hepatic disorders. For all infants, we recorded 
birth weight, gestational age, SD scores for weight (7), antenatal corticosteroid usage, 
and severity of illness at entry of the study by means of Apgar and CRIB scores (8). We 
also assessed blood gases and nitrogen balances as described previously (1).
The control and intervention groups were each subdivided into two cohorts (n = 8 
each). In one cohort (A), we studied the effects of early AA administration on leucine 
kinetics on postnatal d 2. In the other cohort (B), we determined glucose kinetics on d 
2 upon early AA administration.
Stable isotopes
[13C]Sodium bicarbonate (NaH13CO3) (99% enriched), L-[1-
13C]leucine (99% enriched), 
and D-[U-13C6]glucose (99% enriched) were purchased from Cambridge Isotope Labo-
ratories (Andover, MA) and were diluted with a 0.9% saline solution by the hospital’s 
pharmacy after which it was tested on sterility and pyrogenicity. For the leucine study, the 
bicarbonate pool was initially enriched with a primed (10 µmol/kg) continuous NaH13CO3 
infusion (10 µmol/(kg·h)). After 2 h, the infusion was replaced by a primed (15 µmol/
kg) continuous L-[1-13C]leucine infusion (15 µmol/(kg·h)) lasting for 5 h (Figure 1A).
In the second cohort (the glucose study), the bicarbonate pool was also enriched with 
a primed (15 µmol/kg) continuous NaH13CO3 infusion (15 µmol/(kg·h)). After 2 h, the 
infusion was replaced by a primed (10 µmol/kg) continuous D-[U-13C6]glucose infusion 
(5 µmol/(kg·h)) lasting for 6 h (Figure 1B).
Tracers were infused with a Perfusor fm infusion pump (B|Braun Medical B.V., Oss, the 
Netherlands) along the same infusion route as the parenterally administered nutrients.
Measurement of isotopic enrichments in plasma
Arterial blood samples were drawn once before the isotope infusions (baseline) and 
twice during the last hour of the leucine or glucose tracer infusion. After collection, the 
samples were put on melting ice immediately and centrifuged, after which the plasma 
was aspired and stored at -80°C until analysis.
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Within the cell, leucine is reversibly transaminated to its keto-analogue, α-KICA. The 
plasma enrichment of [1-13C]α-KICA is very close to intracellular [1-13C]leucine enrich-
ment. Measurement of the enrichment of [1-13C]α-KICA after L-[1-13C]leucine infusion 
will, therefore, reflect both the site of incorporation of leucine in protein and the site for 
the irreversible decarboxylation of [1-13C]α-KICA to isovaleryl-CoA and 13CO2 (9, 10). 
Samples (50 µL plasma) were treated and analyzed as previously described (2, 11). The 
13C enrichment of α-KICA was, after derivatization to butyldimethyl-silylquinoxalinol de-
rivatives, determined with a Carlo Erba GC8000 gas chromatograph coupled to a Fisons 
MD800 mass spectrometer (Interscience BV, Breda, the Netherlands) by measuring the 
intensity of the 259 and 260 fragments in electron impact ionization mode.
The [U-13C6]glucose enrichment of the glucose aldonitril pentaacetate derivatives was 
monitored, after combustion to carbon dioxide at mass 44 for 12CO2 and mass 45 for 
13CO2, using a gas chromatograph combustion isotope ratio mass spectrometer (GC-C-
IRMS) (Delta XP, Thermo Electron, Bremen, Germany).
Oxidation measurements
To determine the fractions of leucine or glucose oxidized, approximately 15 mL of ex-
piratory air was collected in a vacuum tube at the outlet of the ventilator: two times 
in duplicate before the isotope infusion (baseline), five times in duplicate during the 
last hour of the NaH13CO3 infusion, and five times in duplicate during the last hour 
of the labeled leucine or glucose infusion. We assumed an equal CO2 production and 
retention during the sodium bicarbonate and leucine or sodium bicarbonate and glucose 
infusions. Breath samples were analyzed for 13CO2 enrichment on an isotope ratio mass 
spectrometer (IRMS) (ABCA, Europe Scientific, Van Loenen Instruments, Leiden, the 
Netherlands).
Figure 1. Study design. Infants in both the control and intervention group were subjected to either the 
labeled leucine (A) or the labeled glucose (B) protocol on postnatal day 2.
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Calculations
The turnover rates were calculated by measuring tracer dilution in plasma at steady 
state with standard isotope equations, as previously described for leucine (2) and glu-
cose (12) studies.
Statistics
Based on previous findings from our study group, we calculated that with an α of 0.05, 
a power of 0.80, and a difference in protein synthesis rate of 1.4 g/(kg·d) with an SD of 
0.8, group size in the leucine study needed to be at least six to detect a difference (6). 
A statistically detectable increment in glucose oxidation of 2.0 mg/(kg·min) with an SD 
of 1.0 would also require six infants in each group to be studied (12). However, both in 
the leucine and the glucose studies, we included eight infants in the intervention and 
control groups and the control groups to increase power. One-way ANOVA was used to 
detect differences between group characteristics, clinical laboratory measurements, and 
nutritional intakes between the four subgroups. Differences between intervention and 
control groups were tested by t-tests, Mann-Whitney tests, and χ2 tests, as appropriate, 
using SPSS version 11.0 (SPSS Inc., Chicago, IL). Depending on distribution and type 
of test, values are expressed as mean ± SD, as median (25th to 75th percentile), or as 
percentage, respectively. Significance level was set at p < 0.05.
Results
We included 32 infants, of whom 7 were small for gestational age (<–2 SD) (7). Patient 
characteristics are provided in Table I. Overall, the infants in the intervention group had, 
Table I: Clinical characteristics of the infants in the control and intervention groups. 
CRIB is clinical risk index for babies (8). 
Control Intervention
N (male/female) 16 (9/7) 16 (8/8)
Birth weight (kg) * 0.949 ± 0.231 0.923 ± 0.192
Gestational age (wks) * 27.4 ± 1.4 27.3 ± 1.8
SD score for weight * -0.9 ± 1.4 -1.0 ± 1.3
CRIB score ** 6 (3-9) 5 (2-7)
Apgar score (5 min) ** 8 (7-9) 9 (8-9)
Antenatal corticosteroids (0/1/2 doses) 8/6/2 2/4/10
* Values are expressed as mean ± SD. ** Values are expressed as median (25th – 75th percentile).
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by coincidence, received antenatal steroids more often than those in the control group. 
AA administration to the infants in the intervention group started within 2 h postnatally. 
The stable isotope study was started on the second postnatal day, i.e., between 20 and 
44 h after birth. Isotopic steady state in 13CO2 excretion in expiratory air was reached 
in all infants during the last hour of each infusion (Figure 2). The actual protein intakes 
at time of study were 0 ± 0 and 2.32 ± 0.08 g/(kg·d) (p < 0.001) and the nonprotein 
Figure 2. 13CO2 excretion curve during the leucine (A) and glucose (B) experiment. Enrichment is 
represented in atom percent (AP) as mean ± SD in the control (open circles) and intervention (filled 
circles) groups.
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energy intakes (solely glucose) were 34 ± 8 and 30 ± 6 kcal/(kg·d) (p = 0.10) in the 
control and intervention groups, respectively. Other relevant patient data are provided 
in Table II.
Inasmuch as we only performed a power calculation on protein synthesis and glucose 
oxidation rates, all other outcomes should be regarded as hypothesis-generating data.
Leucine kinetic data are displayed in Figure 3. Infants in the intervention group had a 
higher leucine flux, NOLD rate (indicative of protein synthesis), and oxidation rate. The 
LRP rate (indicative of protein breakdown) was not altered. Leucine balance improved 
Table 2: Study parameters on the second day of life in the control and intervention groups. Values 
depicted as mean ± SD, except for glucose concentration, i.e. median (25th – 75th percentile). 
Control Intervention
glucose intake (mg/(kg·min)) 5.9 ± 1.3 5.2 ± 1.0
glucose concentration (mmol/L) 6.1 (4.2 – 6.9) 4.6 (3.7 – 5.4)
Nitrogen balance (mg N/(kg·d)) -99 ± 42 151 ± 105 *
pH 7.31 ± 0.05 7.30 ± 0.07
Base Excess (mmol/L) -4.4 ± 1.3 -5.4 ± 2.0
Blood urea nitrogen (mmol/L) 6.2 ± 1.5 9.7 ± 2.6 *
* Statistically significant; p<0.05.
Figure 3. Leucine kinetics. Data from the [1-13C]leucine infusion protocol (A) on postnatal d 2 in infants 
in the control (open bars, n = 8) and intervention (filled bars, n = 8) groups. Bars represent mean ± SD. 
NOLD represents protein synthesis. LRP represents protein breakdown. *Statistically significant, p < 
0.05.
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significantly in the infants receiving AAs (p < 0.001). The control group had a negative 
balance, whereas the balance in the intervention group was not different from zero.
The glucose kinetic data are outlined in Figure 4. AA administration did not have any 
significant effects on glucose metabolism with regard to GPR, flux, oxidation, and NOGD 
rate.
In both groups, GPR (gluconeogenesis or glycogenolysis) was not completely inhib-
ited, despite a mean intake of 5.7 ± 1.2 mg glucose/(kg·min) during the study period. 
In the control group, 75% of the glucose flux was oxidized; in the intervention group, 
this fraction amounted to 84% (p = 0.19). The absolute amount of oxidized glucose 
did not differ significantly between groups (5.3 ± 1.3 mg/(kg·min) and 5.8 ± 1.4 mg/
(kg·min), respectively; p = 0.46).
Discussion
We found that AA administration at a relatively high dose from birth onward exerted its 
anabolic effect through increased protein synthesis and not decreased proteolysis. The 
additional energy needed was not derived from glucose, but could, at least partially, be 
derived from a concomitant increase in AA oxidation.
Most studies in premature infants, including the present, show a positive effect of 
AA administration on protein accretion caused by an increased synthesis rate (3, 5, 
6, 13) . Also, in the ovine fetus, AA administration does have a beneficial effect on 
protein accretion by increasing protein synthesis while leaving proteolysis unaltered 
Figure 4. Glucose kinetics. Data from the [U-13C6]glucose infusion protocol (B) on postnatal d 2 in infants 
in the control (open bars, n = 8) and intervention (filled bars, n = 8) groups. Bars represent mean ± SD. 
*Statistically significant, p < 0.05.
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(14). One study, however, investigating a short-term change in nutritional regimen, 
found a simultaneous decrease in proteolysis (15).
Anabolism in adults (16, 17) and healthy term infants (18, 19), unlike in preterm 
infants and ovine fetuses, is predominantly achieved by suppression of proteolysis 
instead of protein synthesis. Possibly, a new balance between protein breakdown and 
synthesis is developing during early life, explaining this observed discrepancy.
We found a positive nitrogen balance, not only in the intervention group of the 135 
infants studied earlier (1), but also in the intervention group of the leucine cohort 
in this study. However, the leucine balance was not significantly different from zero. 
Nevertheless, there is still a significant correlation between both balance methods (r2 
= 0.47, p = 0.003). This discrepancy, which we and others noted before (2, 3), might 
be explained by the relative abundance of leucine in parenteral AA solutions relative 
to the occurrence of leucine in body protein. Because the rate of protein deposition is 
controlled by the rate-limiting AA in the AA solution, all excess AAs are oxidized. Leucine 
in particular might be oxidized pro rata more than other AAs, explaining a negative 
leucine balance despite a positive nitrogen balance. On the other hand, the difference 
between the stable isotope and nitrogen balance techniques could also be partially due 
to the tendency to overestimate nitrogen retention (20).
In our study, early AA administration had hardly any effect on glucose metabolism. 
Glucose oxidation, NOGD, and GPR were unaltered. In adults, AA supplementation, 
and thus provision of gluconeogenic substrates, was found to result in an increased 
endogenous GPR (21). This contrasts with findings in premature neonates from the 
study by Poindexter et al. (13) and the present study. Like in adults, we expected to 
find a higher glucose oxidation rate for generating the energy needed for extra protein 
synthesis after AA administration. Poindexter et al. (13), using indirect calorimetry, also 
suggested a higher glucose oxidation rate after AAs had been introduced, inasmuch as 
the respiratory quotient increased. Surprisingly, we could not detect any difference in 
oxidation rate. The source of the needed extra energy remains, therefore, speculative. 
Nevertheless, the higher leucine oxidation rate might reflect that AA oxidation itself 
might provide some of the energy needed. Other sources of energy could include fatty 
acids and ketone bodies.
In conclusion, AA administration to premature infants from birth onward reverses the 
catabolic state that is otherwise obtained when AAs are withheld. Particularly protein 
synthesis rate especially is increased. The additional energy needed for this process is 
not derived from glucose oxidation.
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Abstract
Recently, we demonstrated that parenteral administration of amino acids (AAs) im-
mediately after birth to premature infants is safe and results in a positive nitrogen 
balance and increased whole body protein synthesis. However, we did not determine 
organ specific effects. Albumin, produced by the liver, is an important protein, but its 
concentration is often low in premature neonates during the first few days after birth.
Our objective was to test the hypothesis that the albumin fractional and absolute 
synthesis rates would increase upon AA administration following birth, even at low 
nonprotein energy intake.
Ventilated premature infants (<1500 g) received from birth onwards either solely 
glucose (control group, n=7) or glucose and 2.4 g AAs/(kg⋅d) (intervention group, n=8). 
On postnatal day 2, all received a primed continuous infusion of [1-13C]leucine and mass 
spectrometry techniques were used to determine the incorporation of the leucine into 
albumin. Results are expressed as median (25th – 75th pctl).
Albumin fractional synthesis rates in the intervention group were significantly higher 
than those in the control group (22.9 (17.6 – 28.0) %/d versus 12.6 (11.0 – 19.4) %/d; 
p=0.029). Likewise, the absolute synthesis rates in the intervention group were higher 
than those in the control group (228 (187 – 289) mg/(kg⋅d) versus 168 (118 – 203) 
mg/(kg⋅d); p=0.030).
In conclusion, AA administration increases albumin synthesis rates in premature 
neonates even at low energy intake.
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Introduction
Plasma albumin concentration is a routinely measured parameter on the neonatal 
intensive care unit (NICU) and is often found to be low in ill premature infants (1, 2). 
Albumin, produced by the liver, has several important roles in neonatal physiology (3, 
4). It is the main preserver of the colloid osmotic pressure in plasma (~75%), functions 
as an anticoagulant, and is an important binding transporter of certain metabolites, 
e.g. bilirubin, free fatty acids, and drugs. Moreover, albumin is an important antioxidant 
because it has specific binding sites for copper ions and a free sulfhydryl group, which 
can scavenge harmful reactive oxygen species (5). The free sulfhydryl group can also 
bind nitric oxide (NO) forming a reservoir for this regulator of vascular tonus (6). Fur-
thermore, albumin synthesis probably provides for temporary ‘storage’ of amino acids 
(AAs) so as to spare them from oxidation (7-9). Albumin consists of 585 AA and is the 
most abundant plasma protein (2), though about 60% of the total albumin pool is in the 
interstitial space (10).
Albumin metabolism has been studied mainly in healthy adults and in adults during 
various stages of renal or liver disease. Most studies in neonates are limited to static 
properties such as concentrations. Measuring albumin synthesis rates would no doubt 
provide more insight into the dynamics of albumin metabolism and its response to 
nutrition, for example.
Several authors have described relations between low albumin concentration and 
morbidity and mortality rates among premature neonates (11, 12). In the fasting state, 
albumin concentrations drop 2 to 3 g/L in the first 24 hours after birth (2). As there is 
discussion about benefit and safety of exogenous albumin infusions in premature infants 
(13-15), stimulating endogenous synthesis via adequate nutritional support might be 
an attractive alternative.
The latter strategy requires good knowledge of premature infants’ protein metabolism. 
Studies using stable isotopes have provided insights into anabolism and catabolism in 
general (16-18). For one, AA administration directly after birth stimulates whole body 
protein synthesis rather than depressing protein breakdown (16). Studying whole body 
metabolism is limited, however, in that it only provides information on the average of all 
metabolic processes in the body rather than organ specific changes.
It is unknown whether exogenous administration of AAs also stimulates organ specific 
protein synthesis, e.g. albumin, in premature infants. Albumin synthesis can be quanti-
fied by measuring the incorporation rate of a stable isotope labeled AA into plasma 
albumin.
We report a study in preterm infants aimed at determining the effect of AA adminis-
tration starting directly after birth on subsequent albumin synthesis. We hypothesized 
that AAs added to glucose would increase albumin synthesis rates.
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Methods
Subjects
Patients were eligible for the study when they were in the Sophia Children’s Hospital, 
had a birth weight less than 1500 g, and required an arterial line for clinical purposes. 
Exclusion criteria were known congenital abnormalities, chromosome defects, and 
metabolic, endocrine, renal or hepatic disorders. The cohort here described is the same 
as in an earlier study on whole body leucine metabolism (16). It is a subset of infants 
participating in a large trial on AA administration in the immediate postnatal phase (19) 
and were selected if born within a predefined time span during that study and if they 
met current inclusion criteria. The study was designed as a randomized open trial and 
was performed in the NICU of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, 
the Netherlands. The study was investigator initiated with no funding from industry. The 
protocol was approved by the Erasmus MC Medical Ethical Review Board and written 
parental consent was obtained prior to study.
Experimental design
Within two hours after birth, infants were randomly assigned to receive during the 
first two postnatal days either glucose only (control group, n=7) or glucose and 2.4 g 
protein/(kg⋅d) as AAs (Primene 10%, Baxter, Clintec Benelux NV, Brussels, Belgium) 
(intervention group, n=8).
The administration of glucose solution or the AA and glucose solution was accomplished 
by continuous infusion. Lipids and/or (minimal) enteral feedings were withheld during 
the study period. None of the infants received exogenous albumin infusions during the 
study. The hospital’s pharmacy dissolved L-[1-13C]leucine (99% enriched, Cambridge 
Isotope Laboratories, Andover, MA, USA) in normal saline and tested it for sterility and 
pyrogenicity. We infused it (prime: 15 µmol/kg; continuous 15 µmol/(kg·h)) with the 
use of an infusion pump (Perfusor fm; B Braun Medical B.V., Oss, the Netherlands).
Arterial blood samples (0.4 mL) were drawn before the isotope infusion (baseline) and 
after 4 and 5 hours of infusion. The blood samples were immediately put on melting ice 
and centrifuged (2500 × g, 10 min, 4 °C), after which the plasma was stored at -80°C 
until analysis.
Analytic methods
To isolate plasma albumin (20), samples (50 µL plasma) were deproteinized and washed 
with 10% trichloroacetic acid. To the protein pellet, water and 1% trichloroacetic acid in 
96% ethanol were added and the sample was centrifuged. The supernatant was mixed 
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with 26.8% ammonium sulfate to precipitate albumin overnight. The pellet was then 
dissolved in 0.3 mol NaOH/L and again precipitated with 2 mol perchloric acid/L. After 
washing, the new pellet was redissolved in 6 mol HCl/L and hydrolyzed for 24 hours, 
after which the acid was dried under nitrogen and dissolved in water. AAs were isolated 
using a cation-exchange column, derivatized with ethylchloroformate, and enrichment 
was measured on a gas chromatograph – combustion – isotope ratio mass spectrometer 
(GC-C-IRMS; Delta XP; Thermo Electron, Bremen, Germany) as previously described 
(21).
As albumin precursor we used the plasma [1-13C]α-ketoisocaproate (α-KIC, the keto 
acid of leucine) enrichment at plateau which had already been measured as described 
in our preceding paper (16). While liver amino acyl-tRNA enrichment forms the true 
precursor, its use requires tissue biopsies and technically demanding assays. Neverthe-
less, α-KIC enrichment adequately represents leucyl-tRNA enrichment and is valuable in 
this type of research (22, 23). Plasma albumin concentrations were routinely measured 
on a Roche Hitachi 912 (Roche Diagnostics, Basel, Switzerland).
Calculations
The FSR reflects the fraction of the intravascular albumin pool that is renewed per unit 
of time (%/d) and can be calculated as follows:
100%
tt
24
E
EE
FSR
12KIC
alb,tleualb,tleu 12 



 
where Eleu–alb is the enrichment in mole percent excess (MPE) of incorporated leucine in 
albumin at t2 and t1 (at 5 and 4 hours after the start of infusion, respectively) and EKIC is 
the mean enrichment in MPE of the precursor, i.e. plasma α-KIC, at both time points.
The ASR represents the absolute amount of albumin that is produced per unit of time 
(mg/(kg⋅d)), and can be calculated as follows:
      -1alb blAS R F S R C vol   (1   Ht) weight
where Calb is the plasma albumin concentration in g/L, volbl is the infant’s total blood 
volume in mL (assumed to be 75 mL/kg body weight (24, 25)), (1 – Ht) is the fraction 
of blood which is plasma, and weight is birth weight in kg.
We also calculated the contribution (%) of albumin ASR in relation to whole body 
protein synthesis in percentage based on previously measured leucine turnover data 
according to the following formula:
AS R 0.104
contribution 100%
NOLD 131.2 24 0.001
×= ×
× × ×
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where NOLD is the non oxidative leucine disposal representing whole body protein 
synthesis in µmol/(kg⋅h) and which was calculated in an earlier study by our group 
(16). Furthermore, 0.104 represents the fraction of leucine residues in albumin on a 
weight basis, 131.2 is the mole mass of leucine, and 24 and 0.001 convert to day and 
milligram, respectively.
Statistics
Calculations were made with Microsoft Office – Excel software (version 2000; Microsoft 
Corp, Redmond, WA, USA) and all statistical tests were done with GraphPad Prism 
software (version 4.0; GraphPad, San Diego, CA, USA). Differences between control and 
intervention groups were tested by Mann-Whitney tests unless otherwise stated. Values 
are expressed as median (25th – 75th percentile) or as mean (SD) and significance level 
was set at p<0.05.
Results
Fifteen premature infants were studied: seven in the control group and eight in the 
intervention group. All infants were mechanically ventilated. Birth weight, gestational 
age, SD score for weight (26), sex, disease scores (Apgar and CRIB (27)), and antena-
tal steroid use to improve lung maturation were not significantly different between the 
groups (Table I). The birth weights of one infant in the control group and two infants 
in the intervention group were below 2 SD when related to gestational age. Blood gas 
parameters, whole blood glucose concentrations, and non-protein calorie intakes (only 
glucose) on the second day of life did not differ between groups (Table II). Because the 
Table I: Clinical characteristics1 2
Control Intervention
No. (male/female) 7 (2/5) 8 (4/4)
Weight (kg) 0.960 (0.780 – 1.080) 0.940 (0.770 – 1.070)
Gestational age (wks) 26.7 (26.4 – 28.9) 26.9 (26.6 – 29.9)
SD-score for weight (26) (SD) -0.53 (-0.75 – -0.11) -1.14 (-2.22 – -0.19)
CRIB score (27) 5 (2 – 8) 3 (1.3 – 5)
5 min Apgar score 9 (7 – 9) 9 (8 – 10)
Antenatal corticosteroids (no/yes) (2/5) (1/7)
1 Values expressed as median (25th – 75th percentile).
2 There were no statistical differences between groups (Mann-Whitney).
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intervention group received AAs, blood urea nitrogen concentration and the nitrogen 
balance were higher in these infants.
The mean leucine enrichments in albumin in the control group were 0.243 (0.12) and 
0.289 (0.13) mole percent excess (MPE) after 4 and 5 hours of infusion, respectively. 
In the intervention group, enrichments were 0.201 (0.050) and 0.249 (0.050) MPE. The 
mean α-KIC enrichments at plateau were 7.16 (0.56) MPE in the control group and 5.18 
(0.46) MPE in the intervention group.
The intervention group showed significantly higher albumin FSR than the control 
group (Figure 1). Albumin plasma concentration was measured in 5 out of 7 infants in 
the control group and in 6 out of 8 infants in the intervention group; it was significantly 
Table II: Study parameters on the second day of life1
Control (n=7) Intervention (n=8)
Non-protein energy intake (kcal/(kg⋅d)) 33.3 (30.7 – 36.9) 31.2 (26.0 – 32.9)
AA intake (g/(kg⋅d))2 0 2.3 (2.3 – 2.4)
Nitrogen balance (mg N/(kg⋅d))2 -110 (-133 – -56) 156 (116 – 226)
Blood urea nitrogen (mmol/L) 2 6.2 (5.8 – 6.9) 9.7 (7.6 – 11.8)
Glucose concentration (mmol/L) 4.9 (3.1 – 6.2) 3.9 (3.0 – 4.8)
pH 7.31 (7.25 – 7.33) 7.31 (7.28 – 7.38)
Base excess (mmol/L) -5 (-6 – -4) -6 (-6 – -3)
1 Values expressed as median (25th – 75th percentile).
2 Statistically significant, p<0.05 (Mann-Whitney).
Figure 1. Albumin FSR in %/d in the control (n=7) and intervention (n=8) groups. Presented as median 
and interquartile range. The intervention group had a significant higher albumin FSR (p=0.029; Mann-
Whitney).
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higher in the intervention group (Figure 2). The calculated ASR was also higher in the 
intervention group (Figure 3).
Because we had also obtained leucine turnover data (16), we were able to compare 
the albumin ASR with the whole body protein synthesis rate. The median NOLD (a 
measure of protein synthesis) increased from 130 (122 – 172) to 185 (169 – 203) µmol 
leucine/(kg⋅h) upon AA administration (p=0.030). The proportion of leucine used for 
Figure 2. Albumin plasma concentration in g/L in the control (n=5) and intervention (n=6) groups. 
Presented as median and interquartile range. The intervention group had a significant higher plasma 
albumin concentration (p=0.030; Mann-Whitney).
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Figure 3. Albumin ASR in mg/(kg⋅d) in the control (n=5) and intervention (n=6) groups. Presented as 
median and interquartile range. The intervention group had a significant higher albumin ASR (p=0.030; 
Mann-Whitney).
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albumin synthesis relative to whole-body NOLD was approximately 4% in both subject 
groups (Figure 4), which implies that AA administration stimulates albumin synthesis 
and whole-body protein synthesis at a similar rate.
Discussion
Our data are consistent with the assumption that parenteral AA administration in pre-
mature neonates stimulates albumin synthesis. For on the second day of life albumin 
FSR, ASR, and plasma albumin concentrations were significantly higher in premature 
infants who had received parenteral AAs from birth onwards.
Plasma albumin concentration is governed by four processes; changes in synthesis, 
degradation, intravascular space, and transcapillary escape. In the present study, we 
were not able to measure the three latter processes, but we speculate that increased 
synthesis is the primary cause for the higher plasma concentration noted.
Alternatively, a rise in albumin synthesis does not automatically coincide with a paral-
lel rise in concentration. Albumin is a negative acute-phase protein, which means that 
its concentration will fall during an inflammatory event. Such falls have been described 
during cholecystitis (28), hemodialysis (29), cancer (30), and in head trauma patients 
(31), despite a coinciding rise in albumin FSR. Cytokines might be responsible for this 
paradoxical increase (29, 32). The lowered concentrations probably result from con-
comitant increases in catabolic rate and transcapillary escape.
Figure 4. Contribution in % of albumin synthesis (ASR) to whole body protein synthesis (NOLD) in the 
control (n=5) and intervention (n=8) groups. Presented as median and interquartile range. There was no 
difference between groups (Mann-Whitney).
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The albumin FSR in healthy adults is about 6-8 %/d (8, 9, 32-36) and seems unre-
sponsive to intravenous nutrients (37). Meals, however, will increase albumin synthesis 
(7, 8, 38). A recent study showed that the protein portion of meals is the effective 
component responsible for this increase (9). Adults suffering from chronic hemodialy-
sis were also found sensitive to nutrition, as albumin FSR improved after intradialytic 
administered nutrition (20). Overall, it seems that albumin synthesis in adults is more 
responsive to gastro-intestinal nutritional uptake than intravenous nutrition, as was also 
demonstrated after surgery (39) and in rats (40). Our findings in human neonates and 
findings in young piglets suggest that other metabolic mechanisms might be regulating 
albumin synthesis in younger individuals, whose albumin synthesis is also responsive to 
parenteral nutrition (41, 42).
Consistent with the general finding that younger individuals have higher metabolic 
rates than adults, higher albumin FSR, ranging from 15 to 20 %/d, have been found in 
12-month-old infants (43, 44). Bunt et al found values of 14 %/d in fasted premature 
infants with a gestational age of 28 weeks on the first postnatal day (21). Yudkoff et al 
calculated a mean albumin FSR of 12%/d in parenterally fed, premature neonates with 
appropriate size-for-gestational-age (which was 28 weeks), after approximately 1 week 
of life (45). These figures correspond well with the synthesis rates we observed in this 
study. Yet, unlike Bunt et al (21), we did not find clear correlations between the FSR 
and SD-scores for weight related to gestational age. This might have been the result of 
reduced power in our study or interference by our nutritional intervention.
We calculated that albumin constitutes about 4% of all proteins synthesized in 
the body. Besides, in healthy humans and rats, it was estimated that of all proteins 
synthesized in the liver, including those not excreted but produced for intrahepatic 
maintenance, 15% was albumin (34, 38). Combining these figures reveals that the liver 
would contribute over 25% to whole body protein synthesis. Normal hepatic functioning 
would therefore seem to be of vital importance.
Apart from all the important roles of albumin mentioned in the introduction, increas-
ing the albumin FSR is also interesting from a nutritional point of view. A higher albumin 
ASR makes premature infants less vulnerable to catabolic insults through the temporary 
storage of AAs in albumin, preventing excess AAs from being oxidized. Later, during low 
protein intake or increased demands, body protein stores can be spared albeit at the 
cost of albumin breakdown, thereby releasing free AAs.
Especially in the first 24 hours after premature birth, nonprotein energy intake is usu-
ally very low (~30-35 kcal/(kg⋅d)) and less than desirable. Recently, energy expenditure 
was measured in premature infants during the first few days after life having compa-
rable caloric intakes (46). Energy expenditure was estimated at 29-35 kcal/(kg⋅d), thus 
leaving, at an intake of approximately 30 kcal/(kg⋅d), no calories for net energy storage 
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or growth. As a consequence, AA efficacy in terms of anabolism is usually moderate in 
that a large fraction will be irreversibly oxidized (16).
Carbohydrate intake is limited due to potential hyperglycemia and fluid restrictions. 
Parenteral lipids are also often withheld in the first 24 hours after premature birth, as 
neonatologists fear pulmonary disease, hypertriacylglycerolemia, and high free fatty 
acid concentrations leading to competition with bilirubin binding on albumin (47).
Albumin is the main transport vehicle for fatty acids to and from the tissues according 
to metabolic demands. Notwithstanding the fact that lipids in blood are largely in the 
form of triacylglycerols, the turnover and utilization of fatty acids bound to albumin 
is high, thus making fatty acids an important contributor to lipid metabolism (48). 
Providing AAs directly after birth increases albumin synthesis and subsequent binding 
capacities, which theoretically improve the tolerance of intravenous lipids. Apart from 
the advantage of delivering essential fatty acids, the high caloric content makes im-
mediate commencement of lipids after birth beneficial by improving the energy balance. 
This in turn might stimulate protein synthesis even more.
A recent study with high dose AAs and lipids initiated immediately after birth, demon-
strated high anabolic use of AAs, probably due to a higher energy availability (49). We 
would like to speculate that an increased albumin synthesis rate was at least partially 
responsible for the increased tolerance of lipids. More clinical trials are required to 
determine efficacy and safety of starting parenteral administration of lipids together 
with high dose AAs immediately after birth to premature infants.
A potential limitation of this study is that the hydrolyzed protein pellet may not have 
contained pure albumin. Jacobs et al earlier reported that after simple ethanol extraction 
about 8% of proteins were contaminants (50). By adding ammonium sulfate we aimed 
to eliminate some of the contaminating proteins (20). However, even if purification of 
the protein pellet was still incomplete, the vast majority must have been albumin.
In conclusion, we have shown that introducing AAs immediately after birth to pre-
mature neonates stimulates not only whole body protein synthesis, but also albumin 
synthesis. This finding might have important implications in view of the vital roles of al-
bumin, among which serving as an antioxidant and binding bilirubin and free fatty acids. 
Improving albumin synthesis might, therefore, have major impact on later outcome.
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Introduction
Since the early 1970s the availability of parenteral nutrition has enabled the admin-
istration of lipids and amino acids (AAs) to preterm infants in the neonatal phase. 
However, administration of first generation AA solutions resulted in serious metabolic 
disturbances, impeding their use in preterm infants, and impacting on nutritional regi-
mens up till the present day.
A large number of studies has been conducted since, on what is described as aggres-
sive early AA administration. In 2005 in this journal, we published data of a randomized 
clinical trial, in which we investigated safety and efficacy aspects of early AA administra-
tion in a group of 135 very low birth weight (VLBW) infants (1). Our results reconfirmed 
metabolic safety of early AA administration while a catabolic state was converted into 
anabolism.
Although it is known that postnatal growth restriction may have long-lasting adverse 
effects, such as short stature and compromised neurodevelopmental outcome (2, 3), 
evidence for improved long-term outcome as a result of early AA administration is 
limited (3). In fact, recently some concerns have been raised about safety and efficacy 
of early aggressive AA administration (4, 5).
In this short report, we describe neurodevelopmental outcome at two years of age in 
our previous cohort of 135 very low birth weight infants. We hypothesized that early AA 
administration at a dose of 2.4 g/(kg·d) does not negatively affect neurologic develop-
ment.
Methods
In our initial study we included 66 infants with a birth weight below 1500 g who received 
AAs (2.4 g/(kg·d)) directly from birth onwards (intervention group), and 69 infants 
who received glucose only for the first two days of life (control group) (1). Of the 135 
infants,132 had a gestational age less than 32 weeks and were therefore considered 
eligible for neurodevelopmental follow-up and anthropometric assessment at 2 years 
of corrected age. All parents gave written permission to use the follow-up data for 
statistical analyses.
The prevalence of handicaps, such as cerebral palsy, visual and hearing impairments 
was documented. The Mental Developmental Index (MDI) was assessed by the Bayley 
Scales of Infant Development (BSID), 2nd edition. Furthermore, anthropometric data 
were recorded.
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Data were analyzed using the statistical package SPSS version 15.0 (SPSS Inc, 
Chicago, USA). Data are described as mean ± SD. A p-value <0.05 was considered 
statistically significant.
Results
In the initial study we included 132 infants with a gestational age less than 32 weeks. 
Eighteen infants died in the neonatal phase (ten infants in the control group; eight 
infants in the intervention group). Twelve of the 114 surviving children were lost to 
follow-up (eight in the intervention and four in the control group). Consequently, in 102 
children (89%, 47 in the intervention and 55 in the control group), follow up data were 
available. There were no differences in demographic data except for a trend towards 
more males in the intervention and more females in the control group (Fisher’s Exact 
Test p=0.05).
Table I shows neurologic outcome at two years of age. No differences were observed 
between the intervention and control group as a whole. In boys but not in girls, the 
Table I: Neurodevelopmental outcome at two years of age in the intervention and control groups.
Any handicap *
Intervention (n=47) Control (n=55) Total (n=102)
Absent 42 (89%) 44 (80%) 86
Present 5 (11%) 11 (20%) 16
Neurology
- 
- 
Normal 38 (81%) 47 (86%) 85
Mildly abnormal 8 (17%) 4 (7%) 12
Cerebral palsy 1 (2%) 4 (7%) 5
Visual deficiency
- 
Absent 47 (100%) 53 (96%) 100
Present 0 (0%) 2 (4%) 2
Hearing deficiency Absent 46 (98%) 54 (98%) 100
Present 1 (2%) 1 (2%) 2
Mental Developmental Index 
(BSDI II )**
 
mdi >85 34 (76%) 36 (77%) 70
mdi 85-70 8 (18%) 6 (13%) 14
mdi <70 3 (7%) 5 (11%) 8
* visual/hearing deficiency, cerebral palsy or MDI<70
** visual/hearing deficiency and cerebral palsy (n=8) and refusals (n=2) excluded
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percentage of handicaps (e.g. visual/hearing deficiency, cerebral palsy and/or MDI<70) 
in the intervention versus the control group tended to be lower (p=0,10) (Figure 1). 
Table II shows anthropometric data of the included children. Again, no differences were 
observed between groups.
Discussion
In the past decade, a large number of studies have been published on early AA admin-
istration and its beneficial effects in terms of promoting anabolism in the early postnatal 
phase. Recently we demonstrated additional benefits upon early AA administration 
in terms of increased albumin and glutathione synthesis rates (6, 7). In our study, 
Figure 1: percentage of handicaps* in males and females in the intervention versus the control group. 
Light gray represents the absence and dark gray represents the presence of handicaps.
*visual/hearing deficiency, cerebral palsy and/or MDI<70
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Figure 1: percentage of handicaps* in males and females in the intervention versus the control 
group. Light gray represents the absence and dark gray represents the presence of handicaps. 
*visual/hearing deficiency, cerebral palsy and/or MDI<70 
 
Table II: Weight and head circumference at two years of age in the intervention and control groups.
Intervention (n=44) Control (n=50)
Weight (kg) 11.6 ± 1.83 11.4 ± 1.68
Head circumference (cm) 48.5 ± 1.85 48.2 ± 1.74
ΔSD weight 2 y minus birth (SD) 0.122 ± 3.10 -0.112 ± 1.39
ΔSD head circumference 2 y minus birth (SD) -0.04 ± 1.58 -0.30 ± 1.52
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however, there was no benefit in terms of growth at two years of age. In most stud-
ies anthropometric measurements improve at discharge after early AA administration 
whereas this effect is disappearing at 18 months of age (8-11). Whether rapid postnatal 
weight gain has a favorable effect on neurodevelopment is yet unclear. Still, favorable 
effects of a rapid postnatal weight-gain on neurodevelopment, as assessed by BSID, 
were found in a study of Latal-Hajnal et al. in 219 VLBW infants (12). No differences, 
however, were found in a study including over 1000 extremely low birth weight infants, 
conducted by Poindexter et al. at 18 months corrected age (8).
In this exploratory study we demonstrate that providing 2.4 g AAs/(kg·d) seems safe 
with respect to the handicap rate at two years of age. On the other hand, no appar-
ent clinical benefits were demonstrated as yet although there are multiple theoretical 
advantages of being anabolic during the early postnatal phase.
Neurodevelopmental outcome in preterm infants is dependent on multiple variables, 
of which one is nutrition. We therefore do not suggest that deprivation of two days of 
AAs will have a major clinically measurable effect on long-term outcome.
While girls tended to have a more favorable neurodevelopmental outcome than boys, 
the handicap rate in boys in the intervention group tended to be lower in the control 
than in the intervention group. The number of studied children is relatively small, how-
ever and the age of 24 months is too young for definitive conclusions regarding more 
neurocognitive outcome at a later age.
In conclusion, in this exploratory study, no negative effects of early AA administration 
on postnatal growth and handicap rate were found. In our opinion, this should strongly 
encourage a nutritional strategy including early AA administration, seeing its beneficial 
effects in the early neonatal phase. Long term follow-up is mandatory to define whether 
early aggressive AA administration will have a a, perhaps subtle, effect on long-term, 
neurocognitive outcome.
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Abstract
A novel analytical method using liquid chromatography coupled to isotope ratio mass 
spectrometry (LC-IRMS) was developed for measuring glutathione (GSH) fractional 
synthesis rate (FSR) in neonates after infusion of [1-13C]glycine as a tracer. After 
transformation of GSH into GSSG, its dimeric form, the intra erythrocytic concentra-
tion and 13C- isotopic enrichment of GSH were determined using 200 µL of blood. The 
results showed that using LC-IRMS, the concentration (range of µmol/mL) was reliably 
measured using norvaline as internal standard with precision better than 0.1 µmol/mL. 
In addition, the 13C-isotopic enrichment measured in the same run gave reliable values 
with excellent precision (with sd lower than 0.3 ‰) and accuracy (measured between 0 
and 2 APE). The inter assay repeatability of δ13C of norvaline used as internal standard 
with in vivo samples was assessed at -26.07 ± 0.28 ‰ with CV at 1.1%. The FSR 
calculated either with GSH or GSSG showed similar results with slightly higher values 
for GSSG (41.6 ± 4.7 and 46.5 ± 4.4 respectively). The slighly lower FSR of GSH is 
probably due to interfering compounds in the biological matrix. Successfully used in a 
clinical study, this rapid and reliable method opens up a variety of kinetic studies with 
relatively low administration of tracer infusates, reducing the total cost of the study 
design. Besides, the small volume of blood needed enables studies even in extremely 
small subjects, such as premature infants as reported in this study.
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Introduction
Glutathione (GSH), or L-γ-glutamyl-L-cysteinyl-glycine, is a tripeptide consisting of 
glutamate, cysteine and glycine. It is synthesized de novo in nearly all mammalian cells. 
Glutathione is present in its monomeric, reduced form (GSH), and its dimeric, oxidized 
form (GSSG). GSH can be oxidized non-enzymatically in vivo to GSSG by electrophilic 
substances, such as reactive oxygen species. GSH is regenerated from GSSG by the 
enzyme glutathione reductase. Glutathione is synthesized de novo in two steps: first, 
catalyzed by glutamylcysteine synthetase, a glutamate is covalently bound to a cysteine 
residue – the rate-limiting step  – and second, catalyzed by glutathione synthetase, gly-
cine is added (1, 2). Nearly all mammalian cells produce glutathione in large amounts, 
reaching intracellular concentrations within the millimolar range (3). In plasma, it is 
mainly present in its oxidized form such as GSSG or protein GSH disulfite, at levels in 
the micromolar range (2-20 μmol/L). The monomeric form, GSH, is actively involved in 
many cellular functions, both as a cofactor for several enzymes and independently (4), 
it acts as antioxidant by scavenging radicals or xenobiotics (such as acetaminophen), 
plays a role in the synthesis of leukotrienes and prostaglandins, in cell proliferations, 
and is involved in many diseases, such as cancer.
It is quite common to measure GSSG concentration in addition to GSH in biological 
samples, as the GSH/GSSG ratio is considered to be inversely related to oxidative stress 
(5). To this aim, high performance liquid chromatography methods using electrochemi-
cal (6) or fluorometric detection (7) or nuclear magnetic resonance have been reported 
(8). However, concentration of GSSG in erythrocytes is very low and possible artifacts 
in sample handling might produce misleading results (9).
Glutathione metabolism has been studied in a variety of species and experimental 
settings (10-14). The emphasis, though, was largely on concentration measurements, 
with a minor role for measuring kinetics using stable isotope tracers. GSH has a 
rapid turnover, as reflected by its high fractional synthesis rate (FSR). In healthy adult 
volunteers, FSR is approximately 65-83 %/d (14, 15), which implies that all GSH is 
completely renewed in 36 hours. Therefore, static parameters such as concentration 
may not necessarily provide useful information if kinetic data are absent. Quantifying 
utilization and synthesis rates of GSH provides a dynamic insight into its metabolism 
under pathological conditions such as oxidative stress or in response to interventions. 
Nowadays, gas chromatography-mass spectrometry (GC-MS) techniques are used to 
study FSR with stable isotope tracers (13C or 2H incorporated into glycine or cysteine 
respectively) and a primed continuous infusion for 6 to 8 hours (16). In addition, FSR 
determination in erythrocytes requires suitable methods to measure both low level of 
isotopic enrichment in GSH and in its precursor. Typically, this information is obtained 
with the incorporation rate of tracer into GSH, using erythrocyte-free glycine or cysteine 
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as the precursor pool from which erythrocytes synthesize GSH (11). Studies in neo-
nates are limited by the small amounts of blood that can be sampled. Then, only small 
amounts of stable isotope tracer can be used, lest metabolism is disturbed.
Although gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-
IRMS) is now the state of the art to measure low isotopic enrichment in tracer studies, 
the targeted compound needs to be volatile after derivatization (17). Thus, for isotopic 
analyses of a tripeptide such as glutathione, the GC introduction might be quite labori-
ous. Then, liquid chromatography coupled to isotope ratio mass spectrometry (LC-IRMS) 
needs to be envisaged as well. The LC-IRMS device became commercially available in 
2004 (18) after several other experiments to link LC to IRMS over the last decade 
(19-23). This coupling is based on a wet chemical oxidation process and presents few 
analytical constraints interfering with LC method development. Typically the LC flow 
rate must be lower than 600 µL/min, organic buffers are prohibited and the presence 
of salt and low pH facilitates CO2 extraction. Various LC separations were developed 
using LC-IRMS for targeted compounds such as underivatized amino acids (18, 24, 25) 
and underivatised carbohydrates (26) but none specifically for routine isotopic analysis 
and concentration measurement in the frame of metabolic studies. Our aim here was 
to develop a novel and robust method to determine low GSH 13C-isotopic enrichments 
requiring a low volume of blood, for use in e.g. premature infants. Therefore, a new 
method was designed based on stable isotope technique using liquid chromatography 
coupled to isotope ratio mass spectrometry (LC-IRMS). To this purpose, we assessed 
GSH kinetics through the measurement of the 13C-isotopic enrichment and the concen-
tration of GSSG entity chemically produced by oxidation of GSH.
Experimental Section
Chemicals and reagents
GSH, glycine, norvaline, norleucine and phosphoric acid (85 % v/v) were purchased 
from Sigma (St Louis, USA). Sodium peroxodisulfate (p.A.) was purchased from Fluka 
(Buchs, Switzerland). Perchloric acid (70% v/v), potassium hydroxide and sodium hy-
droxide were purchased from Merck (Darmstadt, Germany). The [1-13C]-labelled glycine 
was purchased from Cambridge Isotope Laboratories (Buchem, Netherlands). [1,2-13C, 
15N]GSH was a gift from Cambridge Isotope Laboratory, CIL (Andover, MA, USA). Sterile 
water was purchased from Baxter BV (Utrecht, Netherlands) dithiothreitol (DTT) and 
N-ethylmaleimide (NEM) were purchased from Sigma (St Louis, USA).
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Instruments
Experiments were carried out on a Delta XP (Thermo Electron, Bremen, Germany). The 
IRMS was operated at an accelerating voltage of 5 kV. The ion source was held at a pres-
sure of 3.0 x 10-6 Torr, and ions generated by electron impact at 70 eV. Three faraday 
cup detectors monitored simultaneously and continuously the CO2
+· signals for the three 
major ions at m/z 44 (12CO2), m/z 45 (
13CO2 and 
12C17O16O) and m/z 46 (12C18O16O). The 
dynamic range of the instrument is between 0.2 and 50 V. The CO2 working reference 
gas (Linde, quality 5.3, Hoekloos, Schiedam, Netherlands) was calibrated with known 
reference gasses (Messer Griesheim, Krefeld, Germany) against δ 13CVPDB (Vienna Pee 
Dee Belemnite, VPDB). In order to increase filament lifetime, the oxygen signal (m/z 
32) produced by oxidant reagent should not exceed 20 V measured on the first faraday 
cup (resistor 300 MΩ).
An LC-Isolink® interface (Thermo Electron, Bremen, Germany) was coupled to the 
Delta XP with slight modifications. The mixing “Tee” was replaced by a “Tee” with a 
smaller dead volume (Bester BV, Amstelveen, Netherlands) and the stainless steel 
connections for the reagents and acid were replaced by “No-Ox” material (1/8‘’ x 1.5 
mm). A degasser (Alltech, Breda, Netherlands) was placed between the solvent bottles 
and the pumps to remove traces of air in the eluents. “No-Ox” material was used to 
prevent re-gassing of solvents. The temperature of the interface reactor was set at 
99.9 °C. PEEK® tubing was used for connections between the auto sampler the LC 
column and the interface. In addition, the reagent bottles were degassed with helium 
during analysis. To avoid crystallization of reagents the pump heads of the oxidant and 
acid pumps were rinsed with water several times a day. A filter of 0.2 µm (Vici, Bester 
BV, Netherlands) was placed before the mixing chamber of the interface to avoid any 
blockage of particles in the system.
The LC-IRMS interface was coupled to an LC system consisting of two Knauer pumps 
(Berlin, Germany) and a Midas auto sampler (Spark, Emmen, Netherlands) and con-
trolled by Sparklink software (version 3.10, service pack 2, Spark). Figure 1 shows a 
schematic view of the system used for the analysis of glutathione.
The isotopic enrichment of 13C-glycine in human erythrocytes was measured on the 
same Thermo Finnigan Delta-XP isotope ratio MS coupled online with a trace gas chro-
matograph (Thermo Electron, Bremen, Germany) and a combustion interface type III 
(Thermo Finnigan, Bremen, Germany) equipped with a CTC PAL auto sampler (CTC, 
Zwingen, Switzerland). After separation using a capillary GC column VF1701, 30 m x 
0,25 mm ID and 0,5 µm film thickness (Varian B.V. Middelburg, Netherlands), deriva-
tised amino acids were combusted online at 940°C and introduced as CO2 into IRMS ion 
source, where the C13/C12 ratio was measured.
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Isotopic calibration and isotopic measurement
CO2 reference gas was introduced at regular intervals at the beginning of each run for 
20 s at a level of 3.0 ± 0.2 V on cup one (resistor 300 MΩ) and used for calibration.
The 13C/12C abundance ratio was expressed as δ 13C values calibrated against the 
international standard. The delta notation is defined as δ 13C sample = [(Rs / Rst) – 1] × 
1000, where Rs is the ratio of 
13C in the sample and Rst is the ratio of the international 
standard used. The result of this calculation is a relative δ calibrated against the inter-
national standard.
Atom % was calculated as: 
  
   





11000/13   C1
11000/13100
D
D
R
CR
Atom % =, where R is the ratio of (13C/12C) of International Standard of Pee Dee Be-
lemnite, R=0.0112372.
Atom % Excess (APE) is defined as Atom % (background) minus Atom % (sample).
APE can be transferred to Mol % Excess (MPE) using the next formula:
MPE = 



+
100
100
x
APE
APE
Clinical study design
The study design was approved by the Erasmus MC Medical Ethical Review Board 
Committee and informed parental consent was obtained prior to the study. The study 
Figure 1. Schematic overview of LC-IR Mass Spectrometer device.
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population consisted of very low birth weight infants (birth weight <1500 g) admitted 
to the neonatal intensive care unit. A primed (40 µmol/kg) continuous infusion of 1-13C 
labelled glycine (20 µmol/(kg·h)) was administered intravenously for 6 hours. Blood 
samples were taken after respectively 4, 5 and 6 hours (steady state). Portions of 400 
µL freshly drawn EDTA blood were centrifuged at 900 x G for 10 min at 4 °C. The upper 
layer was discarded and the lower layer containing primarily erythrocytes and other 
cells was reconstituted to the original volume with distilled water and stored at -80 °C 
until further analysis.
Glutathione determination
Before analysis erythrocytes were disrupted by freezing and thawing (27). Then 40 
µL of a mixture of 1.53 µmol/mL norleucine and 8.54 µmol/mL norvaline was added 
as internal standard and the samples were deproteinized by adding 200 µl of 6 % 
g/v perchloric acid, left for 10 min on ice and finally centrifuged at 10’000 G for 20 
min. The supernatant was transferred in a new tube and the pH was adjusted to 8 - 9 
with approximately 20 µL of 4 M KOH. Excess of perchloric acid was precipitated and 
removed by centrifugation at 10’000 G for 10 min. 100 µL of 0.5M NaHPO4 was added 
to maintain pH 9. The supernatant was filtered through 0.2 µm Nylon membrane filters 
(Nylon, Alltech, Breda, Netherlands). Then, 150 µL was transferred in a sample vial and 
20 µL was injected for analysis of both GSH concentration and 13C- isotopic enrichment 
by LC-IRMS. The remaining supernatant was used for analysis of both concentration and 
13C- isotopic enrichment of glycine by GC-C-IRMS.
Glycine determination
Aliquots of 200 µl of the remaining supernant were poured on a 1 mL AG50 W-X8, H+ 
cat-ion exchange column (Biorad, Richmond, Virginia, USA). Columns were washed 
thoroughly with 5 mL water to remove non amino acid contaminants. Amino acids were 
eluted with 3 mL 6 M NH4OH and dried under nitrogen at 50°C. Then, the dried residue 
containing glycine among other amino acids was converted to its N-ethoxycarbonylethyl 
ester derivative (28, 29). Finally aliquots of 1 µL of the chloroform suspension con-
taining amino acid derivatives were introduced into the GC-C-IRMS system described 
previously.
Analytical LC-IRMS conditions
Samples were introduced using a Midas auto sampler (Spark) and analysed with a 
linear high-pressure gradient (as reported in Figure 1). Glutathione analyses (concen-
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tration and isotopic enrichment) were performed on a Sielc primesep 100 mixed mode 
column (250 × 3.2 mm, 5 µm), (Aurora Borealis, Schoonebeek, Netherlands) at room 
temperature, (24 ± 2) °C. The LC flow rate was 500 µL/min. The LC gradient was 
linearly increased from 4% to 40 % 1 molar H3PO4 (pH 2.2) in 15 min, followed by a 
linear increase to 80 % 1 molar H3PO4 (pH 2.2) in 5 min and held for 8 min. Sodium 
peroxodisulfate 0.84 mol/L in sterile water was used as oxidation solution. Acid reagent 
was prepared as 1.5 M phosphoric acid solution in sterile water. The flow rate of the acid 
and oxidant reagents in the LC interface was 30 µL/min each.
Calculations and data evaluation
The incorporation of labelled glycine in glutathione was determined by measurement 
of the 13C enrichment of glutathione in erythrocytes. The rate of incorporation of tracer 
is a reflection of the fractional synthesis rate (FSR) of glutathione and was calculated 
according to the equation described below (equation 1):
100%24h
E
E slope
FSR
C]glycine-[1
C]GSSG[1
13
t4,5,6
13
××= −
13C isotopic enrichment of GSSG was measured by LC-IRMS. Slope E[1-13C]GSSGt4,5,6 rep-
resents the increase / hour in isotopic enrichment of GSSG between 4 and 6 hours of 
infusion, expressed in Molar Percent Excess (MPE). E[1-13C]glycine represents the isotopic 
enrichment of intra-erythrocitic glycine, the precursor, in MPE at steady state.
Results & Discussion
In this study, a novel LC-IRMS method was developed to separate underivatised amino 
acids, underivatised GSH and GSSG with a phosphoric acid gradient condition in 2000 
sec (33 min) as illustrated in Figure 1. In order to obtain better chromatographic resolu-
tion between GSH and amino acids eluted near GSH peak (Pro and Cys), helium flow in 
the separation unit was increased (from 1 to 2 mL/min) to reduce peak width (from 85 
sec to 60 sec). This modification affected the overall sensitivity of the analyses without 
compromising GSH isotopic and concentration analyses in blood erythrocytes.
Transformation of GSH into GSSG and its separation in LC-IRMS
Reducing agents such as dithiothreitol (DTT) or N-ethylmaleimide (NEM) are normally 
used to reduce GSSG entity present in low amounts in blood or to prevent oxidation 
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immediately after sampling, respectively. However, these reagents evoked disturbing 
peaks when analyzing them with LC-IRMS (very abundant peaks at the beginning of 
chromatogram causing elevated baseline background). Moreover, GSH is very suscep-
tible to oxidation, which necessitates strict sample collection and storage protocols. A 
recent paper indeed reported the artifactual oxidation of GSH after sample treatment 
with different deproteinizing agents and subsequent alkalinisation (30). We found that 
GSH is completely oxidized as early as after 4 hours at room temperature at pH 8-9. In 
addition, the area where GSH elutes in the chromatogram was not totally free of other 
co-eluting compounds (as illustrated in Figure 2), which increases the risk of incorrect 
measurements (either concentration or isotopic enrichment). Therefore, to avoid the 
problematic baseline separation of GSH, all GSH was completely oxidized and measured 
as GSSG. The complete transformation of GSH into GSSG was performed in 4 hours and 
monitored with the disappearance of GSH peak by LC-IRMS (as illustrated in Figures 
3a and 3b). GSSG was eluting in a part of the chromatogram free of other co-eluting 
compounds as shown in Figure 3b. 13C-isotopic enrichment as well as concentration of 
the total GSH pool was then reliably measured in this condition.
Measurement of concentration of GSSG
The concentration of the tracee is an important parameter in any metabolic study. 
Therefore, two internal standards (I.S.) (norvaline and norleucine) were added and 
eluted closely to the GSH and GSSG peaks, respectively. This spiking of I.S. allowed 
Figure 2. LC-IRMS chromatogram of a 0.25 mmol hydrolysate amino acid standard mixed with 0.5 mmol 
glutathione standard solution at low pH.
!
Figure 2 
 
!
Figure 3a 
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to obtain the GSH and GSSG ratios versus I.S. and thus to assess GSH and GSSG 
concentrations in blood. Five standard solutions of GSSG (using GSSG over I.S. area 
plotted against the µmol/mL of GSSG injected) were measured between 0.2 to 2 mg/
mL. A linear relationship was obtained and gave y = 1.4506 x + 0.008. The regression 
coefficient (r2) was calculated at 0.998 (Figure 4). The area of GSSG measured was 
between 17.7 ± 0.25 V.s to 191 ± 1.6 V.s. Table I shows GSSG concentrations in blood 
measured with only 200 µL of samples for four premature neonates. The concentra-
tion of GSSG measured through different days and showed good reproducibility (CV 
of 12.3 %, when measured as duplicates). The mean value (0.54 ± 0.07 µmol/mL) 
Figure 3a. LC-IRMS chromatogram of glutathione analysis in erythrocytes of human blood at pH 4-5.
!
Figure 2 
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Figure 3a 
 Figure 3b. LC-IRMS chromatogram of glutathione analysis in erythrocytes of human blood as its oxidized 
form GSSG (pH 8-9).
!
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of GSSG equivalent to the concentration of GSH was consistent with values reported 
in the literature (31). These findings show that LC-IRMS can analyze concentration of 
metabolites in blood with good precision (better than 0.1 µmol/mL) and a detection 
range of 0.1-5 µmol/mL.
Figure 4. Calibration curve for measurement of glutathione concentration in human blood erythrocytes.
!
Figure 3b 
 
 
Figure 4 
!
 
Hoofdstuk 7 
 
Table I. Concentration and 13C- isotopic enrichments of GSSG in 4 different neonates 
CV (%) = sd / mean x 100
Time (hour) Level (µmol/mL) of GSSG sd (n=2) δ 13C (‰) of 
GSSG
sd (n=2)
neonate A 4H 0.55 0.06 5.48 0.68
5H 0.58 0.001 8.54 0.55
6H 0.61 0.004 13.51 0.64
neonate B 4H 0.61 0.02 -0.70 0.03
5H 0.45 0.001 4.23 0.30
6H 0.52 0.003 7.86 0.18
neonate C 4H 0.49 0.02 10.86 0.03
5H 0.45 0.0003 15.61 0.44
6H 0.44 0.003 22.81 0.04
neonate D 4H 0.53 0.02 -2.22 0.75
5H 0.60 0.02 3.67 0.15
6H 0.59 0.02 8.51 0.33
Mean 0.54
sd 0.07
CV (%) 12.3
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Repeatability and accuracy of isotopic measurement
As illustrated in Figure 5, the intra-assay repeatability assessed with norvaline mea-
sured with three different blood samples from the same neonate showed a sd measured 
at -25.95 ± 0.20 ‰ and a CV calculated at 0.8 % (n=6). The inter-assay repeatability 
measured over different days was measured at -26.07 ± 0.35 ‰ (n = 24). The repro-
ducibility (CV) was calculated at 1.3 %. For each neonate, the δ 13C values of norvaline 
are very close. These values were in the same range as obtained with standard injection 
of I.S showing excellent isotopic precision as well as reproducibility of isotopic measure-
ment at natural abundance.
Accuracy of isotopic measurement was assessed using standard calibration curve 
performed with various amounts of 13C labelled GSH added to a fixed amount of natural 
GSH. By plotting measured APE versus theoretical APE between 0 and 2.5 APE (or 
δ 13C values between -8.7 to 170.5 ‰), the curve was linear and a slope of 1.0124 
was found (Figure 6). This shows that no isotopic fractionation occurred in the sample 
preparation and the analysis. The regression coefficient (r2) was calculated at 1.000, 
showing excellent linearity.
Fractional synthesis rate (FSR) of glutathione
Blood samples were taken at regular intervals (4h, 5h and 6h) when erythrocyte [1-13C 
] glycine levels were in steady state (according to results obtained by GC-C-IRMS and 
not shown). Figures 7a and 7b show a linear rise in time in both GSH APE and GSSG 
Figure 5. Variation of δ 13C (‰) of norvaline added as internal standard and spiked in blood erythrocyte 
for 4 different neonates. Blood was collected at three time points and corresponding values are shown. 
Each point corresponds to duplicate injections.
 
Figure 5 
 
 
Figure 6 
 
91
C
h
a
p
te
r 
6
APE. FSR of GSH and GSSG were calculated from these measurements using equation 
1 reported before. Values for four patients are reported in Table II.
It follows that the glutathione pool of these patients was renewed approximately 
every two days. The calculated FSR slightly, but acceptably, differs for either of the 
forms of glutathione. In all cases the FSR for GSH is slightly lower than for GSSH. FSR 
of GSH was 41.6 ± 4.7 with a reproducibility (CV) calculated at 11.2 % and FSR of 
GSSG was 46.5 ± 4.4 with a reproducibility (CV) calculated at 9.6 % (n = 8). A possible 
explanation for the lower FSR for GSH is dilution of another co eluting (non amino 
Figure 6. Calibration curve for measurement of [7-13C]-glutathione enrichment in human blood 
erythrocytes using [1,2-13C- 15N] glutathione.
 
Figure 5 
 
 
Figure 6 
 
Figure 7a. Graph of the increase of enriched GSH of a subject expressed in APE / hour.
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acid) compound. For this reason, and also because the concentration is more precisely 
determined when measured as a single GSSG peak, we decided to measure GSSG, the 
oxidized form of GSH.
Figure 7b. Graph of the increase of enriched GSSG of the same subject as shown in figure 7a expressed in 
APE / hour.
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Table II. Comparison of the fractional synthetis rates (FSR) of GSH and GSSG in four different subjects; 
GSH, GSSG and glycine analyses were carried out in duplicate.
Sample Compound Precursor MPE
In steady state
Slope 
APE %/ Hour   
Slope 
MPE %/ Hour
FSR %/day
Neonate 1 GSH 3.90 0.0815 0.075358 46.36
GSSG 3.90 0.0880 0.080882 49.77
neonate 2 GSH 2.93 0.0578 0.054642 44.76
GSSG 2.93 0.0656 0.061562 50.43
neonate 3 GSH 3.66 0.0627 0.059001 38.70
GSSG 3.66 0.0736 0.068554 44.97
neonate 4 GSH 3.53 0.057 0.053926 36.66
GSSG 3.53 0.0641 0.060239 40.95
GSH Mean 41.6 Sd 4.7
GSSG Mean 46.5 Sd 4.4
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Conclusion
This novel LC-IRMS method for measuring kinetics of glutathione using its oxidized form 
(GSSG) showed to be a powerful tool in metabolic studies in neonates. Only little pre-
purification was necessary and the analyses reported here were fully automated. The 
measurements of both concentration and 13C isotopic enrichment gave excellent results 
with only 200 µL of blood required, which is extremely important factor in neonatal 
studies. GSSG concentrations were found to be in agreement with results reported in 
literature. The precision and accuracy of isotopic enrichment at natural abundance and 
at higher isotopic enrichment gave excellent results showing no isotopic fractionation 
and an isotopic precision for GSSG in blood assessed at 0.3 ‰.
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Abstract
Synthesis of glutathione (GSH), the major intracellular antioxidant, might be impaired 
in preterm infants due to lack of substrate availability when introduction of amino ac-
ids is delayed. This might exacerbate oxidative stress. We hypothesized that preterm 
infants compensate for oxidative stress by upregulating GSH synthesis upon adequate 
nutritional support on postnatal day 6. We conducted an observational longitudinal 
stable isotope study in extremely low birth weight infants (birth weight <1000 g) to 
determine erythrocyte GSH concentrations and synthesis rates on postnatal day 2 
(when receiving glucose only), and on postnatal day 6, (when receiving both parenteral 
and enteral nutrition). In plasma, we measured advanced oxidized protein products and 
dityrosine as markers of oxidative stress. Ten infants completed the study. Concentra-
tions of advanced oxidized protein products and dityrosine increased significantly from 
day 2 towards day 6. In contrast, despite an overall increase of plasma precursor amino 
acids on day 6, GSH synthesis rates and concentrations were not different between day 
2 and 6. In conclusion, these data indicate ongoing oxidative stress on postnatal day 
6, which is not compensated for by an increased GSH synthesis rate, despite increased 
substrate availability.
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Introduction
The transition from fetal to neonatal life coincides with many physiological changes. 
These are generally adequately anticipated for, e.g. by up- or downregulation of specific 
metabolites. Antioxidant production or its precursors are upregulated just prior to term 
birth in animals (1, 2) and humans (3), most likely to prevent excessive formation of so-
called reactive oxygen species (ROS) such as free radicals, which evolve intracellularly 
upon exposure to the hyperoxic extrauterine environment relative to the intrauterine 
environment. Preterm infants, however, show high levels of protein and lipid (per)oxida-
tion, whereas antioxidant concentrations remain low (4-6). Additional oxygen require-
ments in preterm infants add up to the formation of ROS evoking cellular damage, 
designated as oxidative stress. An association between oxidative stress and diseases 
such as bronchopulmonary dysplasia, retinopathy of prematurity, and periventricular 
leukomalacia has been established earlier (7-10).
Besides numerous metabolic functions, glutathione (GSH) is the body’s main intra-
cellular antioxidant. Its enzymatic synthesis depends primarily on the presence of its 
constituent amino acids (AAs): glutamate, cysteine, and glycine. Ironically, significant 
amounts of (parenteral) nutrition are often withheld in preterm infants during the direct 
postnatal period, because of feared intolerance and possibly because nutrition is con-
sidered less a priority directly after birth. Nevertheless, a delay in providing adequate 
nutrition, in particular AAs, might impede GSH synthesis and exacerbate oxidative 
stress. The more so, since cysteine and possibly glycine have been proposed to be 
essential for the preterm infant (11, 12). Indeed, several studies indicated failure in 
preterm infants to increase GSH concentrations in the first week of life when nutritional 
support was inadequate (4, 13). Low concentrations might be due to compromised 
synthesis because of lack of substrates, increased utilization as a result of oxidative 
stress, or a combination of both.
We hypothesized that preterm infants experience oxidative stress in the first days of 
life which is compensated for by an increased GSH synthesis rate upon full nutritional 
support on postnatal day 6. To test this hypothesis, we quantified markers of oxidative 
stress and GSH synthesis rates in preterm infants while receiving glucose only (postna-
tal day 2) and, subsequently, while receiving full nutritional support (postnatal day 6), 
provided both parenterally and enterally.
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Methods
Study and Subjects
The study was designed as an observational study performed in the neonatal intensive 
care unit of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands. 
The protocol was approved by the Erasmus MC Medical Ethical Committee and informed 
written parental consent was obtained prior to study. This study took place prior to 
a change in nutritional policy which now includes AA administration starting directly 
following birth.
Subjects were extremely low birth weight (ELBW) infants (birth weight <1000 g). 
Each infant was administered parenterally stable isotopes for six hours on two separate 
occasions: on postnatal day 2 (study d2), and postnatal day 6 (study d6). Until comple-
tion of study d2, infants received glucose only. Afterwards, AAs (Primene 10%, Baxter, 
Clintec Benelux NV, Brussels, Belgium) and lipids (Intralipid 20%, Fresenius Kabi BV, ‘s 
Hertogenbosch, The Netherlands) were administered as separate solutions. Upon pro-
gression of enteral feeding, parenteral glucose intake was decreased. After the third day 
of life, all nutrient intakes, including enteral feedings were left to the discretion of the 
attending neonatologist. We excluded infants that received transfusions of erythrocytes 
during or within 12 hours prior to the study, or had known congenital abnormalities, 
chromosome defects, and metabolic, endocrine, renal, or hepatic disorders.
Study Endpoints
Primary endpoint of the study was antioxidant defense in response to increased nutri-
tional intakes, as reflected by GSH synthesis rates in the first week of life and presence 
of oxidative stress. Secondary endpoint was capacity for GSH synthesis in early preterm 
life, for which we studied impact of gestational age, birth weight, or birth weight Z-score 
on GSH synthesis rates on the second day of life.
Stable Isotope Infusion Protocol
 [1-13C]Glycine (99% enriched, sterility and pyrogenicity tested) was purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA). On postnatal day 2 and 6 at 10:00 
a.m., neonates received a primed (40 μmol/kg) continuous (20 μmol/(kg·h)) infusion of 
[1-13C]glycine for 6 hours. Blood samples (400 µL each) were drawn from an indwelling 
arterial catheter after 4, 5, and 6 hours and collected in EDTA containing microtainers. 
Subsequently, samples were treated as described previously (14). Plasma and cell frac-
tions were stored at -80°C until further analysis.
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Glutathione Synthesis Rates and Precursor Amino Acid 
Concentrations
We measured GSH as total GSH, i.e. GSH + oxidized glutathione (GSSG), with a new 
technique using liquid chromatography isotope ratio mass spectrometry, described 
previously (14). For the analysis of 13C- isotopic enrichment of glycine, we used gas 
chromatography – combustion – isotope ratio mass spectrometry, similar to an earlier 
developed method for measurement of the isotopic enrichment of threonine (15). The 
fractional synthesis rate of GSH (FSRGSH) was measured according to the product/pre-
cursor- equation:
100%24h
E
E slope
(%/d) FSR
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13
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 
where E stands for enrichment expressed as mole percent excess (MPE). The nominator 
(product) represents the hourly increase of incorporated [1-13C]glycine into GSH as 
calculated from the increase in enrichment between 4 and 6 hours of infusion. The de-
nominator (precursor) represents the intraerythrocytic free [1-13C]glycine enrichment 
at isotopic steady state. A steady state plateau was defined as an insignificant change 
with time in intraerythrocytic enrichment. Subsequently, the intravascular absolute 
synthesis rate of GSH (ASRGSH) was calculated by the following equation:
ASRGSH (mg/(kg⋅d)) = FSRGSH/100 x conc x 307 x ht x 0.075
where conc is concentration in mmol/L of packed erythrocytes, 307 is the molecular 
weight of GSH, ht is hematocrit, and 0.075 is the estimated circulating blood volume in 
a preterm neonate, expressed as L/kg.
Plasma concentrations of direct precursors of GSH (glutamate, glycine, and cysteine) 
as well as indirect precursors (glutamine, serine and methionine) were determined with 
a Biochrom 30 amino acid analyzer using ninhydrin detection. A reference range of term 
breast-fed infants is included (16).
Plasma Markers of Oxidative Stress
We measured advanced oxidized protein products (AOPP) in plasma according to the 
spectrophotometric assay described by Witko-Sarsat et al. (17). Tyrosine is oxidized to 
dityrosine in response to oxidative stress and can be considered a good endogenous 
marker. Experiments that expose protein to oxygen-free radicals have demonstrated 
the formation of dityrosine. Dityrosine has been recognized as an oxidative stress 
product of pathological response to disease or other environmental stress (18, 19). 
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Its concentration was measured according to the method described by Abdelrahum et 
al., based on liquid-liquid extraction, reversed-phase chromatography and fluorescence 
detection (20).
Statistical Analysis
Statistical analyses were performed using SPSS version 14.0 (SPSS Inc, Chicago, IL, 
USA) and GraphPad Prism version 4 (GraphPad Software, San Diego, CA, USA). Data 
are expressed as means ± SD or as medians (min – max). Differences between study 
days were determined using paired samples T-tests. A P value of <0.05 was considered 
as statistically significant. Primary outcome of the study was the ASRGSH. Based on an 
abstract (Shew S et al., Effects of cysteine on endogenous synthesis of taurine and 
glutathione by premature neonates receiving parenteral nutrition, 2000 PAS Annual 
Meeting, May 12-16, 2000, Boston, MA, USA, Abstract 1750), which showed an increase 
of 80% in ASRGSH upon AA administration, we calculated that with an α of 0.05, a power 
of 0.80 and a difference in ASRGSH of 0.22 mmol/(L∙d) with an SD of 0.06, at least 3 
infants were needed to detect a difference between day 2 and 6. We included 10 infants 
to increase power.
Results
Subjects
In total, ten neonates were enrolled in the study. Birth characteristics and clinical details 
of the infants are shown in Table I. Non protein energy intake as well as protein intake 
(values derived from AA intake) are shown in Figure 1. Infants received vitamin C 
(10-12 mg/(kg·d)) and vitamin E (1.5 mg/(kg·d)) starting upon completion of study 
d2. The standard nutritional policy of our NICU dictated AA and lipid administration 
starting at 2:00 p.m. on the second day of life. As anticipated by study protocol, infants 
received AAs and lipids only after completion of study d2. All infants received ventilatory 
Table I. Clinical characteristics. Values are expressed as means ± SD or median (min – max). 
N (m:f) 10 (8:2)
Birth weight (g) 820 ± 134
Gestational age (wks) 26 4/7 ± 1 1/7
Birth weight Z-score (SD) -1.2 ± 1.2
Apgar (5’) 7 ± 3
CRIB 5 (1-8)
103
C
h
a
p
te
r 
7
support and additional oxygen during the six day period. The target SpO2 range was set 
at 88 – 94%. According to our policy at the NICU, all infants being ventilated receive 
prophylactic antibiotics. Therefore, all infants included received antibiotics. Administra-
tion of these antibiotics were stopped after 48-72 hours whenever C-reactive protein 
concentrations were low and blood cultures were negative. During the study period, 
three infants suffered from intraventricular hemorrhage (grades II-III); eight infants 
received indomethacin treatment for patent ductus arteriosus.
Markers of Oxidative Stress
AOPP and dityrosine concentrations for individual subjects can be found in Figure 2. 
The mean concentrations of AOPP increased from day 2 towards day 6 (16.0 µmol/dL 
[SD: 6.8] vs 29.3 µmol/dL [SD: 7.6]; P < 0.001). A parallel increase was observed for 
dityrosine concentrations (4.0 mg/dL [SD: 2.8] vs 9.6 mg/dL [SD: 3.5]; P = 0.003). 
Figure 1. (A) Actual parenteral and enteral nonprotein energy intakes (kcal/(kg⋅d)); (B) protein intakes 
(g/(kg⋅d)). Values are expressed as mean ± SD.
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We also calculated the ratio between tyrosine and dityrosine to correct for differences 
in total plasma protein concentrations (data not shown). However, in contrast to most 
other AAs, plasma tyrosine concentrations were lower on postnatal day 6, indicating an 
even higher relative increase in dityrosine load as compared to day 2.
Glutathione Kinetics on Day 2 and Day 6
Increased nutritional intake accompanied by increased postnatal age was followed by 
higher plasma concentrations of precursor AAs (Table II). We found, however, no differ-
ence in mean erythrocyte GSH concentration between day 2 and day 6 (1.67 mmol/L 
Figure 2. (A) AOPP en (B) dityrosine concentrations at time of study d2 and study d6. Horizontal lines 
indicate mean and SD. *Statistically significant (p<0.05).
 
 
 
 
 
 
 
 
 
Figure 2. 
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[SD: 0.40] vs 1.57 mmol/L [SD: 0.38], respectively; P = 0.62). Free intraerythrocytic 
[1-13C]glycine enrichment reached a steady state after 4 hours of infusion. Mean en-
richment at plateau was 3.9 MPE [SD: 1.0] during study d2 and 2.8 MPE [SD: 0.6] 
during study d6. In addition, we found a linear increase in GSH-bound [1-13C]glycine 
enrichment between 4 and 6 hours of infusion.
In parallel with GSH concentrations, FSRGSH did not increase from day 2 to day 6 (43 
%/d [SD: 4] and 49 %/d [SD: 11], respectively; P = 0.16). Consequently, also ASRGSH 
was not different (6.1 mg/(kg∙d) [SD: 0.9] and 6.0 mg/(kg∙d) [SD: 1.4], respectively; 
P = 0.76). Individual results are shown in Figure 3.
Birth weight was negatively correlated with FSRGSH on postnatal day 2 (p=0.04), 
whereas gestational age was not. When birth weight was corrected for gestational age, 
i.e. birth weight Z-score, the correlation was more significant (p=0.006) (Figure 4).
Discussion
In this study, we showed that oxidative stress in ELBW infants is ongoing on day 6 
of life, as reflected by higher AOPP and dityrosine concentrations compared to day 2. 
Despite increasing nutritional intakes towards day 6, resulting in higher plasma levels 
of precursor AAs, the erythrocytes of these infants did not appear to be exhibiting a 
response to a plasma oxidant load. Indeed, erythrocyte GSH concentrations and, more 
interestingly, synthesis rates did not increase.
A possible explanation is that specific nutritional requirements, such as cyst(e)ine 
intake, might not be met. Ahola et al. reported earlier on the lack of increase in GSH 
concentration in the first week of life (13). The AA solution used in their study contained 
Table II. Plasma concentrations (µmol/L) of AAs involved in GSH synthesis with a reference range of 
term breast-fed infants (36). Since cysteine is extremely susceptible to oxidation, it was measured as its 
cystine analogue.  *p<0.05
Values are expressed as mean ± SD. 
study d2 study d6 term infants
glutamate 17 ± 6 53 ± 13* 24 – 243
glycine 187 ± 82 318 ± 135* 77 – 376
cystine 12 ± 7 23 ± 11* 35 – 69 
glutamine 308 ± 193 479 ± 132 142 – 851
serine 91 ± 43 171 ± 45* 0 – 326
methionine 11 ± 7 22 ± 6* 22 – 50
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a modest amount of cysteine, which is assumed to be the rate limiting substrate for GSH 
synthesis, especially in preterm infants. Although cysteine administration in our study 
was higher, plasma concentrations remained low and possibly accounted for the lack 
of increase in erythrocyte GSH concentrations or synthesis rates. Within this context, 
it must be noted that AAs and glucose were administered separately, as glucose is 
Figure 3. (A) Glutathione concentrations; (B) fractional synthesis rates; (C) absolute synthesis rates. 
Horizontal lines represent mean and SD. There are no differences between both study days.
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known to react with cysteine, forming its thiazolidine derivative which has decreased 
bioavailability (21).
Another cause for the lack of increase in erythrocyte GSH synthesis might be that 
requirements are highest in the direct postnatal phase, when the infant has to adapt 
to extrauterine life, and decrease subsequently. This theory is supported by a study in 
which we observed a significant rise in erythrocyte ASRGSH on postnatal day 2 in infants 
who had received AAs directly from birth onwards (22).
Still, markers of protein oxidation were higher on postnatal day 6 as compared to day 
2, as was observed earlier (5). It must be noted, however, that these protein oxidation 
markers were determined in plasma, whereas GSH kinetics were determined in eryth-
rocytes. Plasma and erythrocytes may represent two different compartments reacting 
separately. On the other hand, rising AOPP and dityrosine concentrations might reflect 
cumulative oxidative damage resulting from the transition to the relatively hyperoxic 
extrauterine life and the subsequent ventilation with additional oxygen. It might also 
be due to prolonged administration of lipid infusion. Hong et al. recently demonstrated 
increased oxidative stress as reflected by augmented malondialdehyde concentrations 
in rabbit liver following 10 days of parenteral nutrition (23).
AOPP en dityrosine are not independent markers of oxidative stress as they both 
represent protein oxidation. Unfortunately, our mode of sample collection as well as the 
limitations posed to sampling volumes in preterm infants, did not allow us to determine 
alternative markers, such as isoprostanes or non protein bound iron.
We did not find a correlation between erythrocyte GSH synthesis rates and gestational 
age. However, we did find that infants with the lowest birth weight Z-score had the 
Figure 4. Correlation between glutathione fractional synthesis rate and birth weight Z-score (R2=0.63; 
p=0.006).
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highest FSRGSH. Whether this is based on coincidence in this relatively small group, or is 
a stress related phenomenon accompanying low birth weight, these data confirm that 
capacity for GSH synthesis is not hampered in preterm infants. This is supported by data 
showing that preterm infants with gestational ages as low as 26 weeks demonstrate 
presence of GSH synthesizing enzymes independent of postnatal age (24, 25). On the 
other hand, in a study on GSH kinetics in healthy adults using the same method, we 
found an FSRGSH of 62% in erythrocytes (22), which is considerably higher than values 
reported here for preterm infants, but similar to values for adults found by Jackson et 
al. and Lyons et al., although the latter determined GSH kinetics in whole blood rather 
than erythrocytes (26, 27). GSH concentrations, however, were lower in adults resulting 
in an ASRGSH being only slightly higher than in these preterm infants. It must be noted, 
however, that adults were studied in the fasted state, which lasted the whole study 
period.
Besides de novo synthesis, availability of GSH is affected by recycling. Indeed, the 
lower FSRGSH in erythrocytes of preterm infants might be explained by their increased 
recycling capacity of reconverting GSSG into GSH as compared to adults (28, 29). 
Recycling decreases the need for de novo synthesis and could explain, therefore, the 
lower FSRGSH in preterm infants.
Gender was no criterion for inclusion. On the other hand, we must be aware that the 
resulting imbalance between boys and girls in our study might be a confounding factor, 
since sex differences have been described in GSH and cysteine metabolism (30, 31).
In this study we measured total erythrocyte GSH availability instead of individual 
concentrations of GSH and GSSG. A decreasing GSH/GSSG ratio is considered to be 
indicative of oxidative stress. GSH is, however, very susceptible to oxidation and not 
unlikely to cause artificial formation of GSSG (32). In our study, because of repeated 
blood sampling required for studying GSH kinetics, no blood was available to determine 
GSH/GSSG ratio, the more so because this would require procedures which interfere 
with our sample treatment necessary for GSH synthesis measurements.
We studied GSH metabolism in erythrocytes, which are readily available as opposed 
to other tissues. Though antioxidant concentrations or kinetics at organ specific sites 
might be considered as more clinically relevant at first sight, it has been recognized 
over the years that erythrocytes not only reflect, but also significantly contribute to 
overall antioxidant defense (33-35).
We conclude that oxidative stress is ongoing in preterm infants in the first week of 
life, as reflected by markers of oxidative stress. Despite increased substrate availability 
on day 6 as compared to day 2, GSH synthesis rates did not increase. Future research 
should be directed towards defining whether additional specific substrates, such as 
cysteine, might stimulate GSH production.
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Abstract
Availability of glutathione, the main intracellular antioxidant, is compromised in preterm 
neonates. A possible explanation is low substrate availability for synthesis, as many 
neonatologists for fear of intolerance are reluctant to administer amino acids in the 
direct postnatal period.
The objective of the study was to determine effects of amino acid administration 
directly following birth on glutathione synthesis rates and markers of oxidative stress.
Premature infants (<1500 g) received from birth onwards either dextrose (control 
group, n=10) or dextrose and amino acids (2.4 g/(kg⋅d)) (intervention group, n=10). 
On postnatal day 2, [1-13C]glycine was administered to determine glutathione frac-
tional synthesis rates (FSRGSH) and absolute synthesis rates (ASRGSH) in erythrocytes. 
In plasma, advanced oxidized protein products (AOPP) and dityrosine, both markers of 
oxidative stress, were determined. Results are expressed as mean ± SD.
The FSRGSH was not different between groups (44 ± 6 and 48 ± 9 %/d in the control and 
intervention group respectively (p=0.28)). The concentration of erythrocyte glutathione 
in the intervention group (2.28 ± 0.35 mmol/L) was higher than in the control group 
(1.73 ± 0.37) (p<0.001). The ASRGSH was 6.5 ± 1.5 and 11.3 ± 1.9 mg/(kg⋅d) in the 
control and intervention group, respectively (p<0.001).
AOPP and dityrosine concentrations were not different between groups.
In conclusion, amino acid administration directly following birth increases ASRGSH in 
preterm infants. Our data are consistent, however, with higher glutathione concentra-
tion rather than a higher FSRGSH. Greater availability of glutathione, nevertheless, did 
not bring down markers of oxidative stress.
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Introduction
Birth coincides with a sharp increase in oxygen exposure. The formation of reactive 
species, such as superoxide, hydrogen peroxide and hydroxyl radicals evokes up-
regulation of antioxidant defense systems in full term infants (1) or rabbits (2). This, 
however, does not seem to occur in preterm infants, as reflected by poor antioxidant 
availability and presence of protein and lipid (per)oxidation products (3, 4). Yet, upon 
their unanticipated transition to the extrauterine world, preterm neonates frequently 
receive, though not necessarily require, ventilation with high concentrations of oxygen. 
This may result in oxidative stress, which is strongly associated with neonatal diseases 
such as bronchopulmonary dysplasia, retinopathy of prematurity, and periventricular 
leukomalacia (5-8).
With concentrations in the millimolar range, glutathione (GSH) is the most important 
intracellular antioxidant. Most cells are equipped with the enzymatic machinery to 
synthesize this tripeptide of glutamate, cysteine and glycine. Moreover, the enzymatic 
apparatus is present and active already in the second trimester of pregnancy and thus 
not a limiting factor for GSH synthesis in preterm infants (9, 10). GSH concentrations in 
erythrocytes and plasma of preterm infants are high immediately after birth, but then 
drop to significantly lower levels than found in term neonates in the neonatal period (3, 
11). This shortage may be due to the fact that preterm infants do not tolerate significant 
amounts of enteral nutrition in the first days of life, and are, therefore, given parenteral 
nutrition, typically starting off with dextrose only. Meanwhile, however, the safety of 
early amino acid (AA) administration in preterm infants has been well established, as 
relevant studies found no abnormal blood gas values or abnormal plasma AA profiles 
(12, 13). In addition, infants’ catabolic state when receiving dextrose only was found 
to convert into an anabolic state representing true growth upon AA administration 
(14). Despite these findings, AA administration directly after birth is still not uniformly 
standard of care.
We hypothesized that GSH production in preterm infants is compromised by shortage 
of substrates, and that AA administration will stimulate GSH synthesis rates. To test 
this hypothesis, we conducted a stable isotope study designed to determine synthesis 
rates of GSH in infants receiving either dextrose only or dextrose and AAs. Degree of 
oxidative stress was established by measuring concentrations of advanced oxidized 
protein products (AOPP) (15) and dityrosine (16, 17), both markers of oxidative stress. 
We hypothesized that preterm infants receiving dextrose only would show the highest 
concentrations of AOPP and dityrosine.
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Methods
Design
The study was designed as a randomized clinical trial performed in the neonatal intensive 
care unit of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, the Netherlands. 
The study was investigator initiated with no funding from industry. The protocol was 
approved by the Erasmus MC Medical Ethical Committee and informed written parental 
consent was obtained prior to the study.
Subjects
Subjects were premature infants with a birth weight <1500 g, born in the Erasmus MC–
Sophia Children’s Hospital, had an indwelling arterial catheter for clinical purposes, and 
were expected to be completely dependent on parenteral nutrition for the first 2 days 
of life. Directly after birth they were randomly assigned to receive either only dextrose 
during the first 2 days (control group), or dextrose and AAs (2.4 g/(kg·d) (Primene 
10%, Baxter, Clintec Benelux N.V., Brussels, Belgium) within 2 hours postnatally (in-
tervention group). The composition of the AA solution can be found in Table I. AA 
and dextrose solutions were infused constantly without interruptions during the study. 
Lipids were not administered until after the study period. Exclusion criteria included 
erythrocyte transfusions within 12 hours prior to the study or during the study, known 
congenital abnormalities, chromosome defects, and metabolic, endocrine, renal, or he-
patic disorders. For all infants, we recorded birth weight, gestational age, birth weight 
Z-scores, severity of illness at entry of the study by means of Apgar and CRIB scores 
(18). We recorded plasma AA concentrations, and caloric intake and AA intake. In 
addition, we recorded fractions of inspired oxygen, blood glucose levels, and incidence 
of sepsis as evidenced by bacteremia. According to our policy at the NICU, all infants 
being ventilated receive prophylactic antibiotics. Therefore, all infants included received 
antibiotics. Administration of these antibiotics are stopped after 48-72 hours whenever 
C-reactive protein concentrations are low and blood cultures are negative.
Tracer infusion protocol and sample collection
[1-13C]Glycine (99% enriched, sterility and pyrogenicity tested) was purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA) and was dissolved in a 0.9% saline 
solution, filtered (0.2 µm) and sterilized by the hospital’s pharmacy. The final product 
was tested for identity, content, sterility and pyrogenicity.
On postnatal day 2 neonates received a primed (40 μmol/kg) continuous (20 μmol/
(kg·h)) infusion of [1-13C]glycine for 6 hours. Blood samples (400 µL each) were drawn 
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from an indwelling arterial catheter after 4, 5, and 6 hours and collected in EDTA 
containing microtainers to quantify erythrocyte free glycine enrichment, GSH-bound 
glycine enrichment, GSH concentration, plasma oxidative stress markers, and plasma 
GSH precursor AA concentrations.
Samples were immediately put on melting ice after centrifugation at 3500 x G for 10 
min at 4°C. After the plasma fraction was removed, the lower layer containing primarily 
erythrocytes was reconstituted to its original volume with ice-cold distilled water to 
disrupt cell membranes. The plasma and cell fractions were subsequently stored at 
-80°C until further analysis.
Table I. Composition of the amino acid solution Primene 10% (Baxter, Clintec Benelux N.V., Brussels, 
Belgium)
Amino acid g/L
L-Isoleucine   6.70
L-Leucine 10.00
L-Valine   7.60
L-Lysine 11.00
L-Methionine   2.40
L-Phenylalanine   4.20
L-Threonine   3.70
L-Tryptophane   2.00
L-Arginine   8.40
L-Histidine   3.80
L-Alanine   8.00
L-Aspartate   6.00
L-Cysteine   1.89
L-Glutamate 10.00
Glycine   4.00
L-Proline   3.00
L-Serine   4.00
L-Tyrosine   0.45
L-Ornithine-HCl   3.18
Taurine   0.60
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Glutathione enrichments and concentration
Enrichments of GSH and its precursor glycine as well as GSH concentrations were 
determined to measure fractional and absolute synthesis rates. For this purpose, we 
used a new technique described previously, using an LC-Isolink® interface (Thermo 
Electron, Bremen, Germany) coupled to a Delta XP isotope ratio mass spectrometer 
(Thermo Electron, Bremen, Germany) (LC-IRMS) (19). This highly sensitive method 
requires only a very small sample volume, whereas no derivatization is required. Briefly, 
erythrocytes were disrupted by freezing and thawing. Next, 40 µL of a mixture of 0.2 
mg/mL norleucine and 1.0 mg/mL norvaline was added as internal standards and the 
samples were deproteinized by adding 200 µL of 6 % g/v perchloric acid, left on ice for 
10 minutes and finally centrifuged at 10.000 x G for 20 minutes. The supernatant was 
transferred to a clean tube and the pH was adjusted to 8 - 9 with a KOH (4 mol/L) solu-
tion. Excess perchloric acid was precipitated and removed by centrifugation at 10.000 
x G for 10 minutes. 100 µL of NaHPO4 (0.5 mol/L) was added to maintain pH 9. The 
supernatant was filtered through a 0.2 µm Nylon membrane filter (Nylon, Alltech, Breda, 
The Netherlands). An aliquot of 150 µL was transferred to a sample vial and 20 µL was 
injected for each analysis of both GSH concentration and 13C-isotopic enrichment by 
LC- IRMS. The remaining supernatant was used for analysis of 13C- isotopic enrichment 
of glycine by gas chromatography – combustion – isotope ratio mass spectrometry, 
similar to an earlier developed method for measurement of the isotopic enrichment 
of threonine (20). Plasma concentrations of direct GSH precursors glutamate, glycine, 
and cysteine (measured as cystine), and indirect precursors glutamine, methionine 
and serine, were determined with a Biochrom 30 amino acid analyzer, using ninhydrin 
detection (Biochrom Ltd, Cambridge, England).
Calculations
The FSRGSH represents the fraction of the total intraerythrocytic GSH pool that is renewed 
per unit of time, and is expressed as %/d. It was measured according to the product/
precursor- equation:
100%24h
E
E slope
(%/d) FSR
C]glycine-rocytic[1intraeryth
oneC]glutathi[1
GSH
13
t4,5,6
13
 
where E stands for enrichment expressed as mole percent excess (MPE). The nominator 
(product) of this equation represents the hourly increase of incorporated [1-13C]glycine 
into GSH as calculated from the increase in enrichment between 4 and 6 hours of infu-
sion. The denominator (precursor) represents the intraerythrocytic free [1-13C]glycine 
enrichment at isotopic steady state. A steady state plateau was defined as an insignifi-
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cant change with time in intraerythrocytic enrichment. Subsequently, the intravascular 
absolute synthesis rate (ASRGSH) was calculated by the following equation:
ASRGSH (mg/(kg⋅d)) = FSRGSH/100 x conc x 307 x ht x 0.075
where conc is concentration in mmol/L of packed erythrocytes, 307 is the molecular 
weight of GSH, ht is hematocrit, and 0.075 is the estimated circulating blood volume in 
a preterm neonate, expressed as L/kg.
Oxidative stress markers
We measured AOPP in plasma by the spectrophotometric assay described by Witko-
Sarsat et al (15). Dityrosine concentrations were measured by the method described 
by Abdelrahim et al., based on liquid-liquid extraction, reversed-phase chromatography 
and fluorescence detection (16).
Glutathione kinetics in healthy adults
Since kinetic measurements require venous access and an indwelling arterial catheter, 
healthy term neonates cannot serve as controls. GSH kinetics so far have only been 
studied in older infants and adults, as relatively high blood volumes are needed for 
precise determination of enrichment and concentration. In two studies on GSH kinetics 
in healthy adults, mean FSRGSH was found to be 65%/d and 83%/d, respectively (21, 
22). GSH concentrations, however, were found to vary substantially between studies 
(23). Even minimal manipulation of samples can result in loss of GSH, thereby creating 
false assumptions with respect to the in vivo situation. To correct for different methods 
yielding different results, we determined GSH kinetics in healthy adults by exactly the 
same method we used for preterm infants. Studies were conducted after an overnight 
fast, and subjects remained in the fasting state throughout the study.
Statistics
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, 
USA) and GraphPad Prism version 4 (GraphPad Software, San Diego, CA, USA). Data 
are expressed as means ± SD or as medians (min – max). Primary outcome of the study 
was the glutathione fractional synthesis rate. Based on an abstract by Shew et al. (24), 
we calculated that with an α of 0.05, a power of 0.80 and a difference in ASRGSH of 0.22 
mmol/(L∙d) with an SD of 0.06, group size needed to be at least 3 to detect a difference. 
We included 10 infants in each group in order to increase power.
120
Differences between groups were determined using independent t-tests or Mann-
Whitney tests in case of normal or skewed distribution of the study groups, respectively. 
A P value of <0.05 was considered as statistically significant.
Results
Clinical characteristics are listed in Table II.
All infants received additional oxygen as part of their treatment. We found no correla-
tion between fractions of inspired oxygen and GSH concentration or FSRGSH.
Nutritional intakes before and during the study are shown in Table III.
Table II. Clinical characteristics1
control intervention 
N (M:F) 10 (7:3) 10 (4:6)
birth weight (g) 990 ± 205 916 ± 150
gestational age (wks) 27 1/7 ± 2 275/7 ± 21/7
birth weight Z-score (SD) -0.4 ± 1.3 -1.4 ± 0.9
mode of delivery
vaginal:cesarean section
5:5 5:5
Apgar score (5 min) 8 (6 – 10) 7 (4 – 9)
CRIB score2 5 (1 – 7) 4 (1 – 8)
FiO2       minimum 21 (21 – 29) 21 (21 – 24) 
              maximum 54 (24 – 100) 45 (28 – 72)
1 Values are expressed as either mean ± SD or median (min-max). 
There were no statistical differences between groups (Student’s T-test or Mann-Whitney, depending on distribution).
2The CRIB score (Clinical Risk Index for Babies) indicates the degree of illness. The score is positively correlated with 
the severity of illness.
Table III. Nutritional intakes before and during the study1
control (n=10) intervention (n=10) P value
nonprotein energy intake (kcal/(kg⋅d)) 38 ± 4 42 ± 8 0.22
amino acid intake (g/(kg⋅d))2 0 ± 0 2.5 ± 0.1 <0.001
1 Values are expressed as mean ± SD (Student’s T-test).
2 As anticipated by study design, the control group did not receive amino acids during or prior to study.
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Blood glucose levels were not different between groups and none of the infants 
received insulin during or prior to the study (data not shown). Also, there were no 
differences in incidence of hyperglycemia.
In one blood culture micrococcus species was isolated, which was considered contami-
nation. None of the other infants had either a rise in C-reactive protein concentrations 
or positive blood cultures before or during the study.
Concentrations of plasma precursor AAs
Table IV shows plasma concentrations of all AAs involved in GSH synthesis with refer-
ence values obtained from healthy term breast-fed infants (25); AA concentrations were 
significantly higher in the intervention group. Concentrations of glutamate, cystine, and 
methionine in the control group were below reference ranges. Although the AA solution 
administered contained cysteine (1.89 g/L), cystine concentrations still were low in the 
intervention group as well.
GSH concentrations and synthesis rates
In Figure 1 precursor and product enrichments are plotted against duration of tracer 
infusion. Free intraerythrocytic [1-13C]glycine, considered as the precursor for GSH 
synthesis, reached a plateau after 4 hours of infusion defined as no significant increase 
in enrichment. Precursor enrichments did not differ between the groups (3.6 ± 0.7 MPE 
in each). Levels of [1-13C]glycine bound to GSH linearly increased between 4 and 6 
hours of infusion, with a mean R2 of 0.996 and 0.994 between the values measured for 
the control and intervention group, respectively. The LC-IRMS method used in this study 
Table IV. Plasma concentrations of amino acids1,2
control (n=10) intervention (n=10) P value term infants
glutamate 19 ± 5 72 ± 47 0.017 76 – 551
cystine 14 ± 9 27 ± 10 0.011 33 – 55
glycine 206 ± 71 341 ± 154 0.047 66 – 432
glutamine 280 ± 167 566 ± 243 0.012 147 – 623
serine 94 ± 31 189 ± 91 0.022 79 – 227
methionine 12 ± 5 36 ± 24 0.026 21 – 55
1 Amino acids that are directly or indirectly involved in glutathione synthesis with a reference range of term breast-
fed infants(25). 
2 Values are expressed as mean ± SD (Student’s T-test).
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quantified [1-13C] enrichment of the total GSH pool, since IRMS is known to combust all 
carbon elements of GSH into CO2. We, therefore, were not able to discriminate between 
[1-13C] enrichment of GSH originating from glycine or cysteine. We studied, however, 
the cysteine peak in our chromatogram, and we did not find any enrichment, thereby 
excluding possible overestimation of the FSR.
GSH kinetic data are shown in Figure 2. FSRGSH did not differ between groups. The 
concentration of erythrocyte GSH in the intervention group was higher, however, than 
that in the control group. As a result, also ASRGSH was higher in the intervention group.
Plasma levels of oxidative stress markers
Results are shown in Figure 3. We found no differences between groups for both mark-
ers. These results are in agreement with earlier studies on AOPP levels in preterm 
infants and indicate the presence of oxidative stress (4, 26). Increased GSH availability 
as a result of AA administration did not result in lower AOPP levels on postnatal day 2.
GSH kinetics in healthy adults
We included 5 healthy non smoking adults. They had an age of 34 ± 8 years and a Body 
Mass Index of 22.5 ± 1.2 kg/m2 (mean ± SD).
We found a mean concentration of 1.43 ± 0.13 mmol/L which is comparable to the 
concentrations reported by Darmaun and colleagues (22). The mean FSRGSH in eryth-
rocytes was 62 ± 2 %/d resulting in a mean ASRGSH of 7.7 ± 1.1 mg/(kg⋅d). Thus, the 
ASRGSH of fasted adults is lower than that of fed preterm infants.
Figure 1. Means and SD’s of isotopic steady state of [1-13C]glycine (precursor) enrichments (A) and  [1-
13C]glutathione (product) enrichments (B) in the control (, n=10) and intervention (, n=10) groups. 
There were no significant differences in either isotopic steady state of [1-13C]glycine enrichment or 
increase in [1-13C]glutathione enrichment (Student’s T-test).
 
Figure 1 
 
 
!  
Figure 1 
 
 
!
123
C
h
a
p
te
r 
8
Figure 2. Glutathione fractional synthesis rates (A), concentrations (B) and absolute synthesis rates (C) 
in erythrocytes in the control (, n=10) and intervention (, n=10) groups expressed as individual cases 
with horizontal lines representing means and SD’s. There were no significant differences in fractional 
synthesis rates between groups (Student’s T-test). Glutathione concentrations and absolute synthesis 
rates were higher in the dextrose + AA group (P<0.001 for both concentration and absolute synthesis 
rate, Student’s T-test).
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Figure 3. Plasma concentrations of advanced oxidized protein products (AOPP) (A) and dityrosine (B) in 
the control (, n=10) and intervention (, n=10) groups expressed as individual cases with horizontal 
lines representing means and SD’s. There were no statistically significant differences for either AOPP or 
dityrosine concentrations (Student’s T-test).
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Discussion
We showed AA administration to be a safe, simple and efficacious means of increasing 
GSH synthesis rates. We demonstrated a 32% increase in erythrocyte GSH concentration 
and a 74% increase in the ASRGSH following administration of 2.4 g AAs/(kg⋅d) as com-
pared to dextrose administration solely. These results clearly bring out the discrepancy 
between, on the one hand, demands of the body and, on the other hand, the scarce 
availability of substrates if only dextrose is administered. Antioxidant defense build-up 
was not associated, however, with lower concentrations of oxidative stress markers.
The observed increase of the ASRGSH can almost exclusively be attributed to the in-
crease in concentration. This is fascinating, since in adults and children alike increases 
in ASRGSH seem to arise primarily from increases in FSRGSH rather than from elevated 
concentrations (21, 27, 28). We have two explanations. For one, the FSRGSH might have 
been increased already on the first day of life, and then have dropped as a result of 
negative feedback. A study performed on the first day of life under the same conditions 
could provide more insight. Second, the lack of increase in FSRGSH might be related to the 
function of GSH as an AA reservoir. Plasma glycine concentration rose 65% after AA ad-
ministration (Table III). It follows that plasma glycine enrichment must have been lower 
in the intervention group, since infusion rates of [1-13C]glycine were identical for both 
groups. Despite theoretically lower plasma glycine enrichment in the intervention group 
as compared to the control group, intraerythrocytic enrichment did not differ between 
groups, as shown in Figure 2. Seeing that GSH itself is the major intraerythrocytic pool 
of glycine, the most plausible explanation is decreased breakdown of intracellular GSH 
in the intervention group compared to the control group, as proposed earlier (29). Note 
that GSH is an important AA reservoir, its intracellular concentration being in the milli-
molar range whereas the free fractions of its constituent AAs, especially cysteine, are in 
the micromolar range. Altogether, these data strongly suggest decreased consumption 
of GSH in the intervention group, possibly resulting – as we showed recently – from 
increased synthesis of other antioxidants such as albumin (30).
An explanation for the overall low FSRGSH in preterm neonates as compared to adults 
is increased recycling of GSSG to GSH in neonates. Normally, GSSG concentrations are 
kept very low to protect the cell from a shift in redox equilibrium. This is achieved by 
either reducing GSSG to GSH or exporting it to the extracellular space, dependent on 
the availability of the enzyme glutathione reductase and NADPH (31). Indeed, increased 
recycling of GSSG into GSH in erythrocytes of preterm neonates as opposed to adults 
was observed earlier (32, 33). More efficient recycling could very well decrease the 
need for de novo synthesis and perfectly fits our data, i.e. a relatively low FSRGSH in 
preterm infants as compared to adults.
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Blood glucose concentrations and incidence of sepsis were not different between 
groups. This is relevant, seeing that both hyperglycemia and sepsis are known to pro-
duce oxidative stress (34, 35).
The importance of GSH in maintaining health and preventing oxidative stress has 
been widely studied. Chessex et al. studied the individual effects of hyperoxia and 
nutrient restriction on liver and lung GSH availability in preterm guinea pigs (36). They 
concluded that total parenteral nutrition not only increased both liver and lung GSH con-
centrations but also protected against hyperoxic lung injury and associated mortality. In 
agreement, Welty et al. and Yeung et al. recommended administration of antioxidants 
or their precursors as soon as possible following birth in order to prevent oxidative 
stress related diseases, such as bronchopulmonary dysplasia (37, 38).
GSH kinetics were measured using a new technique which transforms all GSH to its 
dimeric form (GSSG). We did not, therefore, discriminate between GSH and GSSG. 
However, since the fractional synthesis rate is a relative measure, it will not be influ-
enced by a difference in redox state. We measured GSH kinetics in erythrocytes, which 
are readily accessible as opposed to other tissues. Moreover, erythrocytes can protect 
other tissues, such as the lung, by providing intracellular antioxidants (39) or by directly 
taking up ROS (40). In a very recent study, Giustarini et al. provided strong evidence for 
a role for erythrocytes as GSH donor for other tissues (41). They demonstrated active 
GSH export towards the plasma, indicating that, besides the liver, erythrocytes might 
significantly contribute to the extracellular GSH pool. These studies, however, fail to 
elucidate the mechanism by which the GSH is exported, since GSH is assumed unable 
to cross the cellular membrane intact.
We measured AOPP and dityrosine as markers of oxidative stress. Tyrosine is oxidized 
to dityrosine in response to oxidative stress and can be considered a good endogenous 
marker. Experiments that expose protein to oxygen-free radicals have demonstrated the 
formation of dityrosine. Dityrosine has been recognized as an oxidative stress product 
of pathological response to disease or other environmental stress (17, 42).
The AOPP concentrations were higher than those found in older, more stable preterm 
infants as well as healthy adults (4, 15).
Cysteine is generally assumed to be the rate limiting substrate for GSH synthesis. It 
is also considered to be an essential AA in the preterm neonate on the grounds of high 
cystathionine concentrations (43) and low cystathionase activity impeding the conver-
sion of methionine into cysteine (44). Although evidence is mounting that preterm 
infants are in fact able to synthesize cysteine (45, 46), demands may still exceed capac-
ity to synthesize. Indeed, earlier we showed that plasma cyst(e)ine concentrations were 
below reference values, both in group not receiving any AAs and in a group receiving 
AAs including cysteine (14). The AA solution we used provides methionine and cysteine, 
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delivered as cysteine-HCl. Premixed AA solutions can only contain modest amounts of 
cysteine-HCl due to instability of cysteine at higher pH.
We demonstrated that AA administration to preterm infants directly postnatally is a 
safe and efficient way to increase GSH synthesis rates. Our data suggest that this does 
not increase GSH consumption, as intracellular GSH breakdown seems to decline. Levels 
of oxidative stress markers nevertheless remained high. Plasma cystine concentrations 
rose upon AA administration, but still remained low. Worthy of further research is the 
question whether higher doses of AAs, or additional cysteine in particular, would further 
increase GSH synthesis rates.
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Abstract
Preterm infants have diminished antioxidant defense mechanisms. Although glutathione 
(GSH) concentration, the main intracellular antioxidant, increases upon amino acid (AA) 
administration in preterm infants, the fractional synthesis rate of GSH (FSRGSH) was not 
increased on day 2. We hypothesized that GSH synthesis is already upregulated directly 
postnatally, with a subsequent negative feedback on day 2.
The objective was to determine GSH synthesis rates on day 1 or day 2 in preterm 
infants receiving AAs directly following birth.
GSH synthesis rates were measured using stable isotope techniques in very low birth 
weight (VLBW) infants on postnatal day 1 or 2. Advanced oxidized protein products 
(AOPP) were determined to quantify oxidative stress. Results are expressed as mean 
± SD.
Eighteen infants (mean birth weight of 988 gram and gestational age of 27 6/7 weeks) 
were studied at either 7 or 31 hours postnatally. Concentration of GSH increased with 
postnatal age (1.45 ± 0.48 versus 1.99 ± 0.40 mmol/L, p=0.019). FSRGSH was not 
significantly different between groups. In contrast to the hypothesis, the absolute syn-
thesis rate of GSH (ASRGSH) tended to be higher on day 2 (8.1 ± 2.7 versus 10.6 ± 2.4 
mg/(kg·d), p=0.054). AOPP concentrations were not different between groups.
In conclusion, GSH concentration in VLBW infants on postnatal day 2 is significantly 
higher than that on postnatal day 1. A concomitant increased synthesis rate on day 1 
was not found, suggesting that GSH consumption decreases upon AA administration.
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Introduction
The sudden increase in oxygen pressure accompanying birth results in the increased 
formation of reactive oxygen species (ROS). Furthermore, if birth is marked by a period 
of ischemia followed by reoxygenation (e.g. asphyxia), ROS formation is further aug-
mented through the hypoxanthine-xanthine oxidase pathway (1, 2). In addition, pre-
term infants are frequently exposed to ventilation with high concentrations of oxygen, 
further adding up to this ROS formation (3). Therefore, newborn infants, and especially 
preterm infants, are exposed to increased levels of ROS.
In term infants, antioxidant defenses are present at birth to counteract this hyperoxic 
challenge, since antioxidant enzymes mature during late gestation (4). Several weeks 
prior to birth, parallel with the rapid rise in lung surfactant, there is a 150-200% in-
crease in superoxide dismutase and glutathione peroxidase (5, 6). Also, the transfer of 
several antioxidants across the placenta is increased during the last days of pregnancy 
(4). So when born premature, most antioxidant defense mechanisms function subop-
timal at birth. The resulting redox imbalance causes oxidative stress, which is thought 
to be instrumental in the pathogenesis of the so-called ‘Oxygen Radical Disease in 
Neonatology’, which comprises diseases such as bronchopulmonary dysplasia (BPD) and 
periventricular leukomalacia (PVL) (7).
Glutathione (GSH) is the most important intracellular antioxidant. GSH is a tripeptide 
consisting of the amino acids (AA) glutamate, cysteine and glycine. It is synthesized in 
virtually every tissue, but is mainly produced in liver and erythrocytes with erythrocytic 
concentrations being in the millimolar range (8). Erythrocytes are suggested to function 
as antioxidant defense by being a physiological source of GSH and by taking up ROS 
(9, 10).
While preterm infants show diminished availability of other components of the anti-
oxidant defense systems, the GSH concentrations in cord blood of preterm infants at 
birth exceed those of term infants (9, 11, 12). GSH concentration falls rapidly, however, 
immediately after birth in preterm infants. Recently, we demonstrated that amino acid 
(AA) administration to preterm infants from birth onwards results in a higher GSH 
concentration on day 2, when compared to the levels found in infants receiving dextrose 
only (13). This was, however, not accompanied by a higher fractional synthesis rate 
(FSR) on day 2. We, therefore, hypothesized that GSH synthesis is already upregulated 
directly after birth, and that negative feedback subsequently lowers GSH synthesis rate 
on postnatal day 2. The purpose of the present study was to reveal the mechanism 
behind the increased availability of GSH with early administration of AAs. To this aim 
we conducted a stable isotope technique to determine glutathione synthesis rates on 
postnatal day 1 or 2 in infants receiving AAs directly following birth.
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In addition, we quantified oxidative stress by determining concentrations of the 
advanced oxidized protein products (AOPP), first described as a marker for protein 
oxidation in uremic patients (14). Hypoxic preterm infants showed higher plasma con-
centrations of AOPP than did normoxic preterm infants and concentrations correlated 
with plasma levels of hypoxanthine, which is considered a reliable marker of oxidative 
stress (15).
Methods
This study was designed an observational clinical trial in which infants were randomized 
to be studied either on postnatal day 1 or 2. The study was performed at the neonatal 
intensive care unit of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, the 
Netherlands. The study was investigator initiated with no funding from industry. The 
Erasmus MC Medical Ethical Review Board approved the protocol and informed written 
parental consent was obtained prior to the study.
Subjects
Preterm infants with a birth weight <1500 g, who had an indwelling arterial catheter 
for blood sampling, and who were completely dependent on parenteral nutrition for 
the first 2 days of life were eligible for this study. Exclusion criteria included receiving 
erythrocyte transfusions during or prior to the study, known congenital abnormalities, 
chromosome defects, and metabolic, endocrine, renal, or hepatic disorders.
Patients received dextrose and 2.4 g of AA/(kg·d) (Primene 10%, Baxter, Clintec 
Benelux N.V., Brussels, Belgium) intravenously, starting within 2 hours after birth. AAs 
and dextrose solutions were infused constantly without interruptions during the study. 
The AA solutions did not contain riboflavins, which are known to generate H2O2 when 
exposed to light (16). Lipids were not administered until the end of the study period.
Birth weight, gestational age, birth weight Z-scores, antenatal corticosteroid usage, 
and severity of illness at entry of the study by means of Apgar and CRIB scores (clinical 
risk index for babies) (17) were recorded for all infants. Furthermore, blood gases, 
plasma AA concentrations, dependence on supplemental oxygen (expressed as the 
median (min-max) FiO2 from birth until the end of the study), caloric intake and AA 
intake were recorded.
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Tracer infusion protocol
Patients received a primed (40 μmol/kg), continuous (20 μmol/(kg·h)) infusion of [1-
13C]glycine during 6 hours either on day 1 or on day 2. [1-13C]Glycine (99% enriched, 
sterility and pyrogenicity tested) was purchased from Cambridge Isotope Laboratories 
(Andover, MA, USA) and was diluted with a 0.9% saline solution by the hospital’s phar-
macy after which it was again tested for sterility and pyrogenicity. Tracers were infused 
with a Perfusor fm infusion pump (B|Braun Medical B.V., Oss, the Netherlands) along 
the same infusion route as the parenterally administered nutrients. Blood was sampled 
from an indwelling arterial catheter after 4, 5, and 6 hours and collected in microtainers 
containing EDTA to quantify GSH fractional synthesis rates (FSRGSH) in erythrocytes. Dif-
ferent infants were used for the tracer infusion study on either day 1 or day 2, because 
of the washout time of [1-13C]glycine.
Sample analyses
Blood samples were immediately put on melting ice, after which they were centrifuged 
at 3500 x G for 10 min at 4°C. The plasma fraction was removed and stored separately 
for measurement of oxidative stress markers. The lower layer, containing primarily 
erythrocytes, was reconstituted to its original volume with ice-cold distilled water. The 
plasma fraction and cell fraction were subsequently stored at -80°C until further analy-
sis.
Glutathione enrichments and concentration
Enrichments of GSH and its precursor glycine as well as GSH concentrations were 
determined to calculate fractional and absolute synthesis rates. For this purpose, a 
recently described technique, based on a LC-Isolink® interface (Thermo Electron, 
Bremen, Germany) coupled to a Delta XP isotope ratio mass spectrometer (Thermo 
Electron, Bremen, Germany) (LC-IRMS) was used (18). This highly sensitive method 
requires only a very small sample volume, and does not require derivatization. In short, 
erythrocytes were disrupted by freezing and thawing. Then 40 µl of a mixture of 0.2 
mg/ml norleucine and 1 mg/ml norvaline was added as internal standards and the 
samples were deproteinized by adding 200 µl of 6 % g/v perchloric acid, left for 10 min 
on ice and finally centrifuged at 10’000 G for 20 min. The supernatant was transferred 
to a new tube and the pH was adjusted to 8 - 9 with 4 Molar KOH. Excess of perchloric 
acid was precipitated and removed by centrifugation at 10’000 G for 10 min. 100 µl of 
0.5M NaHPO4 was added to maintain the pH at 9. The supernatant was filtered through 
a 0.2 µm Nylon membrane filter (Nylon, Alltech, Breda, The Netherlands). An aliquot of 
150 µl was transferred in a sample vial and 20 µl was injected for analysis of both GSH 
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concentration and 13C- isotopic enrichment by LC-C-IRMS. Analysis was performed in 
duplicate. The remaining supernatant was used for analysis of 13C- isotopic enrichment 
of glycine, for which we adapted our earlier developed method on the derivatization of 
threonine and measurement with GC-C-IRMS (19, 20).
The concentration of GSH in human blood erythrocytes was measured by LC-IRMS 
using an internal standard method as described previously (18).
Calculations
The FSRGSH represents the fraction of the total intraerythrocytic GSH pool that is renewed 
per unit of time, and is expressed as %/d.
100%24h
E
E slope
(%/d) FSR
C]glycine-rocytic[1intraeryth
oneC]glutathi[1
GSH
13
t4,5,6
13
 
where E stands for enrichment expressed as mole percent excess (MPE). The nomina-
tor (product) of this equation represents the hourly increase in [1-13C]glycine bound 
GSH as calculated from the increase in enrichment between 4 and 6 hours of infusion. 
The denominator (precursor) represents the intraerythrocytic 1-13C enrichment of free 
glycine at isotopic steady state. A steady-state plateau was defined as an insignificant 
change in time in intraerythrocytic enrichment.
Subsequently, the intravascular absolute synthesis rate of GSH (ASRGSH), which rep-
resents the absolute amount of GSH that is produced per unit of time (mg/(kg·d)), can 
be calculated using the following equation:
ASRGSH (mg/(kg⋅d) = FSRGSH/(100 x conc. x 307 x ht x 0.075)
where conc. is concentration in mmol/L packed erythrocytes, 307 is the molecular 
weight of GSH, ht is hematocrit, and 0.075 is the estimated circulating volume in a 
preterm neonate, expressed as L/kg.
Amino Acid concentrations
Plasma concentrations of direct GSH precursors glutamate, glycine, and cysteine (mea-
sured as cystine), and indirect precursors glutamine, methionine and serine, were de-
termined with a Biochrom 30 amino acid analyzer, using ninhydrin detection (Biochrom 
Ltd, Cambridge, England).
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Plasma markers of oxidative stress
We measured AOPP in plasma by the spectrophotometric assay described by Witko-
Sarsat et al (14). The AOPP were calibrated with chloramine-T solutions that absorb at 
340 nm in the presence of potassium iodide. In test wells, 40 µL of plasma was diluted 
with 120 µL PBS and transferred to a 96-well microtiter plate, followed by addition 
of 20 µL of acetic acid. In standard wells, 10 µL of 1.16 M potassium iodide were 
added to 200 µL of chloramine–T solution (0–100 µmol/L) followed by 20 µL of acetic 
acid. The absorbance of the reaction mixture was immediately read at 340 nm on the 
microplate reader against a blank containing 200 µL of PBS, 10 µL of potassium iodide, 
and 20 µL of acetic acid. AOPP measurements were performed in duplicate. Because the 
absorbance of chloramine-T at 340 nm is linear up to 100 µmol/L, AOPP concentrations 
were expressed as µmol/L chloramine-T equivalents.
Statistics
Statistical analyses were performed using SPSS v14.0 (SPSS Inc, Chicago, IL, USA) and 
Graph Prism v4 (GraphPad Software Inc, California, USA). Data are expressed as means 
± SD or as medians (min – max). Primary outcome of this study was the glutathione 
absolute synthesis rate. Based on earlier research from our research group (13), we 
calculated that with an α of 0.05, a power of 0.80 and a difference in ASRGSH of 4.5 
mg/(kg·d) with an SD of 1.9, group size needed to be at least four to detect a differ-
ence. We included 8 and 10 infants in each group in order to increase power. Differences 
between groups were determined using independent t-tests or Mann-Whitney tests in 
case of normal or skewed distribution of the population respectively. For differences 
in frequency of mode of delivery, Chi-Square test was used. A p value of <0.05 was 
considered as statistically significant.
Results
The stable isotope infusion was started either on day 1 or day 2 (7 ± 4.8 and 31 ± 
5.9 hours after birth, respectively). Clinical characteristics are displayed in Table I. 
The maximum inspired oxygen fraction was significantly higher in the group of infants 
measured on day 2. Nutritional intakes before and during the study are shown in Table 
II.
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Concentrations of plasma precursor AAs
Table III shows the plasma concentrations of all AAs involved in GSH synthesis with 
reference values obtained from healthy term breast-fed infants (21). Cystine concentra-
tion on day 2 was significantly lower than that on day 1 and was below the reference 
value (21). Concentrations of glutamate, glutamine, methionine and serine were not 
different between the groups, although glutamate concentrations were below reference 
values.
Table I. Clinical characteristics
Day 1 Day 2
N (male : female) 8 (7:1) 10 (8:2)
Gestational age (wks) 28 2/7 ± 4/7 27 4/7 ± 2 0/7
Birth weight (g) 1023 ± 180 961 ± 288
Birth weight Z-score -0.8 ± 1.1 -1.0 ± 1.6
Mode of delivery (vaginal : cesarean section) 0:8 5:5 *
Apgar score 9 (8-10) 9 (4-9)
CRIB score2 2 (1-4) 4 (1-10)
Cord blood pH 7.28 ± 0.07 7.27 ± 0.17
Cord blood BE (mmol/L) -5.1 (-6.6 – -1) -2.5 (-22 – 1.6)
FiO2 minimum (%) on day 1 21 (21-25) 21 (21-21)
       maximum (%) on day 1 30 (21-45) 55 (29-100) *
FiO2 minimum (%) on day 1 + 2 21 (21-21) 21 (21-21)
       maximum (%) on day 1 + 2 31 (21-80) 58 (29-100) *
Values represent either mean ± SD or median (min-max). Mode of delivery and maximum FiO2 were significantly 
different between groups. Other characteristics were not different between groups
* p < 0.05  
1The CRIB score (Clinical Risk Index for Babies) indicates the degree of illness. The score has a maximum of 23 point 
and is positively correlated with the severity of illness.
Table II. Nutritional intakes on each study day. As anticipated, infants received increased caloric intake 
on day 2 compared to day 1.
Day 1 Day 2
nonprotein energy intake (kcal/(kg·d)) 30 ± 4 40 ± 12 *
amino acid intake (g/(kg·d)) 2.3 ± 0.5 2.4 ± 0.1
Values are expressed as mean ± SD (Student’s T-test).
* p < 0.05
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GSH concentrations and synthesis rates
Free intraerythrocytic [1-13C]glycine enrichments reached a plateau after 4 hours of 
infusion (Figure 1). Enrichments did not differ between the groups (mean 3.9 ± 0.9 and 
3.4 ± 0.5 MPE in Day 1 and Day 2 group, respectively, p = 0.18).
GSH kinetic data are shown in Figure 2. The concentration of erythrocyte GSH on 
day 2 was significantly higher than that on day 1. However, FSRGSH was not different 
between groups. Also, the ASRGSH did not differ between the groups although there was 
a trend towards increased ASRGSH on day 2 (p=0.054).
Table III. Plasma AA concentrations in µmol/L. AA concentrations for one patient of the day 2 group 
could not be determined because of shortage of plasma.
Term healthy infants1 Preterm
Day 1
(n=8)
Preterm
Day 2
(n=9)
methionine 21 – 50 46 ± 17 51 ± 19
cystine 33 – 55 51 ± 11 31 ± 11 *
glutamate 76– 551 66 ± 27 77 ± 46
glutamine 147 – 623 657 ± 270 636 ± 114
glycine 66 – 432 386 ± 166 344 ± 54
serine 79 –227 214 ± 94 194 ± 53
Values are expressed as mean ± SD (Student’s T-test).
1Reference levels of plasma amino acid concentrations in healthy term breast-fed infants
* p < 0.002
Figure 1. Means and SD’s of isotopic steady state of intracellular [1-13C]glycine (precursor) enrichments 
expressed as mole percent excess on Day 1 (, n=8) and Day 2 (, n=10). There were no significant 
differences in isotopic steady state of [1-13C]glycine enrichment (Mann-Whitney test). 
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Plasma levels of AOPP
Results are shown in Figure 3. No differences were found between groups for plasma 
concentration of AOPP. The mean plasma concentration of AOPP of both groups was 217 
Figure 2. Glutathione concentrations (A), fractional synthesis rates (B) and absolute synthesis rates (C) 
in erythrocytes on day 1 (n=8) and day 2 (n=10) expressed as box-plots. Glutathione concentrations on 
day 2 were significantly higher than those measured on day 1 (* p<0.05, Student’s T-test). There were 
no significant differences in fractional synthesis rates and absolute synthesis rates between groups 
(Student’s T-test).
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Figure 3. Plasma concentrations of advanced AOPP (expressed as µmol/L chloramine-T equivalents) 
in preterm infants on day 1 (n=8) and day 2 (n=10). Data are expressed as box-plots. There were no 
statistically significant differences in AOPP concentrations between groups (Student’s T-test).
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± 108 µmol/L, which is in agreement with earlier studies on AOPP levels in preterm 
infants and indicates the presence of oxidative stress as compared to term infants (15, 
22, 23).
Discussion
In this study, preterm infants receiving AAs from birth onwards showed an age-related 
rise in GSH concentration without a concomitant rise in GSH synthesis rate, despite an 
increased inspired oxygen fraction on day 2. One would expect that the higher inspired 
oxygen fraction would cause more reactive oxygen species, which subsequently would 
decrease GSH concentrations or upregulate GSH synthesis.
In preterm infants, there is a rapid decline of GSH immediately after birth, possibly as 
a result of higher oxidative stress after birth. Recently, we demonstrated that early AA 
administration directly after birth leads to an increased GSH concentration on postnatal 
day 2, though without a concomitant rise in GSH fractional synthesis (13). We, there-
fore, speculated that GSH synthesis is already increased immediately after birth and 
that the increased GSH concentration subsequently down regulates synthesis on day 
2 through negative feedback. In the present study, however, the fractional synthesis 
rate was not increased on the first day after birth, whereas the GSH concentration was 
still low. There was even a trend towards a higher absolute synthesis rate on day 2. It 
would seem, therefore, that the increased GSH concentration accompanying early AA 
administration is not caused by increased synthesis, suggesting that GSH consumption 
decreases upon AA administration.
Intracellular GSH concentration is determined by de novo synthesis, recycling of GSSG 
(oxidized, dimeric form of GSH) back to GSH, transport to the extracellular space, and 
utilization by peroxides, transferases, transhydrogenases, and transpeptidases (24). 
The method for measuring GSH concentration in the present study does not discriminate 
between reduced and oxidized GSH. Therefore, the increased total GSH concentration 
on day 2 cannot be explained by different recycling rates between the groups. Moreover, 
recycling of oxidized GSSG back to GSH seems to be enhanced rather than decreased 
in preterm infants (25, 26). Consequently, the increased GSH concentration is likely to 
be caused by decreased consumption of GSH after early AA administration in preterm 
infants.
AAs can serve as antioxidants themselves. A study in healthy elderly people, dem-
onstrated reduced oxidative stress after the administration of essential AAs, including 
methionine and cysteine (both sulfur AAs) (27). It is possible that the latter two AAs 
brought about the antioxidant effect. Previous studies indeed showed that methionine 
residues may protect proteins from critical oxidative damage (28), and that oral supple-
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ments with whey proteins, which contain high amounts of sulfur AAs, increase plasma 
GSH levels in patients with HIV(29). The mechanism behind this increase in plasma GSH 
remains to be elucidated as kinetic studies were not performed.
Another possible explanation is that increased availability of AAs, as shown by in-
creased plasma concentrations (13), upregulates synthesis of other antioxidants. Van 
den Akker et al. showed that AA administration to preterm infants results in increased 
albumin synthesis (30) and albumin also exerts antioxidant properties (31). Increased 
levels of other antioxidants might decrease the consumption of GSH, resulting in its 
increased concentrations and availability.
Besides antioxidant properties, GSH also functions as a cysteine reservoir. Conse-
quently, GSH is broken down in response to shortage of cysteine and compromised 
protein synthesis. This follows from the observation that GSH levels become depleted 
if intakes of sulfur amino acids are minimal but sufficient to maintain protein synthe-
sis at adequate levels (32, 33). It is therefore possible that increased availability of 
cysteine reduces breakdown of GSH to generate free cysteine. Besides increased GSH 
concentration, plasma cysteine concentrations were also increased in infants receiving 
AAs from birth onwards (13), suggesting decreased necessity for GSH breakdown to 
release cysteine. In the present study, however, plasma cysteine (measured as cystine) 
concentrations dropped after birth resulting in lower plasma cysteine concentrations on 
day 2 than on day 1, whereas erythrocytic glutathione concentrations had increased on 
day 2. Although plasma and erythrocytes represents two compartments, this decrease 
suggests that serving as a substrate for GSH synthesis is the metabolic fate of cysteine, 
most likely due to increased requirements imposed by extra uterine life. In addition, 
cysteine might be used for synthesis of important proteins like albumin.
AOPP concentrations typically increase significantly in the first week in preterm in-
fants, both in hypoxic and non-hypoxic infants (22). In the present study, however, 
plasma AOPP concentrations were not yet increased on day 2, even though the maxi-
mum inspired oxygen fraction was significantly higher on day 2. It might well be that 
antioxidant defense mechanisms, like the increased availability of GSH on day 2, avert 
some of the oxidative stress in preterm infants after birth. It would have been useful to 
quantify oxidative stress in a broader perspective, going beyond protein oxidation only. 
For example, determining isoprostanes as a marker for lipid peroxidation (34). Further-
more, the ratio between erythrocytic reduced and oxidized GSH is also suggested to be 
an excellent marker for oxidative stress and is already used to this aim in infants (35). 
Regrettably, we could not obtain enough plasma for determining these markers, as a 
consequence of limited possibilities of blood withdrawal in these preterm infants.
The proportion of cesarean sections in the Day 1 group was significantly higher than 
that in the Day 2 group. It is argued that the mode of delivery might influence the degree 
143
C
h
a
p
te
r 
9
of oxidative stress in the neonate, but literature on this topic is contradictory. Some 
authors report increased, while others report diminished oxidative stress (36-39).
In this study, we demonstrate an increase of GSH concentration in the first days after 
birth in preterm infants receiving AAs, without a concomitant rise in GSH synthesis. 
Normally, glutathione is rapidly depleted after birth in preterm infants, possibly as 
a consequence of increased oxidative stress postnatally. Whether AA could serve as 
antioxidants themselves, promote synthesis of other antioxidants and thereby reducing 
the need for glutathione as an antioxidant or whether the increased plasma cystine 
concentrations (13) decrease GSH breakdown to release free cysteine remains to be 
clarified.
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Abstract
Cysteine is thought to be the rate limiting substrate for glutathione synthesis, the major 
intracellular antioxidant. Our aim was to evaluate whether administration of additional 
cysteine is safe and stimulates glutathione synthesis in preterm infants’ early life.
We conducted a prospective, randomized clinical trial in infants with a birth weight 
<1500 gram (n=20). They were randomly assigned to receive either a standard dose 
(45 mg/(kg·d)) or a high dose of cysteine (81 mg/(kg·d)). Intakes of other amino acids 
were similar, providing a total protein intake of 2.4 g/(kg·d) in both groups. Safety was 
confirmed by monitoring pH and base excess in the first 6 days of life. On postnatal day 
2, we conducted a stable isotope study to determine glutathione concentrations and 
synthesis rates in erythrocytes.
Except for a lower base excess on the third day of life in the supplemented group 
(p=0.03), safety parameters were not clinically different between groups. Despite an 
80% increase in cysteine intake, plasma cystine concentration did not increase. Gluta-
thione concentrations and glutathione synthesis rates did not increase upon additional 
cysteine administration.
In conclusion, administration of a high dose of cysteine (81 mg/(kg·d) to preterm in-
fants appears clinically safe, but does not stimulate glutathione synthesis as compared 
to a lower dose (45 mg/(kg·d)).
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Introduction
Cysteine, a nonessential amino acid (AA) synthesized de novo from methionine and 
serine, has been considered essential in preterm infants for the last decades. This 
notion was primarily based on experiments in human fetal tissues demonstrating lack 
of cystathionase activity, the enzyme catalyzing the final step in the cysteine synthesis 
pathway (1-3). In support of these observations, cysteine concentrations in preterm 
infants not receiving cysteine through their diet were found to be lower than those in 
term infants and the human fetus (4, 5).
Although recent studies of Riedijk et al. and Thomas et al. demonstrated adequate 
capacity of cysteine synthesis in enterally fed preterm infants (6-8), this might not hold 
true for preterm parenterally fed infants in the first postnatal days. Apart from the fact 
that the cysteine synthesizing pathway might not be fully active (9), demands may be 
increased directly after birth. Indeed, apart from being a substrate for protein synthesis, 
cysteine is considered to be the rate limiting substrate for glutathione (GSH) synthesis. 
GSH is required to prevent oxidative stress, which is strongly associated with a number 
of serious diseases observed in the neonatal period, such as bronchopulmonary dyspla-
sia and periventricular leukomalacia (10). GSH is found in low concentrations in preterm 
infants deprived of exogenous AA administration (11). In these infants, concentrations 
of cysteine or its dimer cystine are particularly low (12, 13). As cysteine is feared to 
cause metabolic intolerance and to be unstable in parenteral solutions, most neonatal 
parenteral AA solutions contain only marginal amounts of cysteine or none at all. On 
the other hand, providing cysteine might decrease the need for methionine, which is 
associated with hepatotoxicity (14). In addition, it increases calcium and phosphorus 
solubility by lowering the pH of the AA solution (15).
Hypothesizing that a higher cysteine intake is metabolically safe and results in in-
creased GSH synthesis rates, we conducted a randomized clinical trial in very low birth 
weight (VLBW) infants comparing effects of a standard (45 mg/(kg·d)) versus a high 
dose (81 mg/(kg·d)) of parenterally administered cysteine.
Methods
Design
The study was designed as a randomized clinical trial performed in the neonatal intensive 
care unit of the Erasmus MC – Sophia Children’s Hospital, Rotterdam, the Netherlands 
between March 2007 and September 2007. The study was investigator initiated with no 
funding from industry. The protocol was approved by the Erasmus MC Medical Ethical 
Review Board and informed written parental consent was obtained prior to the study.
150
Patients
Subjects were inborn premature infants with a birth weight <1500 g who had an indwell-
ing arterial catheter for clinical purposes, and were expected to be exclusively dependent 
on parenteral nutrition for the first 2 days of life. Besides glucose, all neonates received 
AAs directly following birth (2.4 g/(kg·d)) (Primene 10%, Baxter, Clintec Benelux N.V., 
Brussels, Belgium). Standard cysteine concentration of Primene is 1.89 g/L, thus pro-
viding a daily dose of 45 mg/kg (0.37 mmol/L) at an AA intake of 2.4 g/(kg·d). Directly 
after birth, infants were randomly assigned using a random-number table to receive 
either AAs including this standard amount of cysteine (CYS) or AAs including additional 
cysteine (CYS+) (Hospira, Inc. Lake Forest, IL, USA, and SICOR Pharmaceuticals, Inc., 
Irvine, CA, USA) providing a total daily cysteine intake of 81 mg/kg (0.67 mmol/L). The 
additional cysteine was administered by the attending nurse. This was performed in a 
non-blinded fashion, since the study was not placebo-controlled. Intake of all other AAs 
did not differ between groups. Glucose and AAs were administered in separate solu-
tions. Lipids and vitamins were not administered until after the stable isotope study on 
postnatal day 2 had been concluded. Exclusion criteria included erythrocyte transfusions 
within 12 hours prior to the study or during the study, known congenital abnormalities, 
chromosome defects, and metabolic, endocrine, renal, or hepatic disorders.
Study endpoints
Primary endpoint with respect to efficacy of cysteine administration was GSH concentra-
tion and synthesis rates in erythrocytes on postnatal day 2. Secondary endpoint was 
safety of cysteine administration, as confirmed by monitoring pH and base excess (BE) 
for the first six days of life. For all infants, we recorded birth weight, gestational age, 
birth weight Z-scores, and severity of illness at entry of the study by means of Apgar and 
CRIB scores (16). We also recorded requirements for base administration. Furthermore, 
we monitored use of supplemental oxygen and also documented antibiotics administra-
tion and incidence of sepsis, as sepsis is known to contribute to oxidative stress (17). 
We daily recorded actual nutritional intakes. We recorded plasma AA concentrations on 
the second day of life both as a safety and an efficacy parameter.
Tracer infusion protocol and sample collection
[1-13C]Glycine (99% enriched, sterility and pyrogenicity tested) was purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA) and was dissolved in a 0.9% saline 
solution, filtered (0.2 µm) and sterilized by the hospital’s pharmacy. The final product 
was tested for identity, content, sterility and pyrogenicity.
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On postnatal day 2 neonates received a primed (40 μmol/kg) continuous (20 μmol/
(kg·h)) infusion of [1-13C]glycine for 6 hours. Blood samples (400 µL each) were drawn 
from an indwelling arterial catheter after 4, 5, and 6 hours and collected in EDTA 
containing microtainers to quantify erythrocyte free glycine enrichment, GSH-bound 
glycine enrichment and GSH concentration. Samples were immediately put on melt-
ing ice after centrifugation at 3500 x G for 10 min at 4°C. The plasma fraction was 
removed and stored separately for measurement of individual AA concentrations. The 
lower layer containing primarily erythrocytes was reconstituted to its original volume 
with ice-cold distilled water to disrupt cell membranes. The plasma and cell fractions 
were subsequently stored at -80°C until further analysis.
Glutathione and amino acid measurements
We measured GSH as total GSH, i.e. GSH + oxidized glutathione (GSSG). Enrichments 
of GSH-bound glycine and GSH concentrations were determined according to a re-
cently developed technique, using an LC-Isolink interface (Thermo Electron, Bremen, 
Germany) coupled to a Delta XP isotope ratio mass spectrometer (Thermo Electron, 
Bremen, Germany) (LC-IRMS) (18). This highly sensitive method requires only a small 
sample volume (200 µL whole blood), and does not require derivatization (18). Gas 
chromatography-combustion-isotope ratio mass spectrometry was used for analysis of 
13C- isotopic enrichment of intraerythrocytic glycine, similar to an earlier developed 
method for measurement of the isotopic enrichment of threonine (19). Plasma concen-
trations of the direct GSH precursors glutamate, glycine, and cysteine (in vitro oxidized 
and measured as cystine), and indirect precursors glutamine, methionine and serine, as 
well as taurine, the product of cysteine catabolism, were determined with a Biochrom 30 
amino acid analyzer using ninhydrin detection (Biochrom Ltd, Cambridge, England).
Calculations
The FSRGSH was measured according to the product/precursor equation. It represents 
the fraction of the total intraerythrocytic GSH pool that is renewed per unit of time, and 
is expressed as %/d.
100%24h
E
E slope
(%/d) FSR
C]glycine-rocytic[1intraeryth
C]GSH[1
GSH
13
t4,5,6
13
 
where E stands for enrichment expressed as mole percent excess (MPE). The nominator 
(product) of this equation represents the hourly increase of incorporated [1-13C]glycine 
into GSH as calculated from the increase in enrichment between 4 and 6 hours of infu-
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sion. The denominator (precursor) represents the intraerythrocytic free [1-13C]glycine 
enrichment at isotopic steady state. A steady state plateau was defined as an insignifi-
cant change with time in intraerythrocytic enrichment. Subsequently, the intravascular 
absolute synthesis rate (ASRGSH) was calculated by the following equation:
ASRGSH (mg/(kg⋅d)) = FSRGSH/100 x conc x 307 x ht x 0.075
where conc is concentration in mmol/L of packed erythrocytes, 307 is the molecular 
weight of GSH, ht is hematocrit, and 0.075 is the estimated circulating blood volume in 
a preterm neonate, expressed as L/kg.
Statistics
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL, 
USA) and GraphPad Prism version 4 (GraphPad Software, San Diego, CA, USA). Data 
are expressed as means ± SD or as medians (min – max). Primary outcome of the 
study was the glutathione fractional synthesis rate. Based on an abstract by Shew et 
al. (20), which describes a similar study, we calculated that with an α of 0.05, a power 
of 0.80 and a difference in FSRGSH of 30%/d with an SD of 10%, group size needed to 
be at least three to detect a difference. We included 10 infants in each group in order 
to increase power.
Differences between groups were determined using independent t-tests or Mann-
Whitney tests in case of normal or skewed distribution of the study groups, respectively. 
A P value of <0.05 was considered as statistically significant.
Results
We included twenty VLBW infants, equally distributed between the two groups. Twenty-
seven infants were initially assessed for eligibility, of whom six infants were excluded 
due to not meeting inclusion criteria (n=2) or parental refusal (n=5). Group charac-
teristics are shown in Table I. Stable isotope infusion was initiated at 30 ± 7 hours and 
30 ± 6 hours postnatally in the CYS and CYS+ group, respectively. As anticipated by 
study design, daily cysteine intakes were significantly higher in the CYS+ group during 
the entire study period. Actual AA intakes as well as non protein calorie intakes for 
both groups are shown in Figure 1. Both total AA and non protein calorie intake were 
not different between groups at any day. None of the infants developed sepsis during 
the study. All infants were ventilated and therefore received prophylactic antibiotics 
according to our NICU’s policy. Administration of these antibiotics was stopped in all 
infants after 48-72 hours since C-reactive protein concentrations were low and blood 
cultures were negative.
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Table II shows fractions of inspired oxygen in both groups until after the isotope study 
on day 2 (median (min – max)). No differences between groups were observed.
Safety aspects
Figure 2 shows pH, BE, and bicarbonate infusion during the first 6 days of life. Besides 
a statistically significant difference in BE on the third postnatal day (p=0.03), pH or BE 
were not higher in the CYS+ group. Infants in the CYS+ group did, however, require more 
base administration on days 3 (p=0.048), 4 (p=0.002), and 5 (p=0.002).
Relevant plasma AA concentrations are shown in Table III; they did not differ between 
groups. In particular concentrations of cysteine, measured as its dimer cystine, were 
Table I. Clinical characteristics.
CYS CYS+ 
N (M:F) 10 (6:4) 10 (8:2)
birth weight (g) 978 ± 274 1006 ± 120
gestational age (wks) 28 ± 1 5/7 27 3/7 ± 1 2/7
birth weight Z-score (SD) -1.1 ± 1.7 -0.3 ± 1.5
mode of delivery
vaginal:cesarean section
5:5 3:7
Apgar score (5 min) 9 (4 – 9) 8 (6 – 10)
CRIB score 3 (1 – 10) 2 (1 – 5)
Values are expressed as means ± SD or medians (min – max) when appropriate.
There are no differences between groups.
Figure 1. Protein intake (A) and non protein energy intake (B) in preterm infants receiving a parenteral 
cysteine intake of either 45 mg/(kg·d) () or 81 mg/(kg·d) (). The sum of parenteral and enteral 
intake is shown. Values are expressed as means ± SD. There are no differences between groups.
 
Figure 2 
 
Day 1 Day 2
0
100
200
300
400
500
600
A
O
PP
(µ
m
ol
/L
)
 
 
Figure 3 
 
Hoofdstuk 10 
 
1 2 3 4 5 6
1.5
2.0
2.5
3.0
3.5
4.0
A
day
pr
ot
ei
n 
in
ta
ke
 (g
/k
g/
d)
 
1 2 3 4 5 6
0
20
40
60
80
100
B
day
no
np
ro
te
in
 c
al
or
ie
 in
ta
ke
(k
ca
l/k
g/
d)
 
Figure 1 
 
0 1 2 3 4 5 6
7.10
7.15
7.20
7.25
7.30
7.35
7.40
day
pH
A
 
154
not higher in the CYS+ group, despite an almost double intake. Also concentrations of 
taurine, a product of cysteine catabolism, were not significantly increased in the CYS+ 
group.
Glutathione concentration and synthesis rates
All infants in both groups reached isotopic steady state after 4 hours of infusion, as rep-
resented by a non significant rise in intraerythrocytic [1-13C]glycine enrichment (Figure 
3). Mean precursor enrichments were 3.6 ± 0.6 and 3.3 ± 0.6 in the CYS and CYS+ 
group, respectively. Erythrocyte GSH concentration was 1.83 ± 0.28 mmol/L in the CYS 
Table II. Minimal and maximal fractions of inspired oxygen as from birth onwards until the end of stable 
isotope infusion.
CYS CYS+ 
Minimal FiO2 (%) 21 (21 – 27) 21 (21 – 22)
Maximal FiO2 (%) 33 (23 – 89) 31 (21 – 68) 
Values are expressed as medians (min – max). No differences between groups were observed.
Figure 2. pH (A), BE (B), and bicarbonate infusion (C) in preterm infants receiving a standard () or a 
high parenteral cysteine intake (). Values are expressed as means ± SD (A and B) or means ± SEM (C). 
* Statistically significant difference.
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group and 2.02 ± 0.18 mmol/L in the CYS+ group (p=0.10). FSRGSH was identical: 48 
± 11 %/d and 48 ± 8 %/d in the CYS and CYS+ group, respectively. ASRGSH was 8.9 ± 
2.2 mg/(kg·d) and 9.6 ± 2.1 mg/(kg·d) (p=0.49). Figure 4 shows individual data of 
each patient. We did not detect a significant gender specific difference in either plasma 
cystine concentrations or GSH kinetics.
Discussion
As cysteine is feared to cause metabolic intolerance and to be unstable, parenteral 
AA solutions contain only low amounts of cysteine or none at all. Few products offer 
separate cysteine solutions to be added to the AA mixture just prior to administration. 
In this randomized clinical trial, we demonstrate that it appears safe to administer 
Table III. Plasma amino acid concentrations.
CYS CYS+ 
glutamate 57 ± 28 61 ± 27
cystine 32 ± 10 33 ± 14
glycine 325 ± 120 281 ± 106
glutamine 570 ± 190 516 ± 176
serine 179 ± 54 166 ± 37
methionine 45 ± 24 33 ± 11
taurine 73 ± 55 85 ± 54
Values are expressed as means ± SD. There are no significant differences between groups.
Figure 3. Isotopic steady state was obtained in the standard dose () and the high dose group () 
after 4 hours of infusion, as represented by a non significant rise in intraerythrocytic [1-13C]glycine 
enrichment. Values are expressed as means ± SD.
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cysteine at a dose of 81 mg/(kg·d), although infants in the high dose group did require 
more base administration on several days. In a previous trial we showed that GSH 
synthesis was stimulated upon administration of 2.4 g/(kg·d) including cysteine at a 
dose of 45 mg/(kg·d) (11). The higher dose of cysteine in this trial nevertheless does 
not further stimulate GSH synthesis as compared to the lower dose, nor does it increase 
plasma cystine concentrations. There are a number of explanations. First, the additional 
cysteine might conserve GSH by acting as an antioxidant itself, decreasing its consump-
tion. This should, however, have resulted in either a higher GSH concentration or a 
lower synthesis rate while having similar concentrations. In addition, a higher cysteine 
dose might very well preserve GSH through inhibition of its breakdown, as one of the 
main functions of GSH is being a cysteine reservoir. Since GSH synthesis is feedback 
inhibited, GSH concentrations might be adequate already in the CYS group. In agree-
ment, Cho et al. observed that feeding cystine above the supposed requirements did 
not increase GSH of any tissue in growing rats (21). Another explanation for the lack 
of increase in GSH synthesis rate might be that cysteine is used for other purposes. In 
the present study, the additional cysteine does not seem to be broken down to form 
taurine, as taurine concentrations hardly rose upon a higher cysteine dose. Besides for 
GSH synthesis, cysteine is likely to be rate limiting for a number of proteins as well and, 
Figure 4. GSH fractional synthesis rate (A), GSH concentration (B), and GSH absolute synthesis rate (C) 
in the standard dose (CYS) and high dose (CYS+) group. Individual values are shown. The horizontal 
lines represent means ± SD. No differences were observed between the groups.
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consequently, a higher cysteine availability might be preferentially incorporated into 
proteins such as albumin. Albumin has major antioxidant capacities apart from other 
functions and is rapidly upregulated upon AA administration in preterm infants directly 
following birth (22). In addition, cysteine is abundantly present in acute phase proteins 
(23). Using cysteine for other purposes than GSH would also explain why plasma cystine 
concentrations did not rise upon a higher cysteine dose.
Compromised bioavailability of cysteine in preterm infants could be another expla-
nation why GSH synthesis rates did not increase. For example, when simultaneously 
delivered with glucose in a TPN bag, cysteine is known to form adducts (24). However, 
glucose and AAs are infused separately at our NICU. We infused cysteine as cysteine-
HCl, which is more stable in solutions than cysteine. Infused cysteine is subsequently 
rapidly taken up by the neutral amino acid transport system ASC and might then be 
used for GSH synthesis (25, 26). On the other hand, plasma is much more oxidized 
than the intracellular environment and free cysteine might be auto-oxidized to cystine, 
which is transported intracellularly via another transporter, the xc-transport system. 
This carrier also transports glutamate, which competes with cystine.
Lavoie et al. demonstrated a maturity dependent fashion of cellular cysteine uptake in 
vitro (27). Apart from maturity, gender was found to influence cellular cysteine uptake. 
Still, the present study did not find any correlation between gender and erythrocyte 
GSH concentrations in, possibly reflecting a type II error.
To overcome stability issues, more stable cysteine analogues such as N-acetylcysteine 
(NAC) have been administered to improve GSH availability or clinical outcome in pre-
term infants. Although NAC has been shown to be very effective as GSH enhancing 
substrate in rodents as well as human children and adults (28-30), it did not have any 
effect on lung damage in preterm neonates (31, 32). In children and adults, NAC is 
rapidly taken up by cells and deacetylated subsequently, making it available for GSH 
synthesis. The apparent relative inability of the preterm infant to deacetylate was con-
sidered after the observation that 53% of the intake of NAC and 38% of the intake of 
N-acetyl tyrosine (NAT) was excreted unmetabolized in urine of one-week-old preterm 
infants (33). Moreover, plasma concentrations of NAC and NAT were higher than those 
of cysteine and tyrosine. So far there are no data on long term safety aspects of these 
acetylated products.
A limiting factor for GSH synthesis, other than cysteine, might be another explanation 
for the present findings. Since the enzymes necessary for GSH synthesis are pres-
ent already during midgestation and are readily upregulated in case of increased GSH 
requirements, these are unlikely to be limiting GSH synthesis (34, 35). With respect 
to availability of other substrates: glycine has been found to be essential in preterm 
infants in a number of studies. Van Lingen et al., using [15N]glycine, found that hardly 
any added tracer was detectable in urinary urea, particularly in small for gestational 
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age infants (12). In addition, Jackson et al. measured urinary 5-L-oxoproline in preterm 
and term infants. Higher concentrations of 5-L-oxoproline are associated with decreased 
availability of glycine for GSH synthesis. The authors found a significant inverse linear 
correlation between the excretion of 5-L-oxoproline and length of gestation or birth 
weight (36). Indeed, glycine might be limiting under particular circumstances. Still, 
plasma concentrations of both glycine and glutamate, which are used as cysteine in 
equimolar amounts to synthesize GSH, are much higher than cystine concentrations in 
the present as well as other studies.
Because of ethical considerations, we did not include a group receiving no cysteine at 
all. The importance of cysteine availability per se in relation to GSH has been confirmed 
earlier in healthy adults in which turnover of GSH accounts for approximately half the 
cysteine flux in the post absorptive state (37). Two studies in preterm infants, presented 
only in abstract form, demonstrated a significant rise either in GSH fractional synthesis 
rates (erythrocytes) or concentrations (whole blood) upon amino acid administration 
containing cysteine as compared to no cysteine (20, 38). Rats fed a low protein diet 
(3%) were unable to increase GSH production upon administration of 98% oxygen, 
in contrast to rats fed a 25% protein diet. When the 3% diet was supplemented with 
cysteine, lung GSH concentrations increased during oxygen exposure. However, supple-
mentation of the 25% protein diet with cysteine did not further protect these animals 
(39).
Conclusions
Cysteine administered at a dose of 81 mg/(kg·d) appears to be safe, but does not 
increase GSH synthesis rates as compared to a dose of 45 mg/(kg·d). Further research 
should be directed towards defining the requirements of cysteine in the parenterally fed 
preterm neonate in the direct postnatal phase.
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Abstract
Critically ill infants requiring aggressive ventilatory support are subjected to a high 
load of reactive oxygen species (ROS) and may experience serious oxidative stress 
and therefore have increased antioxidant consumption. Glutathione (GSH) is the major 
intracellular antioxidant but might not function optimally in the direct neonatal phase.
We performed an observational study including infants suffering from perinatal as-
phyxia, infants requiring extra corporeal membrane oxygenation (ECMO), and relatively 
healthy, partially enterally fed preterm infants. We measured plasma concentrations of 
advanced oxidized protein products (AOPP) and dityrosine, both markers of oxidative 
stress. In addition, using stable isotopes ([1-13C]glycine) we determined GSH fractional 
and absolute synthesis rates in erythrocytes.
Eleven asphyxiated infants, eight infants on ECMO, and ten preterm infants were 
included in the first week of life. Both AOPP and dityrosine concentrations were present 
in significant amounts in all groups. As compared to relatively healthy preterm infants, 
GSH concentrations and synthesis rates are not higher in asphyxiated infant, but GSH 
absolute synthesis rates were higher in infants on ECMO. This was primarily due to the 
larger pool size in infants on ECMO.
In conclusion, both asphyxiated infants, infants requiring ECMO and preterm infants 
experience major oxidative stress as reflected by the presence of markers of oxida-
tive stress. GSH absolute synthesis rate is markedly higher in infants receiving ECMO 
therapy.
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Introduction
Critically ill neonates requiring intensive care are often subjected to aggressive treat-
ment modalities, including ventilatory support with high fractions of inspired oxygen. 
Hyperoxia, but also hypoxia and reperfusion are known to generate significant amounts 
of reactive oxygen species (ROS), which may cause irreversible cellular damage if not 
counterbalanced by adequate antioxidant availability. Indeed, these infants are prone 
to develop oxidative stress, which may contribute to the risk of morbidity and mortality 
(1, 2).
Glutathione (GSH), the major intracellular antioxidant, built up from glutamate, 
cysteine, and glycine, is synthesized de novo within almost all cells (3). As we have 
recently shown, its synthesis is readily upregulated following amino acid (AA) admin-
istration in preterm infants receiving hyperoxic treatment (4). A number of clinical 
conditions and treatment strategies involving increased ROS production are likely to 
increase GSH demands. Here, we report on oxidative stress and antioxidant defense in 
i) asphyxiated infants receiving conventional ventilatory support and ii) infants treated 
with extra corporeal membrane oxygenation (ECMO) for various reasons, such as 
congenital diaphragmatic hernia or meconium aspiration syndrome, and iii) relatively 
healthy preterm infants.
Perinatal asphyxia
Incidence rates of perinatal asphyxia vary dependent on definitions being used, but 
may occur in 1.8 to 6.9 per 1,000 live borns (5). ROS, which are believed to play a role 
in the development of hypoxic ischemic encephalopathy in asphyxia (6), are formed 
during the hypoxic event, and in the reperfusion phase directly following hypoxia (7), 
as well as during resuscitation with high concentrations of oxygen (8). In the postnatal 
course, the AI is often in need of mechanical ventilation with supraphysiologic oxygen 
concentrations, which can cause further intracellular ROS formation.
Treatment with extra corporeal membrane oxygenation (ECMO)
ECMO is a highly invasive procedure that uses an artificial lung to take over the work 
of the lungs with regard to gas exchange, and depending on the mode (veno-venous or 
arterial-venous), also the heart. ECMO is used most often in newborns and young children 
and may be continued up to several weeks. Indications for ECMO are very strict and the 
number of infants and children eligible for ECMO treatment is small. The purpose is to 
support or replace temporarily failing lungs by providing oxygen and removing carbon 
dioxide waste products so the lungs can rest and recover. Infants needing ECMO may 
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include those with meconium aspiration syndrome, persistent pulmonary hypertension, 
and congenital diaphragmatic hernia. One of the characteristics of ECMO treatment, 
and in view of this study of particular interest, are the dramatic fluctuations of partial 
oxygen pressure (pO2). A high pO2 is associated with low GSH availability (9).
Augmenting GSH availability by increasing its production rate might be effective to 
remedy oxidative stress. We therefore conducted an observational study to measure 
synthesis rates of GSH in erythrocytes of asphyxiated infants and ECMO treated infants. 
We compared these infants with a group of relatively healthy, anabolic preterm infants, 
since it is ethically not justified to determine GSH kinetics in healthy term infants, due 
to the required venous access and blood sampling. To quantify oxidative stress, we 
measured advanced oxidized protein products (AOPP) and dityrosine, both markers 
of protein oxidation (10, 11). We hypothesized that asphyxiated infants and infants 
requiring ECMO experience high amounts of oxidative stress which is compensated for 
by a high GSH synthesis shortly after birth.
Methods
Patients
Asphyxiated infants, infants requiring ECMO treatment, and relatively healthy preterm 
infants, admitted to the neonatal intensive care unit and the children’s intensive care unit 
of the Erasmus MC - Sophia Children’s Hospital in Rotterdam, respectively, were enrolled 
in the study. Infants were born between September 2005 and June 2007. Written and oral 
parental informed consent was obtained prior to study. The study was approved by the 
Erasmus MC Medical Ethical Review Board. The following inclusion criteria were applied 
for the group of asphyxiated infants: gestational age > 35 weeks; umbilical cord pH 
<7.10; 5-minute Apgar score ≤ 6 and clinical signs of asphyxia (Sarnat stage II or III). 
Exclusion criteria were known congenital abnormalities, chromosome defects, hemolytic 
disorders, endocrine, renal or hepatic disorders or transfused with erythrocytes during 
or within 12 hours prior to the study. During and prior to the study, asphyxiated infants 
received parenteral nutrition and, if tolerated, minimal enteral feeding.
Inclusion criteria for ECMO treatment were failure to respond to conventional medical 
support including high frequency ventilation, surfactant therapy, inhaled nitrogen oxide 
(20 ppm), vasopressors and hydrocortisone. Infants were eligible for ECMO when the 
oxygenation index was higher than 40. Infants on ECMO received both parenteral and 
enteral nutrition.
Inclusion criteria for preterm infants were birth weight < 1500 g and an indwelling 
arterial catheter. These infants received both parenteral and enteral nutrition as well. 
Exclusion criteria were similar to the group of asphyxiated infants.
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At entry of the study, we recorded birth weight, gestational age, and Apgar scores 
for all infants. For the asphyxiated infants we also recorded umbilical cord pH, BE, 
and postnatal lactate levels. We also recorded plasma amino acid concentrations, and 
protein intake.
Tracer infusion protocol
[1-13C] glycine (99% enriched, sterility and pyrogenicity tested) was purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA) and was dissolved with a 0.9% 
saline solution by the hospital’s pharmacy after it was again tested for identity, sterility 
and pyrogenicity.
All infants received a primed (40 µmol/kg) continuous (20 µmol/kg/h) infusion of [1-
13C]glycine for 6 hours. Blood samples (400 µL each) were collected from an indwelling 
arterial catheter in microtainers containing EDTA after 4, 5 and 6 hours of infusion. 
Samples were immediately put on melting ice after which they were centrifuged for 10 
minutes (3500 x g) at 5ºC. The plasma fraction was removed and stored separately for 
measurement of oxidative stress markers. The lower layer containing primarily erythro-
cytes was reconstituted to its original volume with ice-cold distilled water to disrupt cell 
membranes. The plasma fraction and cell fraction were subsequently stored at -80ºC 
until further analysis.
For studying GSH kinetics, we used a recently developed technique described pre-
viously, based on liquid chromatography coupled to isotope ratio mass spectrometry 
(LC-C-IRMS) (Thermo Electron, Bremen, Germany) (12). This highly sensitive method 
requires only a very small sample volume, whereas no derivatization is required. Eryth-
rocyte [1-13C]glycine was considered the precursor for GSH synthesis and was measured 
according to our earlier developed method on the derivatization of threonine (13, 14).
Plasma concentrations of direct GSH precursors glutamate, glycine, and cysteine 
(measured as cystine), and indirect precursors methionine and serine, were determined 
with a Biochrom 30 amino acid analyzer, using ninhydrin detection (Biochrom Ltd, Cam-
bridge, England). GSH synthesis is depicted in Figure 1.
Calculations
The fractional synthesis rate (FSRGSH) represents the fraction of the total intraeryth-
rocytic GSH pool that is renewed per unit of time, and is expressed as %/d. It was 
measured according to the precursor-product equation: 
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where E stands for enrichment expressed as mole percent excess (MPE). The nomina-
tor (product) of this equation represents the hourly increase in [1-13C]glycine bound 
GSH as calculated from the increase in enrichment between 4 and 6 hours of infusion. 
The denominator (precursor) represents the intraerythrocytic 1-13C enrichment of free 
glycine at isotopic steady state. A steady-state plateau was defined as an insignificant 
change with time in intraerythrocytic enrichment. Subsequently, the intravascular abso-
lute synthesis rate (ASRGSH) was calculated by the following equation:
ASRGSH (mg/(kg⋅d) = FSRGSH/100 x conc x 307x ht x 0.070 (asphyxiated and preterm 
infants)
or
ASRGSH (mg/(kg⋅d) = FSRGSH/100 x conc x 307x ht x 0.210 (infants on ECMO)
where conc is concentration in mmol/L packed erythrocytes, 307 is the molecular 
weight of GSH, ht is hematocrit, and 0.070 and 0.210 are the estimated circulating 
volumes expressed as L/kg, in asphyxiated and preterm infants, and infants on ECMO, 
respectively.
Plasma marker of oxidative stress
We measured the advanced oxidation protein products (AOPP) in plasma by the spec-
trophotometric assay described by Witko-Sarsat et al. (10). Because the absorbance of 
chloramine-T at 340 nm is linear up to 100 µmol/L, AOPP concentrations were expressed 
as µmol/L chloramine-T equivalents.
Dityrosine has been recognized as an oxidative stress product of pathological response 
to disease or other environmental stress (11, 15). Its concentration was measured ac-
cording to the method described by Abdelrahum et al., based on liquid-liquid extraction, 
reversed-phase chromatography and fluorescence detection (16).
Figure 1. GSH synthesis pathway.
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Statistics
Statistical analyses were performed using SPSS v14.0 (SPSS Inc, Chicago, IL, USA). 
Data are expressed as means ± SD or as medians (min – max).
Results
Eleven asphyxiated infants, eight infants on ECMO, and ten preterm infants were in-
cluded. Clinical characteristics of both groups as well as the group of preterm infants 
can be found in Table I.
Asphyxiated infants had a mean umbilical cord pH of 6.89 ± 0.16, an umbilical cord 
base deficit of 21 ± 7, and a lactate concentration of 8.3 ± 5.5 on postnatal day one. All 
asphyxiated infants were resuscitated with 100% oxygen, and subsequently ventilated 
with additional oxygen for at least one day.
Infants in the ECMO group were receiving arterial-venous ECMO treatment for the 
following reasons: three infants had a congenital diaphragmatic hernia, three infants 
suffered from meconium aspiration syndrome, one infant had a congenital cystic ad-
enomatoid malformation of the lung, and one infant had an omphalocele. Asphyxiated 
infants were studied on postnatal day three, and preterm infants on postnatal day six. 
Infants on ECMO were studied at an age of 6 ± 3 days, while ECMO was initiated at day 
5 ± 3 days of life.
The total protein intake of the day of study in the asphyxiated infants was 1.8 ± 0.6 g/
(kg·d) and in the ECMO group 2.3 ± 0.5 g/(kg·d). In the group of preterm infants protein 
intake was 2.7 ± 0.3 g/(kg·d).
Oxidative stress markers are shown in Figure 2. AOPP levels in asphyxiated infants, 
infants on ECMO, and preterm infants were 247 ± 83, 178 ± 47, and 293 ± 76 µmol/L, 
respectively. Dityrosine concentrations were 3.6 ± 5.0 ng/mL in asphyxiated infants, 
15.5 ± 10.2 ng/mL in infants on ECMO and 9.6 ± 3.5 ng/mL.
Figure 3 shows enrichment of the precursor, free intraerythrocytic [1-13C]glycine, 
between four and six hours of infusion. In all groups, a plateau was reached after four 
hours of infusion, which was defined as no significant increase in enrichment.
Figure 4 shows erythrocyte GSH concentrations, FSRGSH and ASRGSH.
FSRGSH was 52 ± 12 %/d in asphyxiated infants, 65 ± 17 %/d in infants on ECMO, and 
49 ± 11 %/d in preterm infants. Erythrocyte GSH concentration was 1.9 ± 0.3 mmol/L 
in asphyxiated infants, 2.0 ± 0.3 mmol/L in infants on ECMO, and 1.6 ± 0.4 mmol/L in 
preterm infants.
Due to the larger pool size in infants in the ECMO group, ASRGSH are clearly higher in 
the ECMO group. Mean values are 9 ± 2 mg/(kg·d) in asphyxiated infants, 23 ± 4 mg/
(kg·d) in infants on ECMO, and 6.0 ± 1.4 mg/(kg·d) in preterm infants.
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Table II shows plasma concentrations of all AAs directly or indirectly involved in GSH 
synthesis in asphyxiated infants, infants on ECMO, preterm infants as well as a refer-
ence group of healthy term breast-fed infants (17).
Discussion
Seriously ill infants such as included in this study require intensive care treatment, 
which is primarily focused on vital functions, such as cardiorespiratory support. Oxida-
tive stress is not anticipated for by any specific form of treatment, although it may have 
profound effect on outcome. In this study we used AOPP and dityrosine to reflect protein 
oxidation. Because amino acids, peptides and proteins are vulnerable to attacks by 
ROS, these attacks can result in amino acid aggregation, cross linking and fragmenta-
tion (18). AOPP and dityrosine concentrations thus reflect protein oxidation following 
oxidative stress and can be considered as reliable markers of oxidative stress. Previous 
studies on AOPP in the neonate showed elevated AOPP levels in hypoxic premature 
neonates at birth and at the 7th day of life (19, 20). From this study, it follows that both 
asphyxiated infants, infants requiring ECMO treatment and preterm infants experience 
oxidative stress, evidenced by presence of AOPP, comparable to results earlier obtained 
in preterm infants (20), and dityrosine.
Oxidative stress in asphyxiated infants is in agreement with earlier studies on lipid 
peroxidation in the neonatal period, showing elevated levels of non protein bound iron, 
a sensitive indicator of oxidative stress, and lipid peroxidation in asphyxiated infants 
compared to healthy neonates (21, 22). Moreover, urinary excretion of lipid peroxida-
tion products may be used to predict death in perinatal asphyxia (23).
Despite presence of oxidative stress, this is not compensated for by an increased FS-
RGSH or ASRGSH. Although asphyxiated infants received the lowest protein intake, plasma 
concentrations of GSH substrates were all within reference ranges. The relatively low 
Table I. Clinical characteristics of asphyxiated infants (Asphyxia), infants on ECMO (ECMO) and preterm 
infants. Data are expressed as mean ± SD. 1Data adapted from Te Braake et al. 2008.
Asphyxia ECMO Preterm infants1
N (male: female) 11 (7:4) 8 (4:4) 10 (8:2)
Gestational age (wks) 39 2/7 ± 2 39 1/7 ± 1 5/7 26 4/7 ± 1 1/7
Birth weight (g) 3458 ± 612 3170 ± 337 820 ± 134
Apgar score (5’) 3 ± 2 6 ± 2 7 ± 3
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ASRGSH might be explained by the fact that the measurements were performed on post-
natal day 3, whereas the hypoxic event had occurred in the perinatal period. Although 
it might be argued that the most dramatic impact on GSH demands is expected to 
occur in the direct postnatal phase, ethical constraints impeded measurements in this 
critical period. On the other hand, the asphyxiated neonates are ventilated with high 
concentrations of oxygen for hours to days, which earlier resulted in elevated levels of 
oxidized GSH on postnatal day 3 which remained present up to 4 wks of age (8, 24). As 
a response to prolonged ROS production, FSRGSH and ASRGSH would be expected to be 
increased for days and therefore measurable on postnatal day 3. Another explanation 
for the seemingly low GSH synthesis rates might be hepatic dysfunction as a sequella 
of asphyxia. The GSH synthesis apparatus is primarily produced by organs such as the 
liver and kidney which are known to be very sensitive to asphyxia inflicted damage.
At time of our study, 100% oxygen was administered to resuscitate asphyxiated 
infants. Nowadays, the use of 100% oxygen is no longer the standard of care in the 
Figure 2. AOPP (A) and dityrosine (B) concentrations. The grey bar shows data obtained in relatively 
healthy anabolic preterm infants. Bars present mean ± SD.
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Figure 3. Precursor enrichment (MPE). Values are depicted as mean ± SD. asphyxiated infants; infants 
on ECMO;  preterm infants.
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resuscitation of the newborn. Using room air instead of 100% of oxygen was found to 
be safe and resulted in a better outcome of asphyxiated infants (25, 26). Currently, we 
don’t know the effects of a lower fraction of inspired oxygen on oxidative stress and 
GSH kinetics, but future studies will be performed to investigate this issue.
GSH is synthesized by glutamate, glycine and cysteine. The latter is considered the 
limiting substrate for GSH synthesis. Although ECMO enables the lung to rest and re-
cover, it is a highly invasive procedure and results in a profoundly hypermetabolic and 
catabolic state (27, 28). However, nutrition is not considered of primary importance in 
Figure 4. FSRGSH (A), erythrocyte GSH concentration (B), and ASRGSH (C). Data are expressed as mean ± 
SD.
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Table II. Plasma concentrations (µmol/L) of amino acids involved in GSH synthesis  in term healthy 
infants. Data are expressed as mean ± SD 1Adapted from Wu et al. 1986.
Asphyxiated infants (n=11) ECMO (n=8) Preterm infants 
(n=10)
Term healthy infants1
Glutamate 105 ± 39 108 ± 71 53 ± 13 76 – 551 
Cystine 40 ± 14 48 ± 33 23 ± 11 33 – 55 
Glycine 380 ± 79 376 ± 21 318 ± 135 66 – 432 
Serine 203 ± 59 188 ± 79 171 ± 45 79 – 227 
Methionine 36 ± 6 41 ± 19 22 ± 6 21 – 55 
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these infants resulting in low cysteine availability (29). In fact, to minimize burden to 
the gastrointestinal tract, some of these sick infants receive parenteral nutrition as their 
primary source of nutrition during the acute phase of their illness. This might negatively 
impact on antioxidant defense and augment oxidative stress. In healthy lambs, it was 
found that treatment with ECMO resulted in a significant drop in antioxidant enzymes, 
such as superoxide dismutase and glutathione reductase (30).
Our data show that the intravascular ASRGSH in infants on ECMO is higher than in 
both asphyxiated infants and preterm infants. Although infants on ECMO showed to 
have the highest FSRGSH, their significantly higher circulating volume is predominantly 
responsible for their ASRGSH. However, there are some limitations with respect to these 
data. First, the ECMO system contains a large amount of donor blood and most infants 
frequently require transfusions. Although the in vivo half life of GSH in erythrocytes 
under conditions of oxidative stress is unknown, it is conceivable to have influenced our 
data. However, blood transfusions are inherent to ECMO treatment, and we performed 
our measurements at least 12 hours after the last transfusion. In addition, by measur-
ing the FSRGSH, we measured real time GSH synthesis.
Second, the significantly higher ASRGSH might not seem surprisingly considered the 
higher circulating volume. On the other hand, erythrocytes have shown to be powerful 
donors of antioxidant defense, including GSH, to other tissues (31-33). In addition, the 
ECMO system is not metabolically active.
Because antioxidants work synergistically, the decline of one oxidant can be prevented 
by another antioxidant. Therefore the GSH concentration and kinetics alone do not allow 
for a total antioxidant activity in the neonate. Although GSH is the main intracellular 
antioxidant which has concentrations in the millimolar range, by only measuring GSH 
kinetics, we demonstrated a limited aspect of total antioxidant status in relation to 
oxidative stress.
In conclusion, in this study, we showed that both anabolic preterm infants, term 
asphyxiated infants as well as term infants on ECMO experience considerable oxidative 
stress. In asphyxiated infants, this was not compensated for by an increased GSH 
synthesis rate, which is not due to a lack of substrate availability. It might be inherent 
to a relatively deficient GSH synthesizing apparatus.
Infants on ECMO show significant GSH synthesis rates, although interpreting these 
values requires caution due to the high circulating volume.
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12 General discussion

Introduction
Historically, innovations in the early postnatal management of preterm infants have 
primarily been targeted to immediate life threatening issues, such as respiratory and 
circulatory support and prevention of infectious disease.
Nutrition is increasingly being recognized as a crucial part of treatment strategies for 
preterm infants. However, nutritional requirements and tolerance of preterm infants 
seem to differ markedly from term newborns who are capable of digesting breast milk 
which provides principally all essential nutrients to meet their specific demands. At 
present we have not determined these specific nutritional requirements of preterm 
infants, both in terms of quality and quantity. Moreover, in defining their needs, we 
are troubled by issues such as fluid restrictions, intolerance to enteral feeding, and 
heterogeneity of the population.
This thesis focuses on amino acids in particular, investigating their effects on differ-
ent biochemical indices of neonatal wellbeing, i.e. protein synthesis and antioxidant 
defense.
In the following paragraphs the major findings and their clinical implications will be 
discussed in the context of relevant literature. Subsequently, some methodological 
considerations will be dealt with and future research purposes will be highlighted.
Major Findings
PART I – amino acid administration and protein metabolism
The first part of this thesis has dealt with safety aspects and anabolic effects of early AA 
administration in preterm infants. Most of the body growth and development of preterm 
infants, such as discussed in this thesis, occurs outside of the uterus. Indeed, when 
the umbilical cord is cut, nutrient delivery abruptly ceases, while organogenesis is still 
incomplete at preterm birth. This necessitates rapid restoration of nutrient supply with 
the goal of minimizing interruption of growth and development.
In the absence of parenteral nutrition and not being able to receive enteral feedings 
in the direct postnatal period, an infant is dependent on its own protein stores for 
obligatory protein catabolism, costing approximately 1.0 g/(kg⋅d) or 1 to 2 % of its 
endogenous protein stores each day when receiving glucose only(1). An age-matched 
fetus will still be accreting protein at a rate of approximately 1.5 g/(kg⋅d). The latter 
growth rate should actually be aimed at in the feeding of preterm infants, but is often 
not achieved(2, 3). As a result, many infants born appropriate for gestational age will 
leave the hospital small for gestational age(4).
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In the first part of this thesis we described early nutritional strategies to promote 
anabolism in the first days of life. We showed that administering AAs (2.4 g/(kg·d)) 
directly following birth is safe and converts a negative nitrogen balance into a positive 
one (chapter 2). In addition, using stable isotopes, we demonstrated this anabolic 
state to be caused by increased protein synthesis rather than decreased proteolysis 
(chapter 3). Several studies on AA kinetics have shown a marked difference in protein 
metabolism between preterm infants and term infants. There is a negative correlation 
between gestational age and protein loss, resulting in a doubling of the protein losses 
in ELBW infants as compared to term infants(5). During protein administration, term 
infants(6) and adults(7) respond by decreasing proteolysis, whereas fetuses(8) and 
preterm infants(9-13) increase protein synthesis, rather than suppressing breakdown.
In chapter 3, we found that the energy required for protein synthesis was not de-
rived from increased glucose oxidation, but seemed partly derived from increased AA 
oxidation. Increased AA oxidation is likely to be the cause of the higher blood urea 
nitrogen (BUN) levels we found in infants receiving AAs as compared to infants receiving 
glucose only.
Amino acid administration directly following birth is safe and converts a cata-
bolic into an anabolic state. Energy for protein synthesis is not derived from 
increased glucose oxidation.
An ideal nutritional strategy provides for amounts of AAs and energy that satisfy the 
needs for both growth and metabolism. There is ongoing controversy whether AAs 
should be regarded as metabolic fuel or not. Their main function lies in protein synthe-
sis, but it remains unsolved to what extent it is physiological for AAs to be oxidized for 
energy generation. Reasons for AAs to be oxidized include energy generation in general, 
and second, to avoid accumulation in case one or more AAs are present pro rata more 
abundantly than those needed for the composition of proteins to be synthesized.
In the ovine fetus, the umbilical supply of AAs highly exceeds the amount deposited 
for tissue growth. Oxidation contributes 25 to 50% of fetal AA uptake(14, 15). To what 
extent this also holds true for the human fetus is largely unknown, since human fetal 
studies are restricted by technical and ethical concerns.
Studies have demonstrated that AA administration combined with as little as 30 
non-protein kcal/(kg·d) can turn the nitrogen balance from negative into zero or even 
positive(16-18). Advanced feeding strategies and improved neonatal AA solutions have 
changed suggested AA intake related to minimal energy intake from approximately 1.0 
g AAs per 30 kcal non-protein energy to 1.0 g AAs per 15 kcal nonprotein energy. As this 
is not an ideal proportion of energy for optimal protein synthesis, a considerable amount 
of the AAs will be oxidized. An intake of 25 to 40 kcal of nonprotein energy per gram of 
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protein will enhance optimal protein deposition, though this is not feasible with glucose 
alone in early preterm life at larger protein intakes(19). However, the effect of increasing 
energy intakes on protein deposition will be greatest below 50-60 kcal/(kg·d), above 
which the beneficial effect of extra energy ceases and the amount of administered AAs 
itself will have a higher correlation with anabolism(20). Besides its anabolic effects, AA 
administration can increase maximal non-protein caloric intake. This can be partially 
attributed to enhanced insulin secretion following AA administration (notably arginine 
and leucine)(21). Many studies indeed found lower glucose concentrations during AA 
administration(12, 18, 22).
Early lipid administration, with its high caloric content of 9 kcal/g, might be benefi-
cial in delivering calories for the cost of protein synthesis. Furthermore, the infant is 
dependent on essential fatty acids for its brain maturation. The fetus receives only a 
small amount of lipids at the beginning of the third trimester, which raises the question 
whether the very preterm infant is suited to metabolize lipids in large amounts. As 
compared to AAs, data on early administration of lipids are scarce. Supposed metabolic 
intolerance (increased risks of sepsis, displacement of bilirubin from albumin, and pul-
monary complications) and an association with development of BPD have led to their 
delayed introduction, often beyond the first 24h postnatally. A recent review from the 
Cochrane Collaboration found no statistically significant effects of early introduction of 
lipids on short term nutritional or other clinical outcomes. Neither benefits nor adverse 
effects were demonstrated in the studies reviewed(23). However, no AAs had been 
administered in the studies included in the review. Concomitant administration of AAs 
could theoretically have enhanced lipid utilization. Indeed, Ibrahim et al. administered 
both AAs and lipids to a small group of preterm infants directly from birth onwards, 
which resulted in an anabolic state without increased BUN levels, suggesting adequate 
use of lipids as energy source(22).
Our present knowledge of feeding the preterm infant is based on research over the 
last decade in relatively healthy preterm infants. Today, however, we treat ELBW in-
fants, who have higher nutritional requirements than VLBW infants, which are even 
more difficult to meet as a consequence of the clinical problems involved. To underline 
this assumption, in a group of 69 ELBW infants energy and protein deficits were found 
to be inversely related to birth weight(24).
In chapter 3 we demonstrated stimulatory effects of AAs on whole body protein 
synthesis, as calculated from leucine incorporation into body protein. Studying whole 
body metabolism has limited value, however, since it only provides information on the 
average of all metabolic processes in the body rather than organ specific changes. 
Therefore, we studied whether administration of AAs directly following birth also stimu-
lates organ specific protein synthesis as compared to glucose only in VLBW infants. We 
studied albumin synthesis, which can be quantified by measuring the incorporation rate 
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of [1-13C]leucine into plasma albumin (chapter 4). Our data show increased albumin 
concentrations and synthesis rates following AA administration as compared to infants 
receiving glucose only. Seeing that albumin has important functions, among which serv-
ing as an antioxidant and binding bilirubin and free fatty acids, stimulating albumin 
synthesis might positively influence outcome.
Early nutrition and clinical outcome
The clinical trials presented in Part I have investigated immediate effects of AA ad-
ministration on protein metabolism (chapter 2, 3, 4). Short-term outcome of early 
nutrition has found to be beneficial. Whether improvements in the postnatal phase are 
extended throughout the neonatal period and thereafter is still unclear. On the other 
hand, improving nutritional care in the direct postnatal phase might contribute to de-
creased infant and early childhood morbidity. Outcome criteria of early nutrition can be 
based upon different aspects, such as intrauterine growth charts(25) or growth charts 
obtained from premature infants(3, 26, 27), incidence of specific disease, hospital stay, 
etc. Although relatively little is known about medium or long-term outcome parameters 
involving early nutrition, it is known that impaired growth due to suboptimal nutrient 
intake in preterm infants has both adverse consequences during hospitalization and 
after discharge. Short-term consequences might include high infectious disease vulner-
ability arising from suboptimal immune defense, free radical mediated damage caused 
by impaired antioxidant production, and increased requirement for ventilatory support, 
partially due to muscle weakness(28).
Some studies found favorable effects of early and/or high AA supplementation in the 
neonatal period on the incidence of BPD(28, 29) and retinopathy of prematurity (ROP)
(28) whereas others did not(30, 31). In most studies anthropometric measurements 
had improved at discharge(30-33) whereas this effect seemed to be disappeared at 18 
months of age(30). An explanation is that preterm infants are likely to have periods of 
growth delays during hospitalization related to the medical or nutritional consequences 
of their illnesses and some former preterm infants will therefore remain small through-
out life.
Not until the 1990s scientists began to show more interest in effects of early malnutri-
tion on neurodevelopment(34, 35). A study of Latal-Hajnal et al. in 219 VLBW infants 
found favorable effects of a rapid postnatal weight-gain on neurodevelopment, as as-
sessed by Bayley Scales of Infant Development(34). In contrast, no differences were 
found in a larger study (including over 1000 ELBW infants) conducted by Poindexter et 
al. at 18 months corrected age(30). However, in this study infants who received ≥3 g/
(kg·d) of parenteral AAs within the first 5 days of life were considered “early”, which in 
fact might not be considered early according to current opinion.
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In chapter 5 we presented data describing anthropometric data and neurodevelop-
mental outcome in our cohort of infants described in chapter 2. The intervention group 
received AAs (2.4 g/(kg·d)) as from birth onwards, whereas the control group received 
glucose only during the first two days of life. Although a trend towards less handicaps 
was observed in the intervention group, these follow-up data do not show any statisti-
cally significant differences between groups. This on the one hand reconfirms safety, 
and on the other hand would suggest no clinical benefit for the preterm infant. Recently, 
concerns have been raised towards safety of early AA administration(36). Therefore, 
this follow up study was conducted primarily to exclude adverse long-term effects. 
Whether early AA administration has significant clinical benefits for early childhood and 
later life, needs to be studied in larger trials specifically designed and thus powered to 
answer these questions.
Increased susceptibility for later disease is another nutrition related long-term effect 
which has gained a lot of interest. Of particular interest is the Barker Hypothesis. This 
theory states that by adapting to an environment with limited supply of nutrients (meta-
bolic imprinting), such as early neonatal malnutrition, the fetus preferably reserves its 
nutrients for essential organs such as the brain. As a consequence, ‘nonessential’ organs 
such as the pancreas and kidney may become deprived. Reduced cell growth in these 
organs during critical periods of malnutrition results in susceptibility to cardiovascular 
disease, diabetes mellitus or renal insufficiency(37).
Early amino acid administration is safe with regard to neurodevelopmental 
outcome at two years of age. Large randomized clinical trials are needed to 
study whether early amino acid administration improves outcome in early 
childhood and later life.
PART II – amino acid administration and antioxidant defense
The second part of this thesis has dealt with nutritional aspects of oxidative stress and 
glutathione (GSH) metabolism. Essentially, there are two different means of preventing 
harm caused by oxidative stress: the first is to prevent excess formation of reactive 
oxygen species (ROS), i.e. beyond physiological levels. However, this seems not a very 
realistic goal, since, as stated in chapter 1, ROS are generated during many events 
and in many pathways, such as hyperoxia, ischemia-reperfusion, and activation of 
phagocytes. The second means of preventing toxicity by oxidative stress is to enhance 
antioxidant defense systems, which can intercept ROS or repair damage. Early nutri-
tion is a key-factor in promoting antioxidant defense and has been the main subject 
throughout this part of the thesis. Although GSH is the main intracellular antioxidant, it is 
important to realize that total antioxidant defense is the result of the interplay between 
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other intracellular and extracellular antioxidants, such as vitamin C and vitamin E. GSH 
synthesis is primarily dependent on presence of its synthesizing enzymes, activity of 
AA transport mechanisms across cellular membranes, and availability of substrates. In 
chapter 7 we demonstrated that birth weight and Z-score for birth weight are inversely 
correlated to GSH fractional synthesis rate (FSRGSH), thereby confirming the GSH syn-
thesizing apparatus to be active. Our data agree with results obtained from earlier 
studies demonstrating presence of these enzymes in leukocytes obtained from tracheal 
aspirates and cord blood and in autopsy samples of fetal liver, lung, and kidney(38, 39). 
In addition, even during starvation, GSH synthetic enzymes appear to be maintained for 
readiness of GSH synthesis upon substrate availability(40).
Uptake of GSH substrates is another requirement for GSH synthesis. Lavoie et al. 
determined L-[35S]cysteine uptake capacity in leukocytes of cord blood and tracheal 
aspirates of infants of varying gestational ages(41). It was found that the maturity of 
female but not male newborns was positively correlated with cysteine uptake and from 
this it was concluded that cysteine uptake might be compromised in preterm infants. 
However, we did find active GSH synthesis in erythrocytes of preterm infants which 
increased dramatically upon AA administration. This can only be achieved by uptake 
of substrates, including cysteine. In addition, our data in chapter 3 and 4, showing 
increased whole body protein synthesis and albumin synthesis upon AA administra-
tion, suggest intact cysteine uptake in other cells besides erythrocytes. Also, Shew et 
al. demonstrated increased GSH synthesis rates upon administration of cysteine(42). 
However, these data were only presented in abstract form. Whether there is a relatively 
compromised uptake of cysteine or the results of Lavoie et al. represent an in vitro 
artifact remains undetermined.
The final requirement for GSH synthesis is availability of substrate. Collectively, the 
results in this thesis suggest this to be the most important determinant in GSH availabil-
ity in preterm infants in the immediate postnatal phase. This will be further discussed 
below.
Glutathione availability in the preterm infant
In 1958, Szeinberg et al. were among the first to report on GSH metabolism in newborn 
infants(43). They concluded that GSH concentration in cord blood and blood obtained 
in the early neonatal phase was significantly higher than in adult blood. Still, term 
newborns experienced a “transient decreased resistance of GSH to oxidative agents” 
during the first hours of life, which could be ameliorated by providing glucose or inosine 
to the infant. The mechanism by which the glucose and inosine exerted their protective 
effect remained unclear.
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In 1984, Lestas et al. compared concentrations of GSH, GSH reductase, GSH peroxi-
dase, and GSH synthesizing enzymes glutamate cysteine ligase and GSH synthetase 
between fetal blood (17-24 wks gestation) and neonatal and adult blood(44). In parallel 
with Szeinberg et al, they found higher GSH concentrations in fetuses (cord blood) 
compared to adults. From these studies, it seemed that there would be a certain prepa-
ration for transition to the extrauterine environment. It was speculated that this would 
anticipate for oxidative stress arising from increased oxygen exposure and other oxidant 
stressors such as inflammation, UV radiation, etc. Frank et al. first demonstrated this 
concept in vivo studying antioxidant enzymes in developing rabbit lung(45). It was 
found that during the final days in utero, superoxide dismutase and catalase activities 
increased by approximately 110% whereas lung GSH peroxidase activity increased by 
approximately 200%. More recently, this phenomenon was demonstrated in human 
infants as well, where term labor was associated with increased erythrocyte GSH con-
centrations whereas preterm labor was not(46).
Nowadays we are able to treat increasingly preterm infants. Improved methodology 
enables measurements of GSH concentrations in smaller sample sizes as required in 
these infants. Early studies of Szeinburg et al., suggesting high GSH concentrations 
in the near term human fetus, contrasts with values obtained in newborn preterm 
infants, which are usually found to be low. In most studies involving human neonates, 
concentrations of GSH and/or its derived enzymes are determined in whole blood, 
plasma, erythrocytes, bronchoalveolar lavage fluid, or occasionally tissue samples 
obtained during surgical procedures or autopsy. Although caution should be exercised 
when comparing those studies due to the different analytical techniques being used, 
the majority of studies report a drop in GSH concentration in preterm infants during the 
first days of life or a low GSH concentration as compared to term infants, older children 
or adults(47-50). When comparing these studies to our study, a marked difference in 
nutritional intakes between preterm infants is observed. In the studies reporting low 
GSH concentrations in preterm infants as compared to term infants, AAs were either 
not provided at all, or did not include any cysteine, which is generally present in low 
concentrations in plasma of preterm infants.
From our studies in human infants, it follows that the compromised GSH availability in 
erythrocytes of preterm infants is primarily due to nutritional deprivation which can eas-
ily be converted into concentrations which seem to be adequate upon more aggressive 
nutritional support. Similar, Chessex et al. fed neonatal guinea pigs either intravenous 
glucose or glucose and AAs. When challenged with oxygen therapy, only the AA group 
increased liver GSH twofold(51).
In chapter 8, we demonstrated that FSRGSH on the second day of life was not higher 
in the group receiving AAs as from birth onwards as compared to infants receiving 
glucose only, suggesting feedback inhibition of GSH synthesis following decreased GSH 
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consumption. This is supported by the fact that we did not find a further increase in GSH 
synthesis upon administering a higher dose of cysteine, generally considered as the rate 
limiting substrate for GSH synthesis (chapter 10).
Decreased glutathione concentration in blood from preterm infants is due to 
nutritional deprivation and can be stimulated by early amino acid administra-
tion. In addition, in response to early amino acid administration, glutathione 
consumption seems to be decreased.
As stated above, GSH concentrations in fetal blood are higher than in blood of children 
and adults(44). However, in chapter 9 we found significantly lower GSH concentrations 
a few hours after birth as compared to the second day of life. We speculate that GSH 
concentrations fall shortly after birth. This rapid drop is in agreement with the observa-
tion that GSH concentrations decrease in the first hours following oxidative stress in 
neonatal piglets and young rats, which was followed by a nearly normal or sometimes 
increased level 24 hours later, suggesting a compensatory effect(52, 53). Yet, this effect 
only occurred if substrate availability was sufficient. Also in preterm infants, there was 
a drop GSH content during the first 24h of life(54). Unfortunately, in this study no 
information was provided on nutritional intakes.
Our data demonstrate a rapid depletion of glutathione postnatally in preterm 
infants. This relative deficiency is reverted by early administration of amino 
acids.
The FSRGSH did not significantly change upon changes in nutritional intake. As compared 
to sick term infants (chapter 11) or healthy adults (chapter 8), FSRGSH was consis-
tently low. However, a number of studies have shown GSSG recycling to be increased in 
preterm infants, which would decrease the need for de novo synthesis(55, 56).
Cysteine. A limiting substrate?
Cysteine is a non essential AA. Its carbon skeleton is derived from serine. The sulfur 
component is derived from methionine, which is converted to homocysteine through 
the intermediate S-adenosylmethionine. Homocysteine and serine are then combined to 
form cystathionine, which is subsequently converted into cysteine by the enzyme cys-
tathionase. Cysteine is involved in many different pathways, of which protein and GSH 
synthesis are quantitatively most important. In healthy adults in the postprandial state, 
half of the cysteine flux could be accounted for by the turnover of GSH(57). Indeed, 
GSH and cysteine metabolism are strongly interdependent: cysteine is unstable as a 
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free AA and is therefore stored in GSH, serving as an ‘on demand’ cysteine reservoir. 
Alternatively, GSH requires cysteine to carry out its antioxidant properties. GSH thus 
both stores and consumes cysteine.
In general, cysteine is considered the rate limiting substrate for GSH synthesis(58, 
59). Indeed, its concentrations in several tissues is significantly lower than glutamate 
and glycine concentrations that are both used in equimolar amounts in the GSH synthe-
sis process. Although glycine demands are probably increased in preterm infants, being 
involved in the synthesis of many other AAs, utilization of glycine for erythrocyte GSH 
synthesis represented less than 2% of the plasma glycine flux(53). However, besides 
cysteine availability per se, its synthesis seems more dependent on the properties of 
glutamate cysteine ligase (GCL), the rate limiting enzyme in GSH synthesis. In humans, 
the Km values of GCL for glutamate and cysteine are 1.8 and 0.2 mM, respectively(60). 
The intracellular concentration of glutamate is significantly higher than the Km value 
of GCL for glutamate, whereas the intracellular concentration of cysteine almost equals 
the corresponding Km value of GCL. From this theoretical point of view, it follows that 
cysteine is indeed the rate limiting substrate for GSH synthesis.
In term infants with respiratory distress receiving ventilation with high fractions of 
inspired oxygen, plasma cysteine concentrations were significantly lower than fasted 
infants not treated with additional oxygen or healthy fed infants(61). However, it re-
mains unclear whether cysteine is actually essential to these infants, especially during 
increased demands, such as in the case of oxidative stress. A number of authoritative 
papers published in the 1970s found cysteine to be essential in preterm infants due 
to absence or low activity of cystathionase in the fetal liver(62, 63). Recently, how-
ever, Riedijk et al. performed a series of studies determining cysteine requirements in 
enterally fed preterm infants. Using sophisticated stable isotope methods, they found 
cysteine not to be essential in preterm infants with a mean gestational age as low as 28 
weeks(64, 65). Whether this equally applies to parenterally fed preterm infants in the 
immediate postnatal phase remains unclear. Miller et al. administered [U-13C]glucose 
to parenterally fed infants and did not detect any enrichment in cysteine. From this, 
they concluded that cysteine synthesis is decreased in parenterally fed preterm infants. 
On the other hand, during the study infants received AAs already containing cysteine 
at a dose of nearly 90 mg/(kg·d)(66). It can therefore not be concluded that cysteine 
synthesis was compromised in these infants.
Animal data has shown GSH levels to be increased upon cysteine supplementation in 
TPN solutions(67, 68). Data on effects of cysteine administration on GSH metabolism 
in human neonates are scarce. In fact, as far as we know, only two abstracts have 
been presented(42, 69), reporting increased erythrocyte GSH synthesis and concen-
trations, respectively. Zlotkin et al. performed a series of studies on the effects of 
cysteine supplementation on nitrogen and sulfur balances and weight gain(70, 71). A 
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control group received an AA solution without cysteine; the intervention group received 
cysteine-HCl at dose of 77 mg/(kg·d), which is almost similar to the amount infants in 
our high dose group received (chapter 10). They found no differences between groups 
and from these papers it was concluded that cysteine was either not essential or not 
bioavailable to the preterm infant. However, mean gestational age of these infants 
was >34 weeks, whereas mean study-age was postnatal day 14. In addition, hepatic 
cystathionase activity in preterm infants was found to reach adult levels after 9 days 
of life(72), suggesting that these infants were already able to synthesize cysteine. 
Extrapolating these data to preterm infants included in our studies seems, therefore, 
incorrect. During increased cysteine requirements, e.g. sepsis and oxidative stress, the 
transsulfuration pathway may not be able to provide for this increased demand. Another 
reason why it is likely that GSH consumption is increased during sepsis is the liberation 
of cysteine which can subsequently be incorporated into acute phase proteins, which 
contain a high content of cysteine.
In chapter 10 we studied the effects of a high cysteine dose on erythrocyte GSH 
kinetics as compared to a standard dose. We did not find any difference in either GSH 
concentration or synthesis rates. Surprisingly, also plasma cystine concentrations did 
not rise. Infants receiving the high dose cysteine did require increased base administra-
tion, indicating that the higher cysteine dose was indeed administered.
Because of its instability in solutions, bioavailability of cysteine has been questioned. 
Moreover, cysteine is said to be auto-oxidized in plasma to cystine, liberating reactive 
species(73). Though perhaps true, it would be expected to increase protein oxidation 
markers such as advanced oxidized protein products (AOPP). In chapter 10 we found 
no difference in AOPP concentrations in infants receiving either the high or the standard 
cysteine dose. Still, its stability in solutions is limited requiring its addition to an AA 
solution just prior to administration. Therefore, a number of alternative sources of 
cysteine have been proposed. N-acetyl cysteine (NAC) is more stable than cysteine-HCl 
and seemed promising. Indeed, NAC has been successfully applied in increasing GSH 
availability in nutritionally deprived children and adults with respiratory distress(59, 
74). Very recently, it has shown to reduce cerebral oxidative stress in asphyxiated 
newborn piglets(75). However, NAC seems to have limited bioavailability to the preterm 
infant. Its administration resulted in increased plasma NAC and not cysteine concentra-
tions. In addition, over 50% of NAC was excreted unmetabolized in urine, suggesting 
that preterm infants have decreased capacity to deacetylate NAC(76). Oxothiazolidine 
carboxylate, a 5-oxoproline analogue, is metabolized by 5-oxoprolinase and converted 
to cysteine. Alike NAC, it has been shown to increase GSH concentrations in adults with 
respiratory distress(74). Lipoic acid, used as a dietary supplement, reduces cystine 
to cysteine which is more easily transported intracellularly and thus enhances GSH 
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synthesis(77). Both oxothiazolidine carboxylate and lipoic acid, however, have yet not 
been tested for use in preterm infants.
Current ESPEN/ESPGHAN guidelines on pediatric parenteral nutrition (2005) advice 
the administration of cysteine to preterm infants. They state that an intake of 0.35 
mmol (42 mg/(kg⋅d)) to 0.46 mmol (56 mg/(kg⋅d)) would result in appropriate plasma 
concentrations. Based on our results, we cannot recommend increasing cysteine intake 
above 45 mg/(kg·d) as far as GSH synthesis concerns. Although we did not observe 
adverse metabolic effects, plasma cystine concentrations were not increased, which 
might reflect its use for other purposes such as protein synthesis, or its catabolism to 
sulfate. 
High dose cysteine (81 mg/(kg·d)) appears safe but does not increase gluta-
thione concentration or synthesis rate in erythrocytes of preterm infants as 
compared to a lower dose (45 mg/(kg·d)).
Clinical outcome
Antioxidants and oxidative stress represent a scientific area consisting of believers 
and nonbelievers. Optimizing antioxidant availability or preventing oxidative stress is 
expected to improve outcome from a theoretical point of view. Unfortunately, the ma-
jority of clinical trials failed to do so. Since pathophysiology of oxidative stress related 
morbidity is likely to be multifactorial, large numbers of infants are required to make 
useful inferences. In addition, there are many antioxidants and most of them work 
synergistically, forming an integrated balanced system of great complexity.
A large Scandinavian trial investigating the effects of NAC supplementation on inci-
dence of bronchopulmonary dysplasia (BPD) did not show any reduction(78), although 
this might be due to the earlier mentioned compromised bioavailability of NAC in 
preterm infants(76). Davis et al. administered intratracheal superoxide dismutase or 
placebo to 302 preterm infants. No difference was found in incidence of BPD(79). Route 
of administration might be an important factor in determining success of antioxidant 
interventional studies. Cooke et al. found that intratracheal administration of GSH in 
ventilated preterm infants resulted in significantly higher levels of GSH in bronchoalveo-
lar lavage fluid, whereas lipid peroxidation was reduced(80). This was, however, only a 
small study including 14 infants, so that it remains to be determined whether alterna-
tives for systemic administration have therapeutic benefits. Also, timing of intervention 
might be an important determinant of its success. Indeed, the pathophysiological base 
for some oxidative stress associated diseases is set very early after birth(81). Interven-
ing with an antioxidant or its precursor might incorrectly be concluded as not efficacious 
only because it was initiated too late.
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Most clinical trials on antioxidant supplementation fail to show positive effects 
on clinical outcome.
Nevertheless, low antioxidant availability has been associated with poor outcome. In 
a study in 144 infants on plasma antioxidant concentrations in relation to incidence of 
BPD and mortality, Silvers et al. found low plasma antioxidant activity at birth to be an 
independent risk factor for mortality(82). In infants developing BPD, it was found that 
elevations in plasma oxidative stress markers were more pronounced in the early days 
of life, indicating the need for early intervention(83, 84).
Facts and Fiction of Oxidative Stress
Oxidative stress has been defined as “an imbalance between pro-oxidants and anti-
oxidants in favor of the former, leading to potential damage. Indicators of oxidative 
stress include damaged DNA bases, protein oxidation products, and lipid peroxidation 
products”(85). Oxidative stress has been described in a large number of different patho-
logical states and diseases, including protein deprivation, atherosclerosis, rheumatoid 
arthritis, diabetes mellitus, Parkinson’s disease, and many others(86-89).
A certain amount of oxidative stress markers, however, are formed independently of 
oxidative stress, as is the case with carbonyls. Comparing concentrations of different 
markers in the same individuals can, therefore, lead to contradictory results as was 
observed by Mocatta et al. who found higher MDA concentrations in plasma of preterm 
neonates as compared to term neonates in the perinatal period, whereas carbonyl con-
centrations were lower(90). This example illustrates the importance of being cautious 
while interpreting presence of markers of oxidative stress.
According to its definition, oxidative stress is a pathological phenomenon. However, a 
number of recent publications report oxidative stress in seemingly physiological events 
such as term uncomplicated birth. As compared to children or adults, increased levels 
of isoprostanes were observed in healthy term neonates during the first three months 
of life. In addition, activity of superoxide dismutase and catalase increased during the 
same period, after which it decreased(91).
In another study, plasma MDA levels were found to be more than doubled in breast-
fed infants as opposed to infants fed cow’s milk(92). This was attributed to the presence 
of polyunsaturated fatty acids (PUFAs) in breast milk. Much controversy exists concern-
ing the role of PUFAs as promoter of oxidative stress(93, 94). PUFAs double bonds are 
susceptible to free radical mediated lipid peroxidation. The resulting peroxyl radicals 
initiate a chain reaction, which can be halted by vitamin E.
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Collectively, whereas we have seen that absence of nutrition will lead to depletion of 
antioxidants, its presence is likewise a potential source of oxidative stress.
Although parenteral AA solutions enhance GSH synthesis as shown in this thesis, TPN 
can be a source of free radicals(95). They generally contain riboflavins, which have 
oxidizing properties when exposed to light by means of promoting hydrogen peroxide 
production(96). It must be stressed, however, that these (per)oxidative effects of 
certain macro- and micronutrients are unlikely to have adverse clinical consequences, 
let alone that it would imply to be reticent about early nutrition. It does advocate a criti-
cal appraisal of composition of neonatal nutrition. The paradoxical effects of nutrition, 
might, nevertheless, explain the ‘physiological’ oxidative stress observed in healthy 
infants(91).
Caution should be exercised when interpreting levels of oxidative stress mark-
ers.
Halliwell has recently put forward a concept which might explain this ‘physiological’ 
oxidative stress. Since maintaining excess antioxidant defenses has a high energy cost, 
it could be energetically ‘cheaper’ to repair or replace damaged biomolecules(97, 98). 
In addition, a rise in oxidative stress markers might result from failure to degrade or 
repair biomolecules, rather than implying oxidative stress per se. In chapter 7, we 
found a rise in both AOPP and dityrosine concentrations in plasma of preterm infants 
towards postnatal day 6. Although irreversibly damaged proteins, such as AOPPs are 
likely to be rapidly degraded by proteases, we do not know their half life. It is prob-
ably safe, however, to conclude that oxidative stress is ongoing. In chapter 8, we 
found no difference in AOPP or dityrosine concentrations in plasma of preterm infants 
administered glucose only for the first two days of life or infants who received AAs as 
from birth onwards. Still, erythrocyte GSH synthesis rates increased significantly. We 
discussed a number of explanations, such as plasma and erythrocytes being different 
compartments.
Another issue raising controversy is mode of delivery. In our studies, mode of de-
livery did not affect either markers of oxidative stress or GSH kinetics. On the other 
hand, we did not perform measurements in cord blood. A number of studies have 
found a beneficial effect of vaginal delivery over cesarean section in terms of oxidative 
stress(99, 100); other studies concluded the opposite(101, 102), whereas some did 
not find a difference at all(103, 104). Infants born by cesarean section are on average 
more likely to experience distress while in utero. This could be a problem in studies in 
which this confounding factor is not accounted for. In a recent study, it was found that 
distressed fetuses delivered by emergency cesarean exhibited higher MDA concentra-
tions in amniotic fluid and cord blood than non distressed fetuses delivered by elective 
cesarean section(105).
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Tissue specific measurements
Although erythrocytes clearly have shown to be a target for ROS in preterm infants(106, 
107), we did not obtain information on GSH kinetics in other tissues. This may have 
consequences for the interpretation and generalizability of our results. Deneke et al. 
performed an in vitro study exposing calf endothelial cells to an hyperoxic challenge. 
Using stable isotopes, they found that this was associated with an enhanced precursor 
AA uptake(108). However, when repeating this experiment in human erythrocytes, no 
stimulation of GSH synthesis was observed(109). Malmezat et al. found that in food 
restricted septic rats, both GSH concentrations and synthesis rates were significantly 
higher than in well-fed control rats in liver, spleen, muscle, lung, heart and large in-
testine(110). From these data, the authors concluded that the inflammatory challenge 
overcame the impact of food restriction. However, in the same study, GSH synthesis 
was lower in blood and small intestine. In contrast to this study, hepatic GSH synthesis 
in rats increased during inflammation only when adequate sulfur AAs were consumed 
before the inflammatory challenge(52).
In a study in humans, measuring GSH kinetics in whole blood, lower GSH concentra-
tions and synthesis rates were found in malnourished septic children as compared to 
non-septic children. Although having essentially acquired the same data as Malmezat 
et al.(110), this study did not provide data on organ level GSH kinetics, which might 
had been increased in parallel Malmezat’s findings. Indeed, GSH concentrations and 
synthesis rates in blood might decrease as to provide substrates for organ specific GSH 
synthesis during increased requirements, such as sepsis. On the other hand, apart 
from being an indicator for oxidative stress, erythrocytes might be able to provide 
antioxidant defense to other tissues as well, such as the lung, either by providing 
intracellular antioxidants(111) or by directly taking up ROS(112). Recently, active GSH 
export towards plasma has been demonstrated. This suggests a role for erythrocytes 
as an active GSH donor to other tissues and the extracellular GSH pool, a role which 
was previously thought to be performed by the liver only. This study, however, failed 
to elucidate the mechanism by which the GSH was exported, since no GSH transport 
systems have been identified yet. It was shown earlier that erythrocytes may actively 
donate antioxidants to other tissues(113). Barbaro et al. found GSH correlations in 
plasma and mononuclear cells to correspond to liver GSH concentrations, suggesting 
that in humans blood GSH may be a sensitive indicator of tissue concentrations(114).
Although erythrocyte glutathione concentration might not reflect glutathione 
status in all tissues, its concentration is decreased during systemic oxidative 
stress.
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Methodological Considerations
GSH is receiving ongoing scientific interest. Annually, over 4,000 new articles are pub-
lished. More than half of these studies is carried out in animals; some of them involve 
in vitro research; many different cell types are studied; age of subjects varies a lot. 
As a result, making general inferences about GSH often comes down to comparing 
apples to oranges. For example, GSH and its associated enzymes have shown to vary 
significantly among different animal species, including humans(115). Another study 
found GSH levels to be subjected to diurnal variation(116). Also, concentrations of 
plasma and erythrocyte GSH in the same subjects seem to rise and fall independently. 
However, these concentrations differ a thousand-fold, thereby increasing the likelihood 
of miscalculation of the plasma GSH concentration(117).
GSH is a central component in the process of eliminating ROS. However, in the absence 
of GSH-containing enzymes to catalyze the many different detoxification reactions, it 
cannot properly function as an antioxidant. In our series of studies, we measured total 
GSH only, without its derived enzymes. The main reason is the limited sample availability: 
kinetic measurements require multiple sampling. In addition, there is a large number of 
GSH dependent enzymes, including GSH peroxidases and GSH-S-transferases, and they 
are all equally important. The presence of reduced GSH, however, is a prerequisite for 
synthesis of all its derived enzymes(118).
In our study, we measured GSH concentrations in erythrocytes, whereas markers of 
oxidative stress were determined in plasma. In part, the rationale for this was limited 
sample availability in preterm infants. Although recent data suggest active GSH export 
from erythrocytes to plasma(113), they remain separate compartments, which might 
explain our results indicating ongoing oxidative stress in plasma despite increased 
erythrocyte GSH synthesis (chapter 7 and 8).
GSH concentrations are much higher than GSSG concentrations both in the physi-
ological state but also during oxidative stress. Therefore, a minimum of artifactual 
GSH oxidation during sample treatment can lead to an overestimation of 10- to 100-
fold(119). Since GSH is very susceptible to artifactual oxidation ex vivo, its measured 
concentration is highly dependent on methodology and sample treatment. This has 
resulted in a wide range of reported concentrations for both GSH and GSSG(119). 
Measurements of antioxidants, such as GSH, should therefore be standardized in order 
to compare results between different studies(120).
The heterogeneity of study design and applied methods requires caution when 
interpreting and comparing data.
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We believe it is justified to be very skeptic towards measurements of GSSG concentra-
tion. A number of authors claim to find statistically significant correlations between 
GSSG concentrations and prematurity, fractions of inspired oxygen, etc. However, most 
of these studies included only a small number of infants, or present graphs showing 
correlations which are, in my opinion, questionable(47, 121, 122).
Future Perspectives
As in all research, many issues involving nutritional aspects of treatment of the preterm 
infant remain to be elucidated. Throughout this chapter we have discussed some of these 
questions. In this paragraph we will recapitulate our suggestions for future research.
With respect to early parenteral nutrition, safety and short-term efficacy of early AA 
administration should no longer be subject of debate. Focus should be directed towards 
long-term neurodevelopmental outcome. In addition, the maximal AA intake as well as 
the effects of early lipid administration as an energy source for protein synthesis need 
to be defined. The role of the composition of lipid infusions and how this is related to 
oxidative stress should be further investigated.
Whether cysteine is a limiting substrate for GSH synthesis in preterm infants remains 
to be determined. Although we did not find any increase in GSH synthesis rates upon 
doubling cysteine intake, we cannot be sure that cysteine-HCl has adequate bioavail-
ability to the preterm infant. In addition, we quantified synthesis in erythrocytes. GSH 
synthesis might be increased in other tissues, such as the liver or the lungs.
A lot of controversies remain on appropriate use of oxygen in neonatal medicine. 
Especially with respect to resuscitation of the preterm neonate, its role should be 
further elicited. In term asphyxiated infants, there is an extensive body of literature 
on providing room air during resuscitation instead of additional or even pure oxygen. 
In particular Saugstad and Vento have performed a lot of research demonstrating in-
creased oxidative stress in infants resuscitated with 100% oxygen as compared to room 
air. Strikingly, mortality decreases upon administering less oxygen. In addition, Apgar 
scores and clinical outcome, such as time to first cry and developing a sustained pattern 
of breathing, improve using room air. Also, resuscitation with 100% oxygen resulted in 
prolonged presence of markers oxidative stress even up to 4 weeks of age(123). Also, 
throughout the neonatal period, a restrictive approach towards use of oxygen seems 
advisable(124-127). However, data with regard to preterm infants are still inconclusive, 
in particular with respect to resuscitation policy(128). Another study found incidence of 
BPD to be almost doubled after resuscitation with 100% oxygen on the first day of life, 
BPD being defined as oxygen dependence on the 36th week postmenstrual age. Because 
it took place in two different centers which might applied different oxygenation manage-
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ment style, results may have been blurred to some extent(129). Spector et al. reported 
on an association between oxygen administration for 3 minutes or longer and childhood 
cancer(130). This association has yet not to be proven causal though. Currently, large, 
multicenter, blinded randomized trials are being conducted to determine optimal oxygen 
saturation levels for preterm infants. As yet, no data have been published. In extending 
our current research design, GSH kinetics should be determined in preterm infants 
resuscitated with low versus high fractions of inspired oxygen.
Besides oxygen, the role of sepsis and its impact on GSH requirements should be 
further elicited. The development of sepsis during the first weeks of life is an important 
cause of morbidity and mortality of premature infants(131). Infants who develop sepsis 
have a significantly prolonged hospital stay and are more likely to die than those who 
do not develop sepsis. Previous research has shown that sepsis leads to an increased 
generation of ROS through different pathways and subsequent oxidative stress(132). 
ROS are generated as part of the physiologic response during sepsis, with the aim of 
killing pathogens(133-135). However, this response can be overstimulated, causing a 
shift in redox balance. The resulting oxidative stress causes tissue damage and could 
play a role in morbidity and mortality. Especially premature infants are at risk, because 
they have both compromised antioxidant defenses as well as increased ROS production 
as a result of additional oxygen requirements. To date, little is known about the specific 
interplay of oxidative stress and sepsis in premature infants.
Defining the optimal moment to intervene for prevention of oxidative stress needs 
further study. GSH levels seem to fall rapidly upon preterm birth whereas markers of 
protein oxidation and lipid peroxidation in early life have been positively correlated 
with adverse outcome, such as BPD(83, 84). Effects of administering antioxidants 
antenatally to pregnant mothers should be investigated. In mice, administration of 
NAC to infected pregnant mothers diminished oxidative stress, increased hepatic GSH 
levels and reduced the rate of preterm birth(136). In another study, pretreatment with 
vitamin C protected against fetal death in pregnant mice who were daily injected with 
lipopolysaccharide (LPS), an oxidant. Postnatal treatment with vitamin C of LPS-treated 
mice had only little effect on intrauterine fetal death(137).
The majority of clinical trials has investigated effects of a single antioxidant(78, 
79). This is required to investigate applicability of a specific antioxidant as a potential 
therapeutic drug. Unfortunately, such studies ignore the fact that most antioxidants 
interact and require presence of another antioxidant to carry out their function, such as 
vitamin C and E. Some elements serve as a co-factor for other substances to function 
as an antioxidant, such as selenium, which is required to synthesize GSH peroxidase. 
However, providing selenium to preterm infants while GSH availability is compromised 
is less likely to increase GSH peroxidase availability.
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We speculate that a cocktail of antioxidants is required to exert significant health 
benefits. There are some difficulties though. As stated in chapter 1, low levels of 
ROS are physiologic and serve important roles in cell signaling, gene expression, and 
cell-mediated cytotoxicity of pathogens(138). In addition, a number of antioxidants 
have pro-oxidant properties beyond certain concentrations, such as vitamin C and E. 
Although these are crucial antioxidants not made by the human body, caution should be 
exerted to prevent overdosing. In this context, providing adequately AAs will enable the 
infant to synthesize protein based antioxidants ad libitum, such as GSH and its derived 
enzymes, whose synthesis is feedback inhibited.
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13 Summary
Summary
Nutrition is increasingly being recognized as an important factor in the treatment of pre-
term infants. In this dissertation we present a number of studies on the effects of early 
parenteral amino acid (AA) administration on protein kinetics (Part I) and antioxidant 
defense (Part II).
In Chapter 1 we provide a general introduction to early nutrition in preterm infants. 
Preterm infants are mostly dependent on parenteral nutrition during the first weeks of 
life. Unfortunately, the use of first generation AA solutions showed significant metabolic 
side-effects. Although present day solutions have been improved, many neonatologists 
are still reluctant to administer AAs in (a substantial amount) during early life. As a 
result, infants become in a catabolic state, slowing down growth as a whole as well as 
synthesis of important proteins, such as albumin. This is likely to negatively influence 
their short-term and possibly long-term outcome. In this thesis, we present studies 
on the effects of early AA administration in preterm infants on protein metabolism and 
antioxidant defense as indices of neonatal wellbeing.
Part I - early nutrition & protein metabolism
Chapter 2 describes a clinical trial investigating safety and efficacy aspects of par-
enteral AA administration directly following birth as compared to glucose only in a 
large group of preterm infants with a birth weight <1500 gram. We used a number of 
biochemical indices, such as pH and base excess, to confirm metabolic safety. Apart 
from higher blood urea nitrogen (BUN) levels in the group receiving AAs, we did not 
find metabolic disturbances. In our opinion, the higher BUN level, however, reflects 
increased AA oxidation rather than intolerance. Nitrogen balance turned positive upon 
AA administration, whereas the control group receiving glucose only had a negative 
nitrogen balance, meaning they were in a catabolic state. Besides promoting anabolism, 
AA administration resulted in higher plasma concentrations of (conditionally) essential 
AAs, which were more within reference ranges as compared to infants receiving glucose 
only. Thus, early AA administration seems safe and results in anabolism.
In Chapter 3, we studied the mechanism by which anabolism in response to exog-
enous AA administration is obtained in preterm infants in the direct postnatal phase. 
Using stable isotope techniques, we found that protein synthesis is stimulated, even 
during very low energy intakes. However, we did not find a concomitant decrease in 
proteolysis. Anabolism in adults and healthy term infants, unlike in preterm infants 
and ovine fetuses, is predominantly achieved by suppression of proteolysis instead of 
protein synthesis. Possibly, a new balance between protein breakdown and synthesis is 
developing during early life, explaining this observed discrepancy.
We also measured glucose oxidation rate, which we expected to increase as a result of 
the higher energy demands necessary for protein synthesis. However, glucose oxidation 
did not rise during AA administration, suggesting that the increased energy demands 
are not made up for by glucose utilization.
Whereas we showed increased protein kinetics on a whole body level in chapter 3, in 
Chapter 4 we determined synthesis rates of albumin, the main plasma protein. We 
found that early AA administration resulted both in increased fractional synthesis rates 
as well as in increased concentrations. This finding might have important implications in 
view of the vital roles of albumin, among which serving as an antioxidant and binding 
bilirubin and free fatty acids.
In the earlier chapters we demonstrated beneficial effects of AA administration in the 
direct postnatal phase. Chapter 5 is a short report on safety and efficacy aspects of 
early AA administration in preterm infants at two years of age. This is a follow up study 
in which we included infants earlier described in chapter 2. In this exploratory study, 
no negative effects of early AA administration on postnatal growth or handicap rates 
were found. However, despite a trend towards a better outcome in the group receiving 
AAs, no apparent clinical benefits were observed either in this exploratory study. Since 
neurodevelopmental outcome in preterm infants is dependent on multiple variables, of 
which only one is nutrition, larger studies are needed to define whether early aggres-
sive AA administration will have a, perhaps subtle, effect on long-term, neurocognitive 
outcome.
Part II - early nutrition & antioxidant defense
Glutathione, a tripeptide and thus build up of AAs, is a very important antioxidant. Its 
requirements are likely to be increased as a result of exposure to so called ‘reactive oxy-
gen species’, which are potential harmful intermediates in the consumption of oxygen. 
However, current feeding regimens not including substantial early AA administration are 
unlikely to meet these increased requirements. This results in oxidative stress and can 
cause serious morbidity.
In Chapter 6, we present a new method for the determination of glutathione (GSH) 
kinetics in erythrocytes of preterm infants. In this method, we used a liquid chroma-
tography interface coupled to an isotope ratio mass spectrometer. This highly sensitive 
method requires only a very small sample volume. In addition, no derivatization is 
required, which is of benefit since GSH is very susceptible to artificial oxidation.
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Chapter 7 describes an observational study in preterm infants in which we determined 
erythrocyte GSH concentrations and synthesis rates on postnatal day two (when receiv-
ing glucose only), and on postnatal day six, (when receiving both parenteral and enteral 
nutrition). In plasma, we measured advanced oxidized protein products (AOPP) and 
dityrosine as markers of oxidative stress. Towards day six both markers of oxidative 
stress increased significantly. However, this increase was not compensated for by an 
upregulation of GSH concentration and synthesis rate, despite an overall increase of 
plasma precursor AAs. This discrepancy results possibly from the two different com-
partments in which GSH (erythrocytes) and oxidative stress markers (plasma) were 
measured.
Early AA administration resulted in increased production of albumin as shown in 
Chapter 4. To investigate whether early AA administration stimulates GSH synthesis, 
we performed a clinical trial, described in Chapter 8, in which we determined GSH 
concentrations and synthesis rates in infants either receiving glucose only during the 
first two postnatal days, or infants receiving glucose and AAs directly following birth. 
In addition, we quantified levels of AOPP and dityrosine. The results showed that AA 
administration directly following birth increased GSH absolute synthesis rate by more 
than 70%. Our data are consistent, however, with higher GSH concentration rather than 
a higher fractional synthesis rate. Greater availability of GSH, nevertheless, did not 
bring down markers of oxidative stress.
As an explanation of the apparent relative decrease in GSH consumption, we speculated 
that the GSH fractional synthesis rate might have been increased already on the first 
day of life, and then have dropped as a result of negative feedback. Therefore, we 
performed another clinical trial, described in Chapter 9, in which we compared GSH 
kinetics in preterm infants in the direct postnatal phase (within four hrs postnatally) and 
on postnatal day two. We found that GSH concentration increased with postnatal age. 
However, contrary to our speculation, GSH fractional synthesis rate was not different 
between groups.
Cysteine is generally considered as the limiting substrate for GSH synthesis. However, 
in the past some raised concerns about its safety and bioavailability in preterm infants. 
In Chapter 10 we studied the effects of doubling the amount of cysteine in a parenteral 
AA solution on GSH concentration and synthesis rate. Although it appeared metaboli-
cally safe, a high dose cysteine did not increase plasma cysteine concentrations. GSH 
concentration and synthesis rate were not altered upon the additional cysteine admin-
istration.
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Alike preterm infants, sick term infants can be subjected to a high load of reactive 
oxygen species, for example during ventilation using additional oxygen. Therefore, 
their GSH requirements may be increased. In Chapter 11, we describe an observa-
tional study including infants suffering from perinatal asphyxia, infants requiring extra 
corporeal membrane oxygenation (ECMO), and relatively healthy, partially enterally 
fed preterm infants. Again, we determined GSH kinetics and we measured AOPP and 
dityrosine concentrations. Both AOPP and dityrosine concentrations were present in 
significant amounts in all groups. As compared to relatively healthy preterm infants, 
GSH concentrations and synthesis rates were not higher in asphyxiated infants, but 
GSH absolute synthesis rates were higher in infants on ECMO.
In Chapter 12, our findings are discussed in the context of relevant literature. In 
addition, recommendations for future research are made.
The main conclusions obtained from the studies described in this thesis are the follow-
ing:
•	 Amino acid administration in preterm infants directly following birth is safe and 
converts a catabolic into an anabolic state by increasing protein synthesis. Energy 
for protein synthesis is not derived from increased glucose oxidation.
•	 Early amino acid administration in preterm infants appears to be safe with regard to 
neurodevelopmental outcome at two years of age.
•	 Decreased glutathione concentration in erythrocytes from preterm infants is due to 
nutritional deprivation and can be stimulated by early amino acid administration. In 
addition, in response to early amino acid administration, glutathione consumption 
seems to be decreased. However, levels of plasma markers of oxidative stress are 
not diminished.
•	 High dose cysteine appears safe but does not increase glutathione concentration or 
synthesis rate in erythrocytes of preterm infants as compared to a lower dose.
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Samenvatting
Voeding wordt in toenemende mate erkend als een belangrijke pijler in de behande-
ling van prematuur geboren kinderen. Dit proefschrift bevat een aantal studies waarin 
het effect van het toedienen van aminozuren direct na geboorte op de aanmaak van 
eiwitten en antioxidanten wordt bestudeerd. Aminozuren zijn de bouwstenen waaruit 
eiwitten en bepaalde antioxidanten zijn opgebouwd.
In Hoofdstuk 1 wordt een algemene introductie gegeven over voeding voor premature 
pasgeborenen in de eerste levensfase. Premature pasgeborenen zijn voor het grootste 
deel van hun voedingsintake afhankelijk van parenterale voeding in de eerste levenspe-
riode. Parenterale voeding is voeding die via een infuus wordt toegediend.
Helaas ging het gebruik van de eerste generatie aminozuuroplossingen gepaard 
met een aantal serieuze bijwerkingen op het metabolisme (stofwisseling). Hoewel de 
huidige oplossingen deze bezwaren in principe niet meer kennen, zijn veel kinderartsen 
nog terughoudend om aminozuren (in een significante hoeveelheid) toe te dienen in de 
eerste levensdagen. Het gevolg is dat deze premature pasgeborenen in deze periode 
meer eiwitten afbreken dan dat ze aan kunnen maken. Het is niet moeilijk voor te 
stellen dat dit op korte termijn negatieve gevolgen heeft en wellicht zelfs ook op langere 
termijn. In dit proefschrift worden studies gepresenteerd waarin we de veiligheid en de 
effectiviteit bestuderen van het direct na geboorte toedienen van aminozuren via het 
infuus. Hierbij kijken we naar hoe de aminozuren verdragen worden. Daarnaast kijken 
we vooral naar effecten op aanmaak van eiwitten en antioxidanten.
Deel I – vroege voeding & eiwitmetabolisme
In Hoofdstuk 2 wordt een onderzoek beschreven waarin algemene aspecten van veilig-
heid en effectiviteit worden bestudeerd van parenterale aminozuurtoediening direct na 
de geboorte in een grote groep van premature pasgeborenen met een geboortegewicht 
van onder de 1500 gram. Een controlegroep kreeg alleen koolhydraten (glucose) toe-
gediend via het infuus gedurende de eerste 2 levensdagen. Qua veiligheid keken we 
onder andere naar de pH en de base excess, een maat voor de zuurgraad van het 
bloed. Afgezien van een wat verhoogd ureum gehalte van het bloed vonden we geen 
significante verschillen tussen beide groepen. Ureum wordt gevormd bij de verbranding 
van aminozuren waarbij energie vrijkomt. Het hogere ureumgehalte dient naar ons idee 
echter niet geïnterpreteerd te worden als intolerantie ten opzichte van aminozuren, 
maar als een teken dat de aminozuren verbrand worden om in de energiebehoefte te 
voorzien. Verder vonden we in deze studie dat door het toedienen van aminozuren een 
anabole voedingstoestand wordt verkregen, wat wil zeggen dat er meer eiwit wordt 
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aangemaakt dan dat er wordt afgebroken. Ook waren de concentraties van enkele 
essentiële aminozuren hoger. Essentiële aminozuren zijn aminozuren die (nog) niet 
door het lichaam zelf gemaakt kunnen worden en dus via voeding dienen te worden 
ingenomen. Concluderend lijkt het toedienen van aminozuren direct na geboorte veilig 
en resulteert het in een anabole voedingstoestand.
In Hoofdstuk 3 bestuderen we hoe het anabolisme na het toedienen van aminozuren 
in de eerste levensdagen verkregen wordt. Met behulp van met stabiele isotopen ge-
labelde aminozuren werd aangetoond dat dit door toegenomen eiwitaanmaak komt, 
terwijl de eiwitafbraak niet geremd wordt door aminozuurtoediening. In tegenstelling 
tot premature pasgeborenen wordt anabolisme bij oudere kinderen en volwassenen 
voornamelijk bewerkstelligd door het remmen van de eiwitafbraak en juist in mindere 
mate door het stimuleren van eiwitaanmaak. Dit verschil heeft mogelijk te maken met 
het vinden van een balans tussen afbraak en aanmaak in het metabool zeer actieve 
premature pasgeboren kind. In deze studie werd ook gekeken naar verbranding van 
glucose. Immers, eiwitaanmaak is arbeidsintensief. Er werd echter geen verschil ge-
vonden in glucose verbranding, wat suggereert dat de energie nodig voor eiwitaanmaak 
niet wordt gewonnen uit een toegenomen glucose verbruik.
Terwijl in hoofdstuk 3 niet naar een specifiek eiwit werd gekeken, werd in Hoofdstuk 4 
de aanmaak van albumine bestudeerd, het in bloedplasma meest voorkomende eiwit. 
Er werd gevonden dat zowel de hoeveelheid albumine als de aanmaaksnelheid ervan 
significant toenam na het toedienen van aminozuren. Aangezien albumine een eiwit is 
met zeer belangrijke functies, is deze bevinding klinisch belangrijk.
In de voorgaande hoofdstukken bestudeerden we effecten van aminozuurtoediening 
in de eerste levensfase. In Hoofdstuk 5 wordt een exploratieve studie beschreven 
die naar lange termijn veiligheid en effectiviteit kijkt van aminozuurtoediening naast 
glucose versus alleen glucose gedurende de eerste twee levensdagen. Kinderen werden 
op de leeftijd van 2 jaar gezien. In deze studie werden dezelfde kinderen geïncludeerd 
als beschreven in hoofdstuk 2. Op de leeftijd van 2 jaar werden geen negatieve effecten 
gevonden van het vroeg toedienen van aminozuren op het voorkomen van lichamelijke 
of verstandelijke handicaps. Ook werd er echter geen (significant) betere uitkomst 
gevonden tussen kinderen die glucose en aminozuren versus alleen glucose ontvangen 
hadden. Aangezien neurologische ontwikkeling afhankelijk is van meerdere variabelen, 
waarvan voeding er een is, zijn grotere studies nodig om aan te tonen of vroege toe-
diening van aminozuren klinisch significante positieve effecten heeft op neurologische 
ontwikkeling.
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Deel II – vroege voeding & antioxidanten
Glutathion, opgebouwd uit aminozuren, is een zeer belangrijke antioxidant. Antioxi-
danten maken afvalstoffen onschadelijk die vrijkomen bij stofwisselingsprocessen, 
zoals vrije radicalen bij het verbruik van zuurstof door het lichaam. De behoefte aan 
antioxidanten en dus glutathion in premature pasgeborenen is verhoogd als gevolg van 
zuurstoftoediening, ziekten, infecties, etc. Echter, zonder aminozuurtoediening zijn er 
mogelijk te weinig bouwstenen om in de behoefte aan glutathion te voorzien. Er onstaat 
dan een situatie die we oxidatieve stress noemen en die tot ernstige ziektebeelden kan 
leiden.
In Hoofdstuk 6 presenteren we een nieuwe methode om glutathion aanmaak te be-
palen in rode bloedcellen van premature pasgeborenen. Deze op massa spectrometrie 
gebaseerde methode is zeer nauwkeurig en behoeft slechts een minimale hoeveelheid 
bloed.
In Hoofdstuk 7 wordt een observationele studie beschreven in premature pasgebore-
nen met een geboortegewicht kleiner dan 1000 gram waarin glutathion concentraties en 
aanmaaksnelheid worden bepaald op levensdag twee (wanneer kinderen slechts glucose 
kregen) en op dag zes (wanneer kinderen zowel parenterale voeding als voeding via 
de natuurlijk weg werd toegediend). In het bloedplasma werd de mate van oxidatieve 
stress bepaald. Op zowel dag twee als dag zes waren de oxidatieve stress markers ver-
hoogd. Dit werd echter niet gecompenseerd door een toegenomen glutathion productie. 
Mogelijk wordt deze discrepantie veroorzaakt door het feit dat glutathion bepaald werd 
in rode bloedcellen, terwijl oxidatieve stress bepaald werd in bloedplasma door gebrek 
aan voldoende rode bloedcellen.
Direct na geboorte toedienen van aminozuren resulteerde in een toegenomen productie 
van albumine, zoals aangetoond in hoofdstuk 4. Om te onderzoeken of ook glutathion 
aanmaak wordt gestimuleerd, werd een studie uitgevoerd, beschreven in Hoofdstuk 
8, waarin glutathion concentraties en aanmaaksnelheid werden bepaald in premature 
pasgeborenen die of naast glucose ook aminozuren toegediend kregen of die alleen 
glucose kregen in de eerste twee levensdagen. Ook bepaalden we weer oxidatieve 
stress markers. De resultaten lieten zien dat de absolute glutathion productie met 
70% toenam. Dit werd echter niet bewerkstelligd door een hogere fractionele aan-
maaksnelheid, als wel door een hogere concentratie van glutathion. Dit suggereert dat 
het toedienen van aminozuren resulteert in een relatieve afname van het glutathion 
verbruik. De grotere glutathion beschikbaarheid leidde verder niet tot een vermindering 
van oxidatieve stress markers in bloedplasma.
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Als verklaring voor de relatieve afname van het verbruik van glutathion, werd gespe-
culeerd dat de fractionele aanmaaksnelheid al verhoogd was op de eerste levensdag, 
waarna het afnam als gevolg van voldoende beschikbaarheid. Om dit te onderzoeken, 
onderzochten we glutathion concentraties en aanmaaksnelheid al binnen enkele uren 
na de geboorte en vergeleken dit met waardes verkregen op levensdag twee. Dit is 
beschreven in Hoofdstuk 9. Terwijl de concentratie naar levensdag twee duidelijk 
toenam, vonden we geen toegenomen fractionele aanmaaksnelheid direct na geboorte, 
wat suggestief is voor een afname van glutathion verbruik.
Van cysteine, een van de drie aminozuren waaruit glutathion is opgebouwd, wordt 
algemeen aangenomen dat het de limiterende bouwsteen is voor de glutathion aan-
maak. Het is van de drie aminozuren in de laagste concentratie in bloed aanwezig. 
De veiligheid van het toedienen van het losse aminozuur cysteine heeft volgens som-
migen mogelijk bijwerkingen tot gevolg. Daarnaast is het onzeker of het lichaam het 
in losse vorm kan verwerken. In Hoofdstuk 10 wordt een studie beschreven waarin 
we een groep premature pasgeborenen de standaard hoeveelheid cysteine aanwezig 
in de aminozuuroplossing toedienden en vergelijken dit met een groep die de dubbele 
hoeveelheid ontving. Hoewel er geen aanwijzingen werden gevonden voor intolerantie 
van de hogere concentratie cysteine, was de concentratie van cysteine in bloedplasma 
niet hoger in de groep die meer cysteine ontving. Ook waren glutathion concentratie en 
aanmaaksnelheid niet verhoogd.
Net als premature pasgeborenen, kunnen zieke op tijd geboren pasgeborenen worden 
blootgesteld aan grote hoeveelheden vrije radicalen, zoals bij blootstelling aan hoge 
concentraties zuurstof als onderdeel van hun behandeling. Hierdoor is hun behoefte 
aan antioxidanten als glutathion mogelijk vergroot. In Hoofdstuk 11 wordt een obser-
vationele studie beschreven waarin pasgeborenen met een periode van zuurstofgebrek 
rondom de geboorte, pasgeborenen aan de hart-long machine en relatief gezonde pre-
mature pasgeborenen werden geïncludeerd. Bij deze kinderen werden weer glutathion 
concentraties en aanmaaksnelheid als ook oxidatieve stress markers in bloedplasma 
bepaald. In alle groepen leek er sprake van oxidatieve stress. Vergeleken met prema-
ture pasgeborenen was er geen verschil in glutathion concentratie en aanmaaksnel-
heid in pasgeborenen met zuurstofgebrek rondom de geboorte. Zowel concentratie als 
aanmaaksnelheid van glutathion was echter beduidend groter in pasgeborenen aan de 
hart-long machine.
In Hoofdstuk 12 worden de bevindingen in dit proefschrift bediscussieerd in de con-
text van relevante literatuur. Daarnaast worden suggesties gedaan voor toekomstig 
onderzoek.
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De belangrijkste conclusies volgend uit dit proefschrift zijn als volgt:
•	 Aminozuurtoediening aan premature pasgeborenen direct na de geboorte is 
veilig en resulteert in een anabole voedingstoestand door middel van het stimuleren 
van de eiwitproductie. De energie nodig voor toegenomen eiwitproductie wordt niet 
verkregen uit verbranding van glucose.
•	 Aminozuurtoediening direct na geboorte in premature pasgeborenen lijkt veilig 
voor wat betreft de neurologische ontwikkeling op tweejarige leeftijd.
•	 Een lage glutathion concentratie in rode bloedcellen van premature pasge-
borenen in de eerste levensfase is het gevolg van een tekort aan bouwstenen en kan 
worden gestimuleerd door het toedienen van aminozuren. Tevens lijkt het verbruik van 
glutathion door toediening van aminozuren af te nemen. Desondanks zijn oxidatieve 
stress markers in bloedplasma onverminderd aanwezig.
•	 Het toedienen van een hogere dosis cysteine lijkt veilig maar leidt niet tot een 
verhoogde aanmaaksnelheid van glutathion in rode bloedcellen van premature pasge-
borenen in vergelijking tot een lagere dosis.
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Dankwoord
Een proefschrift schrijven is een aparte ervaring. Het is hollen, soms slenteren, af en 
toe zelfs stilstaan. Het is multi tasken ten voeten uit! In dat kader is het overigens 
niet verwonderlijk dat het ‘hora est’ voor vrouwelijke promovendi ruim een jaar eerder 
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Zoals uit onderstaande zal blijken is een proefschrift de uitkomst van een gezamenlijke 
inspanning. Graag wil ik daarom op deze plaats de volgende personen bedanken.
Allereerst dank ika de kinderen en hun ouders die belangeloos meegewerkt hebben 
aan de verschillende onderzoeken. Zonder onderzoek geen vooruitgang. De resultaten 
beschreven in dit proefstuk zullen zeker direct of indirect een bijdrage leveren aan het 
verbeteren van de zorg voor prematuur geboren baby’s.
Prof. dr. J.B. van Goudoever, beste Hans. Ondanks je volle agenda zijn laagdrempelig-
heid, enthousiasme en scherpzinnigheid sleutelwoorden in je omgang met promovendi. 
Ik heb het als zeer prettig ervaren dat je me in het onderzoek vrij liet, maar altijd weer 
bijstuurde wanneer nodig. De vele congresbezoeken waren met recht fantastische kr-
enten in de pap, met afgelopen voorjaar met de hele neo naar Hawaii als hoogtepunt!
De leden van de Kleine Commissie, prof. dr. D. Tibboel, prof. dr. A.J. van der Heijden en 
prof. dr. H.J.G. Boehm, dank ik hartelijk voor het beoordelen van het manuscript. Prof. 
Tibboel, zeer veel dank voor het bieden van de mogelijkheid om onderzoek te doen op 
de toenmalige intensive care chirurgie.
Prof. dr. G. Buonocore, Prof. dr. E.A.P. Steegers, prof. dr. H.N. Lafeber en prof. dr. H.P. 
Sauerwein bedank ik voor het zitting nemen in de Grote Commissie.
Professor Buonocore and Mariangela Longini. Thank you very much for introducing our 
study group into the world of oxidative stress markers. I am confident that our ongoing 
collaboration will lead to exciting data.. and hopefully some more visits to Siena of 
course!
Alle artsen en verpleegkundigen van de afdeling neonatologie wil ik bedanken voor hun 
hulp bij het uitvoeren van de verschillende studies. Er wordt veel onderzoek gedaan op 
de afdeling neonatologie, wat regelmatig vraagt om extra inspanningen van het person-
eel. Van gaasjes in de luier om urine op te vangen en het afnemen van bloedmonsters 
tot hulp bij het includeren van patiënten. Zeer bedankt!
Nynke Weisglas. Enorme SPSS files hebben we doorgespit. Zeer bedankt voor alle hulp 
bij de follow up van de NIPI studie.
Het mass-spec lab. Henk Schierbeek, Darcos Wattimena, Gardi Voortman, Trinet Rietveld 
en Kristien Dorst. Beste Henk, mede door jouw vrolijke nuchterheid, vastberadenheid 
om elke bug in de onderhoudsgevoelige apparatuur op te sporen (zelfs in het weekend 
sprong je op de fiets naar het lab als dat nodig was) werd een dagje labben een aan-
gename bezigheid!
Darcos en Trinet, jullie hebben Chris en mij, groen als gras met pipetten, de beginselen 
van het werken in een lab bijgebracht en daarnaast natuurlijk stikstofbalansen, kica en 
albumine bepalingen.
De apotheek. Er zijn heel wat stabiele isotopen opgelost en cysteine testoplossingen 
gemaakt. En altijd in een rap tempo! Hiervoor ben ik Andras Vermes zeer erkentelijk. 
Ook de verschillende trialapothekers wil ik bedanken voor hun inzet voor het importeren 
van de cysteine oplossingen, wat geen gemakkelijk klus bleek. Met name wil ik Satu 
Siiskonen op deze plaats daarvoor bedanken.
Jan Huijmans wil ik bedanken voor de mogelijkheid om de aminozuurbepalingen in zijn 
lab uit te voeren. Niet zelden had ik nog maar een absoluut minimum aan plasma over. 
Wistaria Rawlin, jij wist toch altijd binnen korte tijd met de resultaten te komen.
Ineke van Vliet. Van het afnemen van ademmonsters, hulp bij het schrijven van PIF’s 
en ABR formulieren voor de METC tot SPSS instructies. Het opzetten van een studie was 
zonder jouw hulp ondenkbaar. Daarnaast was het natuurlijk altijd gezellig om voor een 
praatje bij Unit 4 langs te gaan.
Daniëlla van de Laar! Dank voor de hulp, zeker in de laatste fase van het onderzoek, 
voor het altijd kunnen inplannen van een spoedafspraak bij de baas en natuurlijk voor 
de gezelligheid. Een kwalificatie als ‘het zonnetje van de stafgang’ komt niet voor niets 
natuurlijk!
Collega onderzoekers. Op de eerste plaats uiteraard alle (ex)bewoners van Sk-2210. 
Maaik en Maaik, Kar en Wil, Den en Hes en Anne.
Maaike. Samen een rondje hardlopen langs de White House of Central Park, maar ook 
over de Erasmusbrug. Etentjes met Rogier, Chris en Susan. Gezellig dat jullie ook naar 
het Rotterdamse komen. Ik vind het super dat je nu naast mij staat tijdens mijn promo-
tie! Karien, drie maanden lang heb jij oxidatieve stress markers bepaald. Je hebt daar 
zo hard geklust dat zelfs je eigen stress markers verhoogd bleken.
219
Denise, aan jou om deze onderzoekslijn voort te zetten en verder gestalte te geven. 
Zoals elke onderzoeker heb jij mogen ondervinden dat klinisch onderzoek doen met 
vallen en opstaan gaat. Je hebt wat dat betreft laten zien dat je zeker niet makkelijk uit 
het veld bent te slaan! Fijn dat de studies nu op de rails lijken.
Uiteraard is er ook onderzoek na Sk-2210. Carine, Janine, Joanne, Heleen, Nanda, het 
hele VOBS gezelschap (met als grote initiatoren Emile en Ralph). Freek, alweer enige 
tijd in het Amsterdamse. Zoals je het zelf al zei: parallelle CV’s sinds de zandbak. Ik zie 
ons nog in Voorheen Schoonewelle zitten back in ’97..
Pat & Sas! Altijd gegarandeerd groot vertier en daarnaast bevlogen onderzoekers.. op 
de mooiste Hawaiiaanse stranden fanatiek brainstormen over nieuwe studieopzetten.
Chris, vriend en collega, a.k.a. Jut. Samen zijn we níet naar Madrid gegaan, maar wel 
4 jaar langer op de Sk-2210 gebleven. We zijn aardig wat beren op de onderzoeksweg 
tegengekomen, maar de voetbalsessies op de kamer, Coenense biertjes en de vele 
tripjes rondom congresbezoeken hebben zeker voor de nodige ontspanning gezorgd.
Mijn vrienden dank ik voor hun interesse en betrokkenheid bij mijn onderzoek, maar 
ook vooral voor de broodnodige afleiding! Erik Jan, vriend van ongeveer letterlijk het 
eerste uur. We zijn elkaar nooit uit het oog verloren en het is voor mij dan ook niet 
meer dan logisch dat jij op deze dag naast mij staat. Dank je wel dat je mijn paranimf 
wilt zijn.
Kees en Annemarie, Paul y Emma. Bedankt voor jullie interesse en betrokkenheid bij 
mijn onderzoek. De etentjes in Bavel en de uitstapjes met jullie ben ik erg gaan waar-
deren.
Mijn ouders, lieve pap en mam. De constante en onvoorwaardelijke factor! Mijn grote 
zus Clementine, Obbe-Gert, Anne en Jikke. De tocht naar het Groningse bleek voor mij 
het laatste jaar tot mijn grote spijt regelmatig een forse hindernis, maar dat gaat nu 
veranderen.
Lieve Susan. Vooral de laatste maanden was de studeerkamer voor mij the place to be. 
Op jou kon ik gelukkig elke keer weer rekenen als ik het boekje even moe was. Samen 
met jou gaat de blik vanaf nu weer op de toekomst!
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